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Cysteinyl leukotriene (LTC4, LTD4 and LTE4) are proinflammatory lipid mediators involved 
in the pathogenesis of asthma. LTE4 the most stable of the cysteinyl leukotrienes elicits 
bronchoconstriction, and unlike LTC4 and LTD4 it enhances bronchial 
hyperresponsiveness. LTE4 can also mediate other features of asthma, such as 
eosinophilia, increased mucus secretion and vascular permeability. None of these LTE4 
activities can be explained by current understanding of classical cysteinyl leukotriene 
receptors, CysLT1 and CysLT2, suggesting the presence of a novel receptor that 
preferentially responds to LTE4. 
LTE4 mediated pulmonary inflammation in a murine model was shown to remain intact in 
the absence of CysLT1 and CysLT2, and was abrogated by the knockout of the purinergic 
receptor, P2Y12. This study aimed to elucidate whether LTE4 directly signalled through the 
P2Y12 receptor. Models of human CysLT1, CysLT2 and P2Y12 overexpressed in HEK293T, 
CHO cells and human platelets were used to characterise responsiveness to cysteinyl 
leukotrienes. LTE4 failed to induce any specific signalling responses in cells expressing 
P2Y12 or in human platelets, showing that LTE4 does not directly signal through P2Y12.  
Previous reports have shown that LTE4 is a potent agonist in human mast cells and so the 
aim was to identify the receptor responsible for LTE4-induced responses using two human 
mast cell lines, LAD2 and LUVA. When intracellular signalling and gene expression were 
compared in response to stimulation, LUVA cells responded to LTC4 and LTD4 but lacked 
the potent responses to LTE4 observed in LAD2 cells. Gene screening by microarrays was 
used to identify 4 target GPCRs which were cloned and their responsiveness to cysteinyl 
leukotrienes analysed in HEK293T overexpression model. CysLT1 was identified as the 
only GPCR responding to cysteinyl leukotrienes and differently expressed in LAD2 cells. 
Stable knockdowns were created and analysed to reveal CysLT1 was responsible for the 
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Asthma is a disorder that affects the airways of 5.4 million people in the UK, of which over 
a million are children. Once thought to be a disease of the airway smooth muscle, it is now 
defined as an inflammatory disease of the conducting airways, which gives rise to specific 
structural and functional changes. It is considered a heterogeneous, multi-factorial 
condition in which not one single gene or environmental factor can be held accountable. 
Instead it is potentially caused by the interplay of several of these factors.  
In this introduction I will be focussing on the involvement of specific proinflammatory 
mediators, known as cysteinyl leukotrienes, which are thought to play critical roles in 
many of the key pathways of the pathogenesis of asthma. I will first introduce the 
discovery and synthesis of these mediators and intracellular signalling pathways that are 
mediated by one of the largest classes of receptors, known as G-protein coupled receptors 
(GPCRs). I will review in detail cysteinyl leukotrienes involvement in asthma with 
particular emphasis on leukotriene E4 (LTE4), the most stable of the cysteinyl leukotrienes 
and potentially the most important leukotriene in terms of pathogenesis of the disease.  
Finally, I will discuss the importance of LTE4 and potential existence of a previously 
unidentified cysteinyl leukotriene receptor.    
 
1.1.1 Lipid mediators 
Lipids are essential molecules for life. They make up the majority of all cell membranes as 
phospholipids and are crucial energy sources. They can also act as signalling molecules 
(lipid mediators) which can directly play pivotal roles in inflammation, immunity and 
homeostasis. Lipid mediators can be distinguished from other signalling molecules such as 
neurotransmitters and hormones by their ability to be produced on demand in a calcium-
dependent fashion from membrane phospholipids. Lipid mediators are also able to 
activate a specific group of receptors, known as GPCRs. Thus lipid mediator generation 
and signalling are highly regulated and so any dysfunction through synthesis or receptor 
can cause and potentiate disease states. This has led to a plethora of enzyme inhibitors 
and receptor antagonists being developed for use as therapeutic targets, especially in the 
field of allergic disorders (namely asthma).     
Leukotrienes, prostanoids (prostaglandins and thromboxanes), hydroxyeicosatetraenoic 
acids, lipoxins and epoxyeicosatrienoic acid are collectively known as eicosanoids. They 
are a large and ever-growing family of lipid mediators that are structurally distinct from 
other lipids as they made up of fatty acid chains that are 20 carbons long (“eicosa” in Greek 
means 20), and their synthesis is the result of the enzymatic metabolism by phospholipase 
A2 (PLA2) of a precursor molecule known as arachidonic acid (Figure 1.1). 




Figure 1.1 Overview of eicosanoid synthesis from precursor, arachidonic acid.  
Phospholipase A2 metabolises membrane phospholipids to arachidonic acid. Arachidonic 
acid can be further metabolised by lipoxygenase to produce leukotrienes, 
hydroxyeicosatetraenoic acids (HETEs) and lipoxins; by cyclooxygenase to produce 
prostaglandins and thromboxanes; by epoxygenase to produce epioxyeicosatrienoic acids 
(EETs). 
 
PLA2s are enzymes that prompt the de-esterification of phospholipids in order to yield 
lysophospholipids and arachidonic acid. They are abundantly expressed in humans and 
are utilised upon certain pathological and physiological stimuli. There are more than 20 
different PLA2s in mammals and these are divided into four groups. Secretory, calcium-
independent, platelet-activating factor (PAF) acetylhydrolyases, and cytosolic. Cytosolic 
PLA2 (cPLA2) has been shown to be the most important for eicosanoid production (1). 
They localise in the cytoplasm and upon cell activation, translocate to the nuclear 
membrane in a calcium-dependent manner. Despite calcium being essential for cPLA2 
functionality it is not required for the catalytic activity, unlike secretory PLA2s (2). At the 
nuclear membrane cPLA2 hydrolyses phospholipids in the sn-2 position (second carbon) 
with a specific preference for yielding arachidonic acid (1). Free arachidonic acid can then 
react with various enzymes to yield the metabolites known as eicosanoids (shown in 
Figure 1.1). Lipoxygenases produce leukotrienes, hydroxyeicosatetraenoic acids (HETEs) 
and lipoxins. Cyclooxygenases produce prostanoids (prostaglandins and thromboxanes) 
and finally epoxygenases, more specifically cytochrome P-450, produces 
epioxyeicosatrienoic acids (EETs). All eicosanoids can activate GPCRs which in the case of 
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cysteinyl leukotrienes can lead to various biological responses that have been implicated 
in many diseases such as asthma, atherosclerosis and cancer. 
 
1.1.2 G-protein coupled receptors and signal transduction 
GPCRs are the largest and most versatile family of transmembrane proteins within 
humans. They can mediate extracellular signals via intracellular interactions with 
heterotrimeric guanine nucleotide-binding proteins (G-proteins) to induce changes within 
the cell. This affects enzymes, ion channels and regulation of gene expression.  GPCR 
signalling is critical in many physiological processes. These include senses (taste, sight and 
smell), neurological, immunological, cardiovascular and reproductive functions and so it is 
not surprising that they make up nearly half of the molecular targets in the current market 
of therapeutic drugs (3). There have been several milestones in GPCR research, one of 
which being the sequencing of the human genome. This revealed that the GPCR family (or 
superfamily) contains more than 800 members, of which approximately 460 are predicted 
to be olfactory receptors. A large proportion of the GPCR superfamily currently have 
unknown functionality and are termed orphan receptors. Characterising these orphan 
receptors represents an interesting group of targets for pharmaceutical companies.  
The GPCR superfamily has been divided into 5 families based on amino acid sequence (to 
avoid confusion with GPCRs of similar names GPCR families will be denoted in italics);  
Rhodopsin (~700 GPCRs), Secretin (15 GPCRs), Glutamate (15 GPCRs), Adhesion (24 
GPCRs) and Frizzled/Taste family (24 GPCRs) (3). All five GPCR families share little amino 
acid sequence homology even in the Rhodopsin family, subfamilies α, β, γ and δ, share only 




X-ray crystallography has been a major development in GPCR research especially for 
structural determination. In 2000, bovine rhodopsin was the first GPCR to have its 
structure resolved (4). Up until 2007, GPCR structural research was focussed on computer 
modelling based on rhodopsin. Due to novel protein crystallisation approaches and wider 
access to x-ray crystallography, an almost exponential boom in resolved GPCR structures 
has been reported. Currently, there are just over 20 GPCRs with resolved structures, in 
which over two-thirds of them were published between 2012 and 2014 (Table 1.1). The 
majority of these GPCRs are from the Rhodopsin family but there are a few exceptions, 
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such as the glucagon receptor, GCGR, smoothened receptor, SMO and the metabotropic 
glutamate receptor, GRM1 from the Secretin, Frizzled and Glutamate families, respectively.  
 
Table 1.1 GPCRs with their structures resolved by x-ray crystallography or NMR 
spectroscopy.  
Receptor name Gene Species Year References 
Rhodopsin RHO Bovine/squid 2000-2013 (4-7) 
Β1 Adrenergic receptor ADRB1 Turkey 2008-2014 (8-12) 
Β2 Adrenergic receptor ADRB2 Human 2007-2014 (13-18) 
Adenosine A2A ADORA2A Human 2008-2012 (9,19-21) 
Chemokine CXCR4 CXCR4 Human 2005 (22) 
Dopamine receptor 3 DRD3 Human 2010 (23) 
Histamine receptor 1 HRH1 Human 2011 (24) 
Muscarinic M2 CHRM2 Human 2012-2013 (25,26) 
Muscarinic M3 CHRM3 Human 2012 (27) 
Kappa-opioid receptor OPRK1 Human 2012 (28) 
Mu-opioid receptor OPRM1 Mouse 2012 (29) 
Delta-opioid receptor OPRD1 Human/Mouse 2012-2013 (30,31) 
Nociceptin receptor OPRL1 Human 2012 (32) 
Protease-activated (PAR1) F2R Human 2012 (33) 
Neurotensin receptor 1 NTSR1 Human 2012-2014 (34,35) 
Chemokine CXCR1† CXCR1 Human 2012 (36) 
Sphinogosine-1 receptor 1 S1P1 Human 2012 (37) 
Glucagon receptor GCGR Human 2013 (38) 
Smoothened receptor SMO Human 2013-2014 (39-41) 
5-hydroxytryptamine HTR2B Human 2013 (42-44) 
Chemokine CCR5 CCR5 Human 2013 (45) 
Glutamate receptor GRM1 Human 2014 (46) 
Purinergic P2Y12 receptor P2RY12 Human 2014 (47,48) 
† structure resolved by NMR spectroscopy. Coloured backgrounds indicate GCPR family; 
Rhodopsin (blue), Secretin (green), Frizzled (purple), Glutamate (orange). 
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Despite low sequence homology, all GPCRs share a common structure comprised of 7 
transmembrane domains (TMs) that exist as α-helices, 3 extracellular and intracellular 
loops, an extracellular amino-terminus (N-terminus) and an intracellular carboxy-
terminus (C-terminus), shown in Figure 1.2A as a flattened representation. The free 
protein within the lipid bilayer forms a barrel-like structure, shown in Figure 1.2B, which 
creates a binding pocket for many ligands, although ligand binding does not exclusively 
occur at this site.  
 
Figure 1.2 Schematic of GPCR structure.  
(A) Flattened GPCR schematic to show characteristic structural features; amino-terminus 
(N-terminus), carboxy-terminus (C-terminus), 7 transmembrane domains, extracellular 
and intracellular loops. (B) Representation of the barrel structural confirmation that 
GPCRs naturally form in the lipid bilayer. Blue cylinders represent amino acid α-helixes, 
purple lines represent the lipid bilayer, NH2 (amino-) and COOH (carboxyl). 
 
Diversity within this common structure, which can occur in all parts of the GPCR structure 
(TMs, extracellular loops, side chains), allows variations within the size and shape of the 
GPCR, as well as binding pocket selectivity. These factors lead to a vast array of ligands 
that can activate these receptors. These ligands include photons, ions such as hydrogen 
and calcium, peptides, lipids, hormones and proteins. Generally, the sites in which the 
largest amount of diversity occurs in are within the C-terminus, the intracellular loop 
between TMs 5 and 6 and the N-terminus (49). The diversity in the C-terminus and the 
intracellular loops are thought to be almost exclusively related to intracellular signalling 
events, i.e. binding of the heterotrimeric G-protein. Diversity within the N-terminus differs 
from family to family and is more important in the Glutamate and Secretin family where 
the N-terminal tail can be 350-600 amino acids long, and even longer in the Adhesion 
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family where it is highly glycosylated to form rigid structures (50). Within the Rhodopsin 
family, N-terminal diversity is not as extensive as the other families but will usually occur 
in the extracellular loops.  
In terms of drug discovery, being able to predict the site of ligand binding would greatly 
improve rational drug design but the extensiveness of GPCR diversity makes this process 
very difficult. Unfortunately, ligand size alone is not a determining factor and having small 
molecules or ions as ligands does not necessarily mean that they will activate the receptor 
within the binding pocket. For example, the glutamate receptor, GRM1, has a “venus 
flytrap” module that consists of the N-terminal tail forming two lobes that exist in open 
and closed conformations for binding of its ligand, glutamate (51).  
 
GPCR activation 
One of the major paths in GPCR research has been to examine how ligand binding causes 
intracellular signalling. The current data supports a multi-state mechanism in which 
specific changes in the GPCR structure are key to the receptor’s activation (Figure 1.3).  
This builds on the original model of an inactive (R) and active (R*) state, introducing 
intermediary conformations (R’ and R’’) that are crucial to receptor activation. Rhodopsin, 
Adenosine A2A and β2 adrenergic receptor are three Rhodopsin family GPCRs that have had 
crystal structures resolved in a multitude of these conformational states (ligand free, 
bound by agonist, inverse agonist, antagonist, thermostabilised, nanobody stabilised, 
Table 1.1). GPCRs are believed to have a dynamic behaviour and certainly in the case of 
amino acids, movement does occur within the side chains irrespective of activation status 
(52). This means that proteins can have many structural conformations: both stable and 
unstable, but it is thought that due to the very nature of crystallisation only the more 
stable conformations have been resolved, and so there could be many other 
conformational states not yet identified (53). Surprisingly, even though sequence 
homology is low between Rhodopsin, Adenosine A2A and the β2 adrenergic receptor, 
common features in major conformational changes (i.e. helical shifts) have been identified 
for receptor activation. For example, the intracellular parts of TM 5 and 6 have been 
shown to shift in an outward direction in its activated state (9,54). It has also been 
demonstrated that there are backbone rearrangements in the TM 7, and some specific 
movements in TM 3. If there are common features in GPCR activation then this could help 
to explain how a range of ligands and receptors activate similar signalling cascades, but 
more research is required to fully elucidate such mechanisms.     




Figure 1.3 Schematic showing GPCR conformational states that lead to activation 
and signalling.  
R represents a GPCR in an inactive conformation, either unbound, bound to an inverse 
agonist or to an antagonist (not depicted). R’ represents a GPCR that has bound to its 
ligand (shown as green oval) with only minor conformational changes. R’’ represents an 
active GPCR. The ligand is bound and major conformational changes have occurred that 
allows the heterotrimeric G-protein to bind. R* is the GPCR in complex with the G-protein. 
A full signalling state is when GDP is released and replaced with GTP which allows 
intracellular signalling to occur. The double arrow signifies a reversible reaction and the 
single arrow is a one-way reaction.   
 
G-protein-dependent signalling 
G-proteins are the most common form of signalling for GPCRs. The G-protein is a 
heterotrimeric protein consisting of three subunits, α, β and γ (denoted as Gα, Gβ and Gγ, 
respectively), that are membrane-bound by lipid anchors on the Gα and Gγ subunits. Their 
name, guanine nucleotide-binding protein, arises from their mode of action. In an inactive 
state, guanosine diphosphate (GDP) is bound to the active site of the Gα subunit. Once a 
receptor has been activated and is within its R’’ conformational state, G-proteins can bind 
to the GPCR. Little is known about the interactions between the GPCR and the G-protein. X-
ray crystallography of GPCRs bound to their appropriate G-protein is difficult due to 
instability issues with and without a bound guanine nucleotide (15,55).  Crystallisation of 
the β2 adrenergic receptor with its G-protein revealed that only Gα interacts directly with 
the receptor while Gβ and Gγ aid stabilisation of the Gα complex (15). Site-directed 
mutagenic studies have identified that the third intracellular loop (Figure 1.2) and the C-
terminal tail are very critical for binding with the G-protein (56).  
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It is believed that binding of the G-protein to the receptor causes conformational changes 
within the Gα subunit (57). This then triggers the release of GDP which leaves an active 
site that has high affinity for guanosine triphosphate (GTP). When GTP binds to the active 
site of Gα this also causes conformational changes within the heterotrimeric protein and 
leads to the dissociation of Gα-GTP from the receptor, and also from Gβ and Gγ, which 
remain as a heterodimer (Gβγ). Gα-GTP and Gβγ, which are still membrane-bound, can 
then activate a range of downstream effector molecules. This process continues until the 
Gα subunit hydrolyses GTP into GDP and then Gα-GDP re-associates with Gβγ. There are 
21 different Gα subunits, 6 Gβ and 12 Gγ within humans (58). The Gα subunits are divided 
into four groups based on amino acid sequence; Gαq Gαs Gαi Gα12/13 and all activate specific 
effector molecules. All receptors signal via specific G-proteins and in certain instances they 
can signal via multiple G-proteins, usually Gαq and Gαi.   
Gαq signalling is most commonly associated with the activation of phospholipase Cβ (PLC-
β) and the influx of intracellular calcium (Figure 1.4). PLC-β is an enzyme that metabolises 
phospholipids. In this signalling cascade, the membrane-bound phospholipid 
phosphatidylinositol-4,5-biphosphate (PIP2) is broken down by PLC-β to form inositol-
1,4,5-triphosphate (IP3) and diacylglycerol (DAG) which causes an amplification of 
signalling as both IP3 and DAG can activate further signalling cascades (59). DAG will 
activate a protein kinase enzyme known as protein kinase C (PKC). There are many 
isozymes of PKC (alpha, beta, delta, epsilon, eta, gamma, lambda, mu, iota, theta and zeta) 
that are categorised depending on their signalling requirements (60,61). Conventional 
isozymes (alpha, beta and gamma) are calcium and DAG-dependent. Novel isozymes 
(delta, epsilon, eta, mu and theta) are independent of calcium but are activated by DAG 
and phosphatidylserine. Atypical isozymes (lambda and zeta) are thought to be 
independent of both calcium and DAG. Due to the vast array of PKC isozymes, multiple 
effector molecules can be activated, such as myosin phosphatase inhibitor, CPI-17, the 
glycogen synthase kinase 3β (GSK3β) and the kinase c-Raf-1 (62-64). Once again, these 
can activate multiple pathways which lead to gene transcription and regulation, but most 
of these have not been fully elucidated. However, c-Raf-1 can activate the mitogen-
activated protein kinase (MAPK) pathway, leading to Erk activation and translocation into 
the nucleus, where it can phosphorylate many transcription factors.    
 
 




Figure 1.4 Schematic representation of Gαq signalling pathway.  
Gαq can activate phospholipase Cβ (PLCβ) which converts phosphatidylinositol-4,5-
biphosphate (PIP2) to diacylgycerol (DAG) and inositol-1,4,5-triphosphate (IP3). DAG 
activates protein kinase C (PKC) which can activate multiple pathways; myosin 
phosphatase inhibitor (CPI-17), glycogen synthase kinase 3β (GSK3β), kinase c-Raf-1 and 
mitogen-activated protein kinase (MAPK). IP3 activates the IP3 receptor which depletes 
calcium (Ca2+) store which can activate multiple pathways including calmodulin and 
calcineurin. Black lined boxes indicate possible signalling pathways. 
 
The other pathway involves IP3 which is a unique inositol phosphate as its target is a 
channel (Figure 1.4). IP3R is a channel located on the endoplasmic reticulum and its main 
function is to regulate the calcium stores (65). On binding of IP3 to IP3R, major 
conformational changes occur within the channel which allow the release of calcium into 
the cytosol (66). This is a rapid process and fluxes in intracellular calcium can be detected 
within seconds of GPCR activation. Calcium can affect multiple pathways as well as 
proteins, such as calmodulin and calcineurin, which can regulate gene transcription.  
Gαs signalling is mostly associated with the generation of cyclic adenosine 3,5-
monophosphate (cAMP) (Figure 1.5). Gαs can activate membrane-bound adenylyl cyclase 
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which will then convert cytosolic adenosine triphosphate (ATP) into cAMP. cAMP can then 
activate exchange proteins activated by cAMP (EPACs) like cAMP-regulated guanine 
nucleotide exchange factors 1 and 2 (cAMP-GEFI and cAMP-GEFII) and the closely-related 
PDZ-guanine nucleotide exchange factor 1 (PDZ-GEFI) (67). These eventually lead to the 
activation of the MAPK pathway. cAMP can also activate the GTP exchange protein, protein 
kinase A (PKA), which is a tetrameric protein made up of two catalytic subunits. cAMP can 
bind these two subunits which causes a conformational change leading to the activation of 
this enzyme.  PKA can then activate the cAMP responsive element binding protein (CREB) 
which is a transcription factor (68). PKA can also inhibit certain pathways such as GSK3 
and α-adducin which are thought to be involved with oncogenesis and skeletal 
rearrangement, respectively (69). Gαs can also activate Src tyrosine kinase family 
members c-Src and Hck which are thought to be linked with the regulation of G-proteins 
and GPCRs (70). 
 
Figure 1.5 Schematic representation of Gαs and Gαi signalling pathways.  
Gαs can directly activate Src tyrosine kinase family members c-Src and Hck. It can also 
activate adenylyl cyclase which converts adenosine triphosphate (ATP) into cyclic 
adenosine monophosphate (cAMP) thereby activating multiple signalling pathways; 
guanine exchange factors (GEFs), kinases B-Raf and c-Raf, mitogen-activated protein 
kinases (MAPK), protein kinase A (PKA). PKA activates cAMP responsive element binding 
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protein (CREB) and inhibits multiple pathways including glycogen synthase kinase 3β 
(GSK3β) and α-adducin. Gαi inhibits adenylyl cyclase and can also activate multiple 
pathways including B-Raf, MAPK and the GTPase Rho. Red diamond ended lines indicate 
an inhibition of signalling pathway. Black lined boxes indicate possible signalling 
pathways. 
 
Gαi signalling pathways are commonly associated with the inhibition of cAMP production 
(Figure 1.5). Gαi will inhibit adenylyl cyclase and therefore reduce cytosolic levels of cAMP. 
This means that there will be a reduction in PKA activation and so Gαi can be considered a 
negative regulator. Gαi is also thought to be able to activate B-Raf which will lead to the 
MAPK signalling pathway and Rho which is thought to be involved with actin cytoskeleton 
rearrangement (71,72). Identification of this pathway has been refined by the inhibitor 
pertussis toxin. Pertussis toxin is produced by the bacteria Bordetella pertussis and works 
by inducing ADP-ribosylation of the Gαi subunit. This inhibits the interaction between Gαi 
and the receptor therefore inhibiting signal transduction (73).  
Gα12/13 is the least well characterised G-protein signalling pathway due to the difficulties in 
differentiating it from the other signalling pathways. It is most commonly associated with 
the activation of the Rho GEFs, and activation of the GTPase Rho is often cited as evidence 
for activation of this pathway (Figure 1.6). It is thought that Gα12/13 can also activate other 
pathways which involve Ras (and activation of MAPK pathway), the c-Jun N terminal 
kinases (JNKs) and directly the MAPK pathway through MEK5/Erk5 all of which lead to 
various regulations of gene transcription (74-76).  




Figure 1.6 Schematic representation of Gα12/13  and Gβγ signalling pathway.  
Gα12/13 can activate multiple pathways including the GTPase Rho, Ras, c-Jun N-terminal 
kinases (JNKK and JNK1) and the mitogen-activated protein kinase (MAPK) pathways (this 
includes MEK5 and Erk5). Gβγ inhibits and activates adenylyl cyclase (AC I and AC II) 
which produces cyclic adenosine monophosphate (cAMP) that can activate the protein 
kinase A (PKA) signalling pathway. It can activate the MAPK pathway through unknown 
(?) upstream effectors and activate phospholipase Cβ (PLCβ) and phosphoinositide 3-
kinase (PI3K) pathways. It also inhibits and activates ion channels for calcium (Ca2+) and 
potassium (K+) respectively. Red diamond ended lines indicate an inhibition of signalling 
pathway. 
 
The Gβγ heterodimer also has the ability to regulate specific effector molecules. This is a 
relatively new G-protein signalling pathway compared to the extensive research that has 
been carried out on Gα signalling and its physiological role is still to be elucidated. 
However the research to date has shown that Gβγ can activate and inhibit certain 
pathways such as ion channels, adenylyl cyclase and MAPK (although specific upstream 
effectors remain to be determined). It is also able to activate PLCβ which leads to IP3 and 
DAG production therefore depleting calcium stores and activating PKC signalling 
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pathways. Finally the phosphoinositide 3-kinase (PI3K) can be activated which leads to 
the protein kinase B (Akt) signalling cascade. It is important to note that all these 
signalling pathways are not activated at once. It is very dependent on the specific subunit 
being used and the constitutive expression level of any of the effector molecules within 
these signalling cascades (76).   
   
GPCR signal termination and G-protein-independent signalling 
Arrestins are a small family of proteins that can form complexes with GPCRs for the 
regulation of receptor function. There are four different arrestins; visual arrestin, cone 
arrestin, β-arrestin 1 and β-arrestin 2.  Visual and cone arrestins are located in the retina 
as they are involved with light receptor functions, whilst β-arrestins are ubiquitously 
expressed. After receptor activation and dissociation of the G-protein complex, GPCR 
kinases (GRKs) will phosphorylate the intracellular domains of the GPCR, which 
intrinsically reduces receptor activation (a form of desensitisation) (Figure 1.7). β-
arrestins can then bind to the intracellular part of the GPCR which blocks any further G-
protein binding to the receptor and so aids desensitisation of signal transduction. β-
arrestins will then target the GPCR to clathrin-coated pits, where β-arrestin will bind 
clathrin and the AP-2 adaptor complex, which can bind various elements of clathrin 
endocytic machinery such as dynamin. The receptor is endocytosised in clathrin-coated 
vesicles where it can undergo one of two processes. In the first process, the GPCR can be 
dephosphorylated and dissociate from its ligand, meaning that the receptor can be 
recycled back to the surface membrane. The second process is degradation by lysosomes. 




Figure 1.7 Schematic representation of GPCR signal termination and alternative G-
protein-independent signalling.  
Desensitisation - activated receptors are phosphorylated by GPCR kinases (GRKs). β-
arrestin binds the phosphorylated GPCR and targets clathrin coated pits. β-arrestin binds 
adapter protein 2 (AP-2) and clathrin (blue hexagonal shapes). The GPCR complex is 
endocytosed into endosomes or lysosomes. Degradation – The GPCR complex within the 
lysosome is degraded. Recycling – The GPCR complex within the endosome is 
dephosphorylated and the ligand dissociates. The GPCR is transported back to the surface 
membrane. Signal transduction - β-arrestin can activate multiple pathways including 
tyrosin kinase Src, mitogen-activated protein kinases (MAPK) and c-Jun N-terminal 
kinases (JNK). 
 
β-arrestins may also play a direct role in signalling, independent of G-proteins. Studies 
have shown that tyrosine kinase Src is able to directly bind β-arrestin (77). Recruitment of 
Src and other Src family members (Hck and Fgr) have been demonstrated in the rat K-Ras 
transformed kidney cell line, KNRK, and in human neutrophils towards the neurokinin-1 
receptor and CXCR1, respectively (78,79). This is not the only signalling pathway that was 
identified. In KNRK cells, stimulated protease-activated receptor 2 was found to form 
complexes with β-arrestin, Raf-1 and activated Erk1/2 (78). Activation of the angiotensin 
II type 1a receptor has been found to form complexes with other effector molecules, 
namely β-arrestin, Raf-1, MEK1 and Erk1 (80). β-arrestin has also been shown to act as a 
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scaffold of JNK by binding of the C- and N-termini respectively (81). The identification of 
such G-protein-independent GPCR signalling pathways contrasts with the “classical” view 
of GPCRs that is well established. Continued researched has strengthened this alternative 
picture and there is now a call to rename GPCRs, seven transmembrane receptors, 7-TMs 
(82).  
 
1.1.3 Discovery of cysteinyl leukotrienes and their synthesis 
Discovery 
More than 70 years ago Feldberg and Kellaway demonstrated that contractions of smooth 
muscle caused by treatment with various snake venoms were not wholly the result of the 
release of histamine but also the result of the enzymatic actions of venom to form a “slow-
reacting smooth muscle-stimulating substance” (83). The contractile actions of this 
substance on jejunum of sensitised guinea pigs resembled that of anaphylactic antigens, 
implying for the first time that histamine alone does not cause anaphylaxis, but instead a 
combination of both histamine and the “slow-reacting smooth muscle-stimulating 
substance” (84). By the 1960s Feldberg and Kellaway’s discovery was renamed the “slow-
reacting substance of anaphylaxis” (SRS-A) by Brocklehurst who showed that even in the 
presence of anti-histamines, SRS-A-induced potent bronchial constriction (85). These 
actions were shown to be pharmacologically distinct from other smooth muscle 
constriction causing agents such as bradykinin, 5-hydroxytryptamine (serotonin) and 
substance P (86).  
Elucidating the structure of SRS-A involved several spectroscopic and analytical tools from 
a multitude of research groups. Initial investigations were hampered by impure, low yield 
extraction methods but several groups were able to ascertain that SRS-A was a low 
molecular weight acidic lipid that contained sulphur and carboxylic acids with hydroxyl 
groups (87,88). Labelling techniques also concluded that the molecule incorporated 
arachidonic acid (89,90). A few years later, using SRS-A derived from calcium ionophore 
treated rat mastocytoma cells, the structure of SRS-R was finally identified as not one 
molecule, but three bioactive molecules (91,92).  As these three molecules were 
structurally related to other previously identified arachidonic acid metabolites derived 
from leukocytes, leukotriene A4 (LTA4) and leukotriene B4 (LTB4), and also contained three 
conjugated double bonds (a “triene”), they were termed leukotriene C4, D4 and E4 (LTC4, 
LTD4 and LTE4, respectively) (Figure 1.8).         
 




Leukotrienes are synthesised upon activation of many cell types, including mast cells, 
basophils, eosinophils, monocytes and macrophages. Cell activation initiates leukotriene 
production by inducing the translocation of cPLA2 to the nuclear membrane in a calcium-
dependent manner. cPLA2 can then hydrolyse phospholipids in the nuclear membrane 
with a specific preference for yielding arachidonic acid (Figure 1.8) (1). Free arachidonic 
acid then interacts with 5-lipoxygenase (5-LO) and 5-lipoxgenase-activating protein 
(FLAP). Like cPLA2, 5-lipoxygenase is regulated by calcium mobilisation and will 
translocate from the cytosol to the nuclear membrane upon cell activation (93). FLAP 
which is constitutively localised in the nuclear membrane, does not have any enzymatic 
activity but acts as a scaffold by binding arachidonic acid and enhancing substrate-enzyme 
interactions (94). Arachidonic acid metabolism by 5-lipoxygenase forms the unstable 
epoxide known as LTA4, which continues metabolism by one of two routes. Hydrolysis of 
LTA4 by LTA4 hydrolase (LTA4H) will convert LTA4 to LTB4 within the cytoplasm and 
potentially within the nucleus (95). The second pathway for LTA4 metabolism involves the 
enzymatic conjugation of reduced glutathione by LTC4 synthase (LTC4S) at the nuclear 
membrane. This yields the first of the cysteinyl leukotrienes, LTC4 (96). Both LTB4 and 
LTC4 are transported by specific chaperone proteins, namely multidrug resistance-
associated proteins (MRP4 and MRP1, respectively), to the cell surface where they are 
exported (97-99). LTB4 and LTC4 are not the only molecules that are transported across 
the cell membrane. It has been suggested that even LTA4 can be exported to other non-
leukocyte cells containing LTA4 metabolising enzymes. These “acceptor” cells, namely 
endothelial cells and potentially platelets, have the ability to restore leukotriene levels in 
the absence of leukotriene producing immune cells (100,101).  
In the extracellular space, LTC4 is in a peptide moiety and so can undergo further 
metabolism by sequential amino acid hydrolysis. Firstly, LTC4 reacts with γ-glutamyl 
transpeptidase (γ-GT) which removes glutamic acid to form LTD4 (102-104). Next, the 
glycine residue is removed from LTD4 by dipeptidase to produce the last of the cysteinyl 
leukotriene metabolites, LTE4 (105). As previously discussed, all leukotrienes can activate 
specific receptors, GPCRs. 




Figure 1.8 Schematic of leukotriene synthesis.  
Cytosolic phospholipase A2 (cPLA2) and 5-lipoxygenase (5-LO) translocate to the nuclear 
membrane upon cell activation. cPLA2 liberates arachidonic acid from the membrane 
which reacts with 5-LO and 5-lipoxygenase activating protein (FLAP) to yield leukotriene 
A4 (LTA4). LTA4 then reacts with either LTA4 hydrolase (LTA4H) or LTC4 synthase (LTC4H) 
to produce leukotriene B4 or C4 (LTB4 and LTC4). LTB4 and LTC4 are transported 
extracellularly where LTC4 undergoes sequential amino acid hydrolysis by γ-glutamyl 
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1.1.4 Cysteinyl leukotriene receptors 
Despite the identification of the structure of cysteinyl leukotrienes in 1979, cloning of 
specific cysteinyl leukotriene receptors proved difficult and it took a further two decades 
before the first receptor was reported. In fact, receptor antagonists such as Montelukast 
(Singulair®), Pranlukast (Onon®, Azlaire®), Zafirlukast (Accolate®), MK-571 and BAY-
U9773 were all developed prior to the cloning of any cysteinyl leukotriene receptor (106-
110).  The pharmacological activity of these antagonists led a committee appointed by the 
International Union of Pharmacology (IUPHAR) to characterise two classes of cysteinyl 
leukotriene receptors. The first was sensitive to the inhibitory actions of the so-called 
“classical” antagonists (Montelukast, Pranlukast, Zafirlukast and MK-571) and hence 
denoted the nomenclature CysLT1. The second class was insensitive to these classical 
antagonists and was termed CysLT2. BAY-U9773 was the only antagonist that could inhibit 
the actions of both these classes of receptor. 
Early pharmacological data showed that Gpp(NH)p, a stable analogue of GTP, was able to 
alter LTD4 ligand binding. Modification of such binding was also seen with divalent cations 
and sodium ions (enhancement and inhibition respectively) strongly suggesting that 
cysteinyl leukotriene responses were mediated by GPCRs (111,112).  In 1999, using 
reverse pharmacological approaches, i.e. using the receptor to identify the ligand instead 
of the ligand to identify the receptor, these observations were confirmed. Two 
independent groups identified the orphan GPCR, HG55 (also termed HMTMF81), as a 
receptor for cysteinyl leukotrienes (113,114). The receptor’s responses were sensitive to 
the classical antagonists and thus the receptor was renamed CysLT1. A year later 3 
independent groups identified the orphan GPCR, HG57 (also termed PSEC0146) as a 
second cysteinyl leukotriene receptor that was insensitive to the classical antagonists and 
it was named CysLT2 (115-117).  
CysLT1 and CysLT2 are part of the Rhodopsin family of GPCRs and more specifically, part of 
the purine receptor cluster (on the δ branch). CysLT1 shares 38 % homology with CysLT2 
based on amino acid structure and they are highly conserved when compared to the 
mouse versions (88 % and 73 % amino acid homology respectively). Cysteinyl leukotriene 
receptors share a higher homology with the purinergic receptors (P2Y family) than the 
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CysLT1 characterisation and expression 
The human CysLT1 gene, now known as CYSLTR1, is located on the long arm of the X 
chromosome at position Xq13.2-q21.1 (Table 1.2). The major transcript contains three 
exons in which the last exon contains the open reading frame which encodes a 337 amino 
acid structure (118).  
 
Table 1.2 Characteristics of known and potential cysteinyl leukotriene receptors.  
  CysLT1 CysLT2 P2Y12 OXGR1 
Gene Name         
Hs CYSLTR1 CYSLTR2 P2RY12 OXGR1 
Mm Cysltr1 Cysltr2 P2ry12 Oxgr1 
      
Chromosome     
Hs Xq13.2-q21.1 13q14.2 3q24-q25 13q32.1 
Mm X D 14 D3 3 D 14 E4 
      
NCBI seq. no.     
Hs NP_006630 NP_065110 NP_073625 NP_543008 
Mm NP_067451 NP_598481 NP_081847 NP_001001490 
       
Homology         
Hs vs. Mm 88 % 73 % 89 % 85 % 
Hs-R vs. Hs-
CysLT1 
- 38 % 26 % 28 % 
       









HAMI 3379 Clopidogrel 
  
Hs, Homo sapiens; Mm, Mus muscularis; seq., sequence; no., number; vs., versus; R, 
receptor. Information obtained from NCBI and IUPHAR databases (119). Homologies were 
calculated using NCBI BLAST Align (120). P2Y12 and OXGR1 will be discussed in Chapter 3. 
Northern blot analysis of CYSLTR1 expression has indicated that receptor expression is 
highest in peripheral blood leukocytes and in the spleen (113,114). To a lesser extent, 
expression has also been detected in the lungs, placenta, gastrointestinal system, heart, 
pancreas and prostate. There is little or no expression of CysLT1 in the liver, kidney, 
skeletal muscle or brain. Functional CysLT1 expression has been reported in many cell 
types and has been summarised in Table 1.3.  
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Table 1.3 Cell types functionally expressing human CysLT1.  




Dendritic cells (124) 
CD34+ hematopoietic progenitors (122) 
Mast cells (125) 
B lymphocytes (122) 
Lung fibroblasts (126) 
Astrocytes (127) 
Vascular smooth muscle (128) 
Intestinal epithelial cells (129) 
Th2 cells (130) 
Lung type 2 innate lymphoid cells (131) 
References indicated are initial papers showing functional expression. 
CysLT1 is a receptor for all three cysteinyl leukotrienes, LTC4, LTD4 and LTE4 but 
characterisation of their responses has revealed varying affinities. Analysis of intracellular 
calcium mobilisation in transfected HEK293 cells showed EC50s of 24 nM, 2.5 nM and 240 
nM for LTC4, LTD4 and LTE4 respectively and similar affinities were observed in 
transfected Cos-7 cells, showing that the rank order of ligands for CysLT1 to be 
LTD4>LTC4>LTE4 (113,114).  This order of ligand affinities has also been observed when 
pigment dispersion was analysed in CysLT1 transfected melanophores, EC50 0.4 nM, 21 nM 
and 212 nM (LTD4, LTC4 and LTE4 respectively) (113). LTC4 and LTD4 were able to 
produce similar maximal responses while responses to LTE4 were shown to be about 40 % 
of the maximum (114). This has led to the suggestion that LTE4 works as a “partial” 
agonist (i.e. unable to reach maximum response of LTC4 and LTD4), unlike LTC4 and LTD4 
which are “full” agonists, this is in agreement with early work on human pulmonary vein 
preparations (132). 
As already noted, CysLT1 induces intracellular calcium mobilisation. This is typically a 
second messenger for Gαq-related signalling, and in the initial characterisation studies by 
Lynch et al. and Sarau et al. it was shown that calcium mobilisation in transfected human 
embryonic kidney 293 (HEK293) cells and cRNA injected oocytes were unaffected by 
pretreatment of pertussis toxin, a specific inhibitor of Gαi (pertussis toxin mode of action 
described in section G-protein-dependent signalling), suggesting that CysLT1 couples to 
Gαq only. However, further studies using several different cell types have observed 
                                                                                                                                                     Introduction 
39 
 
CysLT1-dependent responses being sensitive to pertussis toxin treatment. For example, in 
a recent study showing that human Th2 cells selectively express CysLT1, LTD4-induced 
intracellular calcium mobilisation was partially inhibited by about 50 % with pertussis 
toxin treatment. The involvement of Gαi coupling was confirmed by LTD4’s ability to also 
inhibit forskolin-induced cAMP (130). These observations have also been confirmed in the 
human monocytic cell lines, THP-1 and dU937, where LTD4-induced calcium mobilisation 
was partially inhibited by pertussis toxin, suggesting in certain cell systems CysLT1 can 
couple to both Gαq and Gαi (133).  It has also been observed in human elutriated 
monocytes that pertussis toxin can completely inhibit LTD4-induced calcium mobilisation, 
gene expression and chemotaxis suggesting a Gαi only coupled CysLT1 (134). Such 
differences in observed responses could be due to constitutive expression levels of these 
G-proteins differing from cell type to cell type. Downstream signalling will be discussed 
further in Chapter 6. 
 
CysLT2 characterisation and expression 
The CysLT2 receptor gene, also known as CYSLTR2, is located on chromosome 13q14.2 
(Table 1.2). There are six exons within the CYSLTR2 gene in which exons 1-5 are located in 
the untranslated region and exon 6 contains the full coding region with no introns. This 
encodes a protein of 346 amino acids long. Eight transcripts have been identified in which 
exons 1 and 6 are always present and expression seems to be cell type dependent (135). 
CysLT2 shares only 38 % homology with CysLT1 and 73 % homology with the mouse 
version when comparing amino acid sequences (Table 1.2).  
Northern blot analysis has identified a very distinct pattern of CYSLTR2 expression from 
CYSLTR1 with only few exceptions. The most striking differences are within the heart and 
the central nervous system (115-117). In situ hybridisation revealed Purkinje fibre cells, 
monocytes and fibroblasts derived from the brain, atrium and adrenal glands to be 
expressing CYSLTR2. Extensive northern blot analysis has revealed high CYSLTR2 
expression throughout the central nervous system, including medulla, mid-brain, 
hypothalamus, amygdala, pituitary, putamen and the frontal cortex. The hippocampus 
showed no CYSLTR2 expression. Such extensive expression within the brain and heart is 
in stark contrast with CYSLTR1, although immunohistochemistry analysis of brain tissue 
has found that CysLT1 expression level is increased in neuron- and glial-appearing cells 
around the site of injury or tumour (136). Moderate expression has also been seen in the 
spleen and peripheral blood leukocytes (115). Unfortunately due to the previous lack of 
any selective CysLT2 antagonists (HAMI 3379 the selective CysLT2 antagonist was first 
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characterised in 2010 (137)), cells functionally expressing CysLT2 are poorly defined 
(Table 1.4). 
 
Table 1.4 Cell types functionally expressing human CysLT2.  
Cell Type Reference 
Coronary artery smooth muscle cells (138) 
HUVECs (135,139) 
Mast cells (140) 
Human umbilical vein endothelial cells (HUVEC). References indicated are initial papers 
showing functional expression. 
The initial papers on CysLT2 by Heise et al., Nothacker et al. and Takasaki et al., analysed 
the second messenger signalling cue, calcium, to characterise receptor responses. All three 
cysteinyl leukotrienes induced intracellular calcium mobilisation in transfected HEK293 
cells with varying affinities (summarised in Table 1.5). All studies concluded that the rank 
order of ligand affinities were LTC4=LTD4>>LTE4 with LTC4 and LTD4 acting as full 
agonists and LTE4 as a partial agonist (115-117). LTE4’s partial agonist properties were 
also observed in human coronary smooth muscle cells (138).   
 
Table 1.5 EC50 for cysteinyl leukotriene induced intracellular calcium mobilisation 
in HEK293 cell transfected with CysLT2. 
Study LTC4 EC50 LTD4 EC50 LTE4 EC50 
Heise et al. (115) 67 nM 104 nM 2300 nM 
Nothacker et al. 
(116)  
8.9 nM 4.4 nM 239 nM 
Takasaki et al. (117) 2.31 nM 2.53 nM 76.8 nM 
 
As CysLT2 also induces intracellular calcium mobilisation, similar to CysLT1, it was 
important to ascertain whether this was through coupling to Gαq, Gαi or both. LTC4 and 
LTD4-induced intracellular calcium mobilisation in cRNA injected Xenopus Laevis oocytes 
were not significantly affected by pertussis toxin treatment (115). In human umbilical vein 
endothelial cells (HUVECs) LTC4-induced intracellular calcium mobilisation and early 
growth response protein-3 (Egr-3) mRNA upregulation was not affected by pertussis toxin 
treatment. This suggests that CysLT2 couples to Gαq only (135,139). Unfortunately, in 
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human mast cells LTC4-induced IL-8 secretion was completely abrogated by pertussis 
toxin treatment, suggesting that CysLT2 could also couple to Gαi, and the ability of CysLT2 
to couple to Gαq, Gαi or both may be cell-type specific, as for CysLT1 (140). 
CysLT2 is a poorly characterised receptor and thus analysis of specific signalling pathways 
is limited. In HUVEC cells, LTC4-induced Egr mRNA expression was partially inhibited by 
the PLCβ inhibitor, U73122, and was fully inhibited by the IP3 inhibitor, 2APB, but not by 
pertussis toxin, suggesting that CysLT2 regulates Egr via a Gαq, PLCβ, IP3 signalling 
pathway (135). In a HEK293 cell line stably expressing CysLT2, LTC4 induced the 
phosphorylation of c-Jun and JNK, but the specific JNK inhibitor SP600125 curiously was 
unable to affect either observation (141). Within this cell type PKC epsilon dominant 
negative constructs inhibited p65 phosphorylation which could be involved in the 
activation of NF-κB signalling pathways (141). Egr-3 and -4 has been shown to interact 
with NF-κB p50 and p65 and so there could be some overlap between these two studies 
(142).  Unfortunately, more research needs to be carried out to fully elucidate CysLT2 
signalling pathways. 
 
Cysteinyl leukotriene receptor immunoregulation 
CysLT1 
The Th2 and mast cell cytokine IL-5 was the first mediator shown to modulate CysLT1 
expression and function. In a myeloid leukaemia cell line (HL-60) differentiated into 
eosinophils, IL-5 was able to upregulate CysLT1 expression level, confirmed at an mRNA 
and protein level using flow cytometry (121). This increase in CYSLTR1 mRNA was 
inhibited by the antibiotic actinomycin D (by blocking new RNA synthesis) which suggests 
that IL-5’s regulation of CysLT1 occurs through a transcriptional mechanism. Upregulation 
of CysLT1 by IL-5 at a protein level has also been seen in peripheral blood isolated 
eosinophils, although increases at an mRNA level were not statistically significant (143). In 
the differentiated HL-60 cell line, LTD4-induced intracellular calcium mobilisation and 
chemotaxis increased in cells that had been pretreated with IL-5 (121). These responses 
were fully inhibited by the selective CysLT1 antagonist MK-571 proving that these 
responses were specifically attributed to CysLT1.  
IL-4, another cytokine commonly associated with Th2 cells, also released by basophils, 
mast cells and eosinophils, is another molecule linked to CysLT1 regulation. In monocytes 
and monocyte-derived macrophages, IL-4 treatment was able to upregulate CysLT1 
expression in a concentration and time-dependent manner, confirmed at both an mRNA 
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and protein level (118,123,143,144). This has also been observed in eosinophils, T cells 
and B cells (143). The functional consequence of receptor upregulation has been 
confirmed using various assays. LTD4-induced calcium mobilisation was increased with IL-
4 pretreatment in monocytes and T cells (123,143). Chemotaxis assays have shown that 
the weakly chemotactic behaviour of monocytes towards LTD4 can be augmented with IL-
4. LTC4 and LTD4-induced CCL2 production by the monocytic cell line THP-1 can also be 
increased several fold by IL-4 pretreatment (118,123). All functional assays showed that 
the LTD4-induced responses were completely inhibited by MK-571. In bronchial smooth 
muscle cells, IL-4 was unable to increase CysLT1 surface expression but increased LTD4-
induced cell proliferation.  
IL-4 has also been implicated in the “priming” of mast cells. Although there were no 
detectable changes in CysLT1 expression and only modest CysLT2 surface expression 
changes, IL-4 pretreatment of cultured human mast cells induced the release of TNF-α, IL-
5 and CCL4 in response to LTC4 and LTD4 (125,140,145). These responses were inhibited 
by MK-571 suggesting the involvement of CysLT1 or “CysLT1 like receptor”. STAT6 has 
been shown to play an essential role in IL-4 signalling (146,147). The CysLT1 gene 
promoter region has two STAT6 binding sites which could help to explain IL-4’s activity.  
In B cells, IL-4 alone is unable to affect CysLT1 expression but co-stimulation with CD40 
(crucial for B cell activation) or with irradiated CD154-transfected murine fibroblasts 
(mimics in vivo environment and stimulation within the germinal centre), upregulates 
CysLT1 expression, confirmed by mRNA and flow cytometry (148). This co-stimulatory 
effect is also seen with IL-13 instead of IL-4. LTD4-induced intracellular calcium 
mobilisation is enhanced by this co-stimulation of CD40 and IL-4 and is completely 
inhibited by Montelukast. 
IL-13, another Th2 cytokine, has also been shown to upregulate CysLT1 at both mRNA and 
protein levels in monocytes, monocytes-derived macrophages, human foetal lung 
fibroblasts (HFL-1), bronchial smooth muscle cells and eosinophils, but had no effect on T 
cells or B cells (123,126,143,144,149). In monocytes these observations were functionally 
confirmed with intracellular calcium mobilisation and chemotaxis assays (123). IL-13 can 
also signal through STAT6 and so may work in a similar mechanism to IL-4. 
In human airway smooth muscle, LTD4-induced cell stiffness was enhanced by 
pretreatment with interferon-γ (IFN-γ), a cytokine secreted by Th1 cells, although IFN-γ 
was shown to have no effect on CysLT1 mRNA levels in monocytes and monocyte-derived 
macrophages (123,150). 
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Not all cytokines upregulate CysLT1 expression. IL-10 can downregulate CysLT1 and 
CysLT2 mRNA in monocytes and monocyte-derived dendritic cells (DCs). Functional assays 
observing intracellular calcium mobilisation, FosB and Egr-2 gene expression and 
chemotaxis showed an inhibition of LTD4-induced responses in cells that had been 
pretreated with IL-10 that was not too dissimilar from that of MK-571. This shows that 
CysLT1 is a highly-regulated receptor affected extensively by a plethora of Th2 cytokines 
and some Th1 cytokines. This could have huge implications when studying diseases such 
as asthma, where both cysteinyl leukotrienes and Th2 cell associated cytokines are 
thought to play critical roles in many of the key pathogenic pathways. 
 
CysLT2 
Information on the immunoregulation of CysLT2 is limited, mainly due to the very few cell 
types that are thought to functionally express CysLT2 only, and the lack of CysLT2 selective 
antagonists. In HUVECs, cultured primary endothelial cells and eosinophils, IFN-γ has been 
shown to upregulate CysLT2 mRNA in a dose-dependent fashion while CysLT1 mRNA 
levels were unaffected (135,151). In HUVECs, LTC4 and LTD4-induced calcium mobilisation 
and LTC4-induced Egr and COX-2 gene expression was enhanced by pretreatment with 
IFN-γ (135). These responses were not inhibited by MK-571 suggesting CysLT2 receptor 
involvement.  
IL-1β and TNFα have been shown to decrease CysLT2 mRNA in HUVECs but contrasting 
studies have shown that these cytokines, as well as TGF-β1, have no effect on receptor 
mRNA level (152,153).  
The fact that both CysLT1 and CysLT2 expression levels are so readily affected by other 
mediators highlights the importance of considering immunoregulation, especially when 
analysing cysteinyl leukotriene responses in primary cultured cells. These may not reflect 
the “true” responses that are seen in vivo since receptor expression level may be altered. 
 
1.1.5 Cysteinyl leukotrienes in asthma 
Asthma is a chronic respiratory disease that presents as variable airway obstruction 
associated with airway hyperresponsiveness and inflammation in response to various 
stimuli. The pathogenesis of asthma involves many different mediators, cell types and 
genetic variations that unfortunately vary from asthmatic to asthmatic and the exact cause 
remains poorly determined. Cysteinyl leukotrienes are produced by an array of different 
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cells (Figure 1.9) and have been shown to be important in many of the key phenotypes 
that define asthma. These include vascular permeability, increased airway smooth muscle 
proliferation and contraction, acting as chemotactic agents for the recruitment of 
inflammatory cells, increased mucus secretion and decrease in mobility, and finally 
increase of airway hyperresponsiveness (Figure 1.9).  
 
 
Figure 1.9 Schematic representation of the role of cysteinyl leukotrienes in asthma.  
Neutrophils, eosinophils, basophils, mast cells, monocytes, macrophages and by the 
transcellular metabolism of leukotriene A4 (LTA4), platelets and endothelial cells can 
produce cysteinyl leukotrienes. Cysteinyl leukotrienes can induce increased vascular 
permeability, airway smooth muscle contraction and proliferation, recruitment of 
inflammatory cells, increase of mucus secretion and bronchial hyperresponsiveness. 
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Increased vascular permeability 
Plasma leakage and mucosal oedema are features of many inflammatory diseases, 
including asthma. It precedes airway inflammation and exacerbates bronchial constriction 
by causing oedema of the airway wall and narrowing of the airway lumen (154). Cysteinyl 
leukotrienes were first implicated in vascular permeability when partially purified rat 
SRS-A was shown to be able to augment vascular permeability when it was injected into 
the skin of guinea pigs (155). The three individual components of SRS-A, LTC4, LTD4 and 
LTE4 were then individually shown to induce leakage of the microvasculature within in 
situ guinea pig tracheal preparation, quantified by extravascular Evans blue dye (156). 
These responses were not inhibited by indomethacin, an inhibitor of cyclooxygenase, or 
mepyramine, a histamine H1 receptor antagonist, suggesting neither cyclooxygenase 
metabolites nor histamine were indirectly involved (156,157).  
In LTC4S-/- knockout mice (LTC4S is a key enzyme in cysteinyl leukotriene production), 
vascular permeability was significantly reduced after antigen challenge (158). In CysLT1-/- 
and CysLT2-/- knockout mice, reduced vascular permeability was also observed after 
antigen challenge. Although the exact mechanism is not fully understood, these studies 
further highlight the importance of cysteinyl leukotriene signalling pathway in the 
induction of vascular permeability (159). 
 
Airway smooth muscle contraction and proliferation 
Alterations in airway smooth muscle (ASM) function by hyperplasia, hypertrophy and 
possibly increased contractility are thought to contribute to asthma pathogenesis. 
Cysteinyl leukotrienes are potent bronchial constrictors and it has been shown in vivo that 
C4 and D4 are ~1000 times more potent than histamine at causing bronchial constriction 
in healthy individuals (160). Unfortunately, the direct mechanism of cysteinyl leukotrienes 
effect on airway smooth muscle has yet to be elucidated and responses in ASM cells do not 
entirely reflect that of the response observed in vivo. 
The first study implicating cysteinyl leukotrienes in ASM proliferation by Noveral et al.  
analysed the mechanism of thromboxane-induced ASM proliferation in cultured rabbit 
ASM (161). This study revealed that the mitogenic responses of thromboxane could be 
abrogated by inhibitors of PLA2, 5-lipoxygenase and cysteinyl leukotriene receptor 
antagonists. Thromboxane’s actions were shown to induce the release of endogenous 
cysteinyl leukotrienes, in which LTD4 was able to induce proliferation of the rabbit ASM 
(161). These results were supported by a study that used OVA-sensitised Brown Norway 
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rats to analyse the effect of allergen challenge on ASM mass (162).  Repeated OVA 
challenge increased ASM mass in the large airways of these rats compared to saline. This 
OVA-induced increase was partially inhibited by MK-571, suggesting that ASM 
proliferation (hyperplasia) is partly mediated via a MK-571 sensitive receptor (162). 
Accomazzo et al. also showed that strips of human bronchus are able to exhibit 
contraction to a similar level as histamine but LTD4 was a far more potent agonist. 
However, when analysing ASM cultured from the same organ, LTD4 was significantly less 
effective at inducing intracellular calcium mobilisation than histamine (the 
phosphorylation of myosin light chain by calcium is a major pathway in ASM contraction) 
(163). This adds to a growing body of evidence that LTD4 alone is unable to alter ASM 
function in cultured cells. In human cultured ASM, LTD4 could only increase proliferation 
in the presence of the growth factor epidermal growth factor (EGF) (164). Similar 
responses have been seen in rabbit tracheal ASM with insulin growth factor-1 (IGF-1) and 
human ASM with IL-13 and TGF-β (149,165).  
This could suggest that immunoregulation is playing a large role in cysteinyl leukotriene 
responses and the reason why in vivo observations do not quite match with in vitro may be 
due to regulation of leukotriene receptor expression. This type of immunoregulation has 
already been seen in human cultured ASM by IFN-γ, which was able to enhance LTD4-
induced ASM cell stiffness. Cultured ASM would be devoid of these growth factors and 
cytokines that would be naturally present at a tissue level. 
 
Recruitment of inflammatory cells 
Increasing emphasis has been put on respiratory inflammation in asthma, especially with 
the use of corticosteroids (used to relieve inflammation) in the treatment of this disease. 
Inflammation can occur in acute phases, usually associated with asthma attacks, where 
severe narrowing of the airways (and increased mucus secretion) leads to difficulties in 
breathing and chronic inflammation. This is associated with persistent inflammation of the 
airways which increases its sensitivity to a variety of mediators. Cysteinyl leukotrienes 
have been shown to contribute to inflammation through the recruitment of specific cell 
subsets both in vivo and in vitro.  
OVA-sensitised guinea pigs have been shown to have an increase in eosinophils in the 
airway mucosa after OVA challenge. This OVA-induced eosinophilia was inhibited by MK-
571 but was not affected by the histamine H1 and H2 antagonists, mepyramine and 
cimetidine or indomethacin (166). In cynomolgus monkeys, the cysteinyl leukotriene 
receptor antagonist, IC1 198615, was able to inhibit both eosinophil and peripheral blood 
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lymphocyte infiltration into the bronchial alveolar lavage fluid (BAL) upon antigen 
challenge (167). Finally in OVA-sensitised C57B1/6 mice, MK-571 was able to significantly 
inhibit total cell number within the BAL which specifically included the infiltration of 
eosinophils, CD8 and B cells (168). As all of these responses are sensitive to cysteinyl 
leukotriene receptor antagonists, this directly associates cysteinyl leukotrienes with 
inflammatory cell recruitment and is further supported by studies showing that inhalation 
of cysteinyl leukotrienes (LTC4, LTD4 and LTE4) can induce an increase in eosinophils in 
BAL and airway mucosa shown in vivo in animal models and in human studies (169-172). 
Data suggests that cysteinyl leukotrienes are inducing inflammatory cell recruitment via 
both direct and indirect mechanisms. In the direct mechanism, cysteinyl leukotrienes are 
acting as chemotactic agents. This has been shown for LTD4 with isolated human 
eosinophils and Th2 cells using a Boyden chamber to quantify migration (173-175). The 
indirect mechanism involves “priming” of these cells. It has also been observed that all 
cysteinyl leukotrienes can upregulate the adhesion molecule, macrophage adhesion 
ligand-1 (Mac-1), a process which is inhibited by Montelukast (174). Finally, LTD4 (LTC4 
and LTE4 were not tested) can increase eosinophil adhesion which can be blocked by an 
anti-β2 integrin antibody and also by Pranlukast (175). This suggests that cysteinyl 
leukotrienes are not only directly involved in cell migration but can also affect the 
regulation of eosinophil adhesion molecules which are crucial elements in tissue 
infiltration.  
   
Increased mucus secretion 
Pathological analysis of individuals that have died from acute asthma attacks revealed 
hyperinflation caused by mucus plugs in the airways (176). These mucus plugs are 
thought to be formed in severe asthmatics due to enhanced mucus secretion and 
disruption of mucus transport.  
OVA-sensitised guinea pig tracheas were labelled with 35SO to quantify mucosal output. 
OVA challenge significantly increases 35SO output and this increase was similarly observed 
upon LTD4 challenge. Both increases in mucosal outputs were inhibited by Pranlukast and 
Zafirlukast (177).  In another study analysing mucus production in guinea pig trachea, 
challenged animals were euthanized and the dissected tracheas were stained with alcian 
blue-periodic acid Schiff to quantify mucus secretion (178). LTD4 challenge increased 
mucus secretion which was inhibited by the cysteinyl leukotriene receptor antagonist, 
Pobilukast. In several studies using human airway mucosa explants it has been observed 
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that both LTC4 and LTD4 can increase mucus secretion which was inhibited by the 
cysteinyl leukotriene receptor antagonist, FPL55712 (179-181). 
It has also been shown in the human airways that cysteinyl leukotrienes can affect mucus 
transport. It was observed in asthmatic individuals that the decrease in tracheal mucus 
velocity induced by antigen challenge could be inhibited by FLP55712 (182). LTC4 and 
LTD4 have been shown to significantly decrease human cilia beat frequency and similarly 
to the in vivo study, were inhibited by FLP55712 (183). However, in contrast to this study, 
scanning electron microscopy used to access cilia activity revealed that LTD4 did not 
decrease cilia mobility but  decreased orientation leading to cilia dysfunction (184). 
The exact mechanism of how cysteinyl leukotrienes affect mucus production and transport 
has still to be elucidated but it has recently been shown in goblet cells isolated from rat 
and human conjunctiva that all cysteinyl leukotrienes can induce mucus secretion which 
was inhibited by MK-571 (185). 
 
Bronchial hyperresponsiveness 
Airway hyperresponsiveness (AHR) is the main characteristic feature of bronchial asthma 
and presents itself as an induction of bronchial constriction by inhalation of allergens or 
agonists that are not active on airways of healthy individuals. The role of cysteinyl 
leukotrienes in AHR is poorly understood. However, studies have shown that asthmatic 
airways are especially hyperresponsive to LTE4 and this will be further discussed in 
section 1.1.7 The third cysteinyl leukotriene receptor. 
 
1.1.6 Cysteinyl leukotrienes antagonists to treat asthma 
A range of drugs exists that can be used in the treatment of asthma including inhaled 
corticosteroids, long-acting β2 agonists and anti-leukotriene drugs. There are two classes 
of anti-leukotriene drugs; leukotriene synthesis pathway inhibitors and cysteinyl 
leukotriene receptor antagonists (LTRAs). Unfortunately, leukotriene synthesis inhibitors 
have been marred by adverse side effects: Zileuton and MK-0633 are inhibitors of the 
enzyme 5-lipoxygenase, and both have been shown to induce hepatotoxicity (186,187). In 
one trial of MK-0633, the study was permanently terminated due to dose-dependent 
increases in alanine aminotransferase and aspartate aminotransferase (187). 
GSK2190915 is a promising 5-lipoxygenase activating protein inhibitor that is already in 
phase II clinical trials and has shown no significant adverse effects on hepatic function 
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(188). LTRAs include Montelukast, Zafirlukast and Pranlukast which are selective CysLT1 
antagonists. Montelukast is generally the favoured LTRA in clinical use within the UK. 
There are no CysLT2 antagonists in clinical use and the role of CysLT2 in the pathogenesis 
of asthma is not clear. 
Due to heterogeneity of asthma and patient to patient variability in response to treatment, 
certain guidelines have been introduced to aid management using first-line and add-on 
therapies (189). 
 
First-line therapy     
Inhaled corticosteroids are considered the standard first-line therapy in the treatment of 
asthma, irrespective of severity. LTRAs have been shown to significantly reduce 
exacerbations and improve symptom scores (compared to placebo) in chronic asthma but 
are generally considered inferior to corticosteroids and are mainly used as an add-on 
therapy (190,191). In a meta-analysis of randomised controlled trials where Montelukast 
was used as a therapy for asthma in adults, including 20 trials in chronic asthma and 6 
trials in acute asthma, Montelukast was inferior at reducing exacerbations compared to 
inhaled corticosteroids alone,  and to the combination of inhaled corticosteroids and long-
acting β2 agonists (192).    
However, LTRAs are considered an acceptable first-line therapy for asthmatics under 5 
who are unable to take inhaled corticosteroids (189). Several trials have been carried out 
comparing LTRAs with inhaled corticosteroids as first-line therapies for treatment of mild 
persistent asthma in children. Garcia et al. have compared Montelukast treatment with 
fluticasone (a corticosteroid) in a 52 week, multicentre, randomised, double blind trial in 
children aged 6-14 years old (193). Both therapies were well accepted and Montelukast 
increased to a similar extent the number of “rescue free days” (days without asthma 
rescue medication or asthma related resource use) as fluticasone (22.4 % vs. 25.2 %; 
Montelukast vs. fluticasone). Although, there were secondary end points that favoured 
fluticasone over Montelukast (for example, there were fewer incidences of asthma attacks 
and less requirement for systemic corticosteroids) it was noted that fluticasone treated 
children were on average significantly shorter in height after the 52 week trial compared 
to Montelukast. 
In an open label, randomised, active-controlled, multicentre trial, Montelukast was 
compared to Budesonide (another inhaled corticosteroid) as a first-line therapy in 
children aged 2-4 years with mild persistent asthma (194). Similar to the Garcia et al. trial, 
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there were no significant differences in primary outcomes such as time to first additional 
medication, and both were considered an acceptable therapy for asthma control. However 
there were again higher incidences of the requirement for oral corticosteroids at 52 weeks 
in the Montelukast group compared to the Budesonide group. 
Recently, Montelukast and Budesonide have been compared as a first-line therapy in a 12 
week trial in children and adolescents aged 2-18 years (195). This was a multicentre, 
randomised and controlled trial with individuals exhibiting mild persistent asthma. There 
was a significant improvement in peak expiratory flow rates, FEV1, symptom scores and 
exacerbation in both groups. However, in the Budesonide group there were significant 
increases in FEV1 and daytime symptom scores compared to Montelukast. 
Each of these trials is in agreement that Montelukast is not an inferior therapy to inhaled 
corticosteroids in the treatment of children with mild persistent asthma. Montelukast was 
considered an acceptable therapy for asthma control and although there were significant 
differences in FEV1 and incidences in extra treatment (corticosteroids) compared to 
inhaled corticosteroids, this should be considered alongside the potential side effects that 
may occur through long-term use of steroids from a young age (such side-effects already 
displayed in Garcia et al.’s study, with significant differences in average height (193)).    
 
Add-on therapy 
LTRAs are commonly used as add-on therapies for uncontrolled asthma that cannot be 
maintained by inhaled corticosteroids. However, it has been noted in several studies that 
LTRAs can be used as an alternative to increasing inhaled corticosteroid dosage. In a 
randomised trial, single dose beclomethasone dipropionate (an inhaled corticosteroid) 
with Pranlukast was compared to double-dose beclomethasone dipropionate in adults 
with moderate asthma (196). Both therapies improved observed asthma control analysed 
by peak expiratory flow rate, symptom scores and addition of β2 agonist treatment and 
there were no significant differences between the two treatments. These results have been 
observed in several trials analysing Montelukast plus budesonide versus double-dose 
budesonide (197,198). These studies revealed a new role of LTRAs in the treatment of 
asthma, especially in treatment of uncontrolled asthma and avoiding increase in inhaled 
corticosteroid dosage that have been linked to increases in local and systemic adverse 
effects (199).    
LTRAs are prescribed generally for all types of asthma but there may be specific asthma 
phenotypes in which LTRAs could show more beneficial outcomes, for example, in 
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exercise-induced asthma. Almost half of asthmatics experience bronchial constriction 
induced by exercise. The cause of this is poorly understood but cysteinyl leukotrienes have 
been reported to increase in exhaled breath condensates and in urine (measured by 
urinary LTE4) after exercise challenge (200,201). Several studies have indicated that 
Montelukast can significantly reduce exercise-induced bronchial constriction, as measured 
by FEV1 (201,202). 
Another phenotype that LTRAs could be particularly beneficial in is Aspirin-exacerbated 
respiratory disease (AERD) (also called aspirin-induced asthma (AIA) or aspirin-sensitive 
asthma (ASA)) which presents as severe bronchial constriction after exposure to aspirin 
and other non-steroidal anti-inflammatory drugs that inhibit cyclooxygenase-1. The 
prostaglandin and leukotriene synthesis pathway are thought to be in balance and 
inhibiting one side leads to the overproduction of the other. This appears to be the case in 
AERD, where inhibition of cyclooxygenase, the key enzyme in the synthesis of 
prostaglandins, shunts this balance to overproduce cysteinyl leukotrienes (203). 
Unfortunately, data are limited on long-term studies that analyse the effect of Montelukast 
treatment for AERD. Dahlen et al. ran a randomised double blind, placebo-controlled four 
week trial to analyse the addition of Montelukast treatment in AERD patients (204). They 
observed significant increases in pulmonary function and quality of life, and there was a 
54 % decrease in incidences of exacerbations compared to placebo. This provides 
promising evidence that LTRAs could help manage AERD and other phenotypes that could 
be linked to cysteinyl leukotrienes. However, in general, long-acting β2 agonists are 
considered the better add-on therapy although this could be different in some patient 
subsets. 
 
1.1.7 The third cysteinyl leukotriene receptor 
LTE4 has become the “forgotten mediator” in leukotriene biology. This could be due to 
several reasons. Cloning of the CysLT1 and CysLT2 receptors revealed that LTE4’s affinity 
for these receptors was far weaker than those of LTC4 and LTD4 (see section 1.1.4 Cysteinyl 
leukotriene receptors). LTE4’s maximal response was more than 50 % lower than 
responses to LTC4 and LTD4 and thus it was labelled a partial agonist. Secondly, CysLT1 
cysteinyl leukotriene antagonists such as Montelukast were successfully introduced as 
treatments for asthma. Montelukast’s ability to improve asthmatic symptoms, coupled 
with LTE4’s weak affinity has skewed research towards CysLT1-mediated responses which 
are thought to be largely attributed to LTD4. However, evidence from early studies has 
shown that LTE4 is a potent agonist in its own right. Recent reports have speculated that 
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this could be due to LTE4 preferential responses acting through a previously unidentified 
cysteinyl leukotriene receptor. 
Early pharmacological data has shown that LTC4, LTD4 and LTE4 (purified products of the 
slow-reacting substance) were able to elicit potent contractile responses on both guinea 
pig tracheal spirals and parenchymal strips with molar ratios of 1:1:0.1 and 1:0.05:0.3 
respectively (LTC4:LTD4:LTE4) (205). This reversal in potencies was one of the first 
indications that there were separate receptors for each leukotriene that were potentially 
expressed in the lungs. This was further supported by Lee et al.’s observations in tracheal 
smooth muscle of guinea pigs. LTE4 was able to enhance airway responsiveness to 
histamine, but LTC4 and LTD4 were not, despite all three leukotrienes inducing 
constriction of the tracheal tissue to the same degree. Indomethacin, a non-selective 
inhibitor of cyclooxygenase, was able to attenuate LTE4’s augmentation of histamine 
reactivity but had no effect on LTE4’s contractile response, suggesting that LTE4’s 
hyperirritability was not completely associated with its contractile response (206). 
Removal of epithelium from guinea pig tracheal strips had no effect on LTE4-mediated 
contraction. However, it did increase sensitivity to histamine 3-fold, but LTE4 
pretreatment did not modify histamine airway responsiveness (207,208). This suggested 
that the loss in LTE4 augmentation of histamine responses could be either due to 
epithelium mediating tissue sensitivity or due to maximal tissue sensitivity being reached 
as a consequence of epithelium removal and so no further increase in sensitivity was 
possible.  
Human studies have complemented the observations found in guinea pigs. In vitro, LTE4 
has been shown to be just as potent as LTD4 at eliciting contraction in small bronchioles, 
and pretreatment of bronchial tissue with LTE4 enhanced the tissues responsiveness to 
histamine (207,209). In the first in vivo study comparing inhaled LTE4 responses to 
histamine-induced responses, LTE4 was 39 times more potent than histamine in normal 
subjects (210). On comparison of cysteinyl leukotriene and histamine responses between 
asthmatic and healthy subjects, a disproportionate augmentation in relative responses to 
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Table 1.6 The relative fold changes in airway responsiveness between normal and 
asthmatic subjects upon inhalation of the indicated agonists 
 
This phenomenon is extended in AERD patients. Inhalation of LTE4 was 1870 times more 
potent than histamine in aspirin-sensitive asthmatics at eliciting bronchial constriction 
and only 145 times more potent than histamine in aspirin-tolerant asthmatic subjects 
(212). After desensitisation with aspirin there was a substantial decrease in 
responsiveness to LTE4 and no change in responsiveness to histamine in aspirin-sensitive 
subjects. Comparisons with aspirin-tolerant asthmatics showed no change in 
responsiveness to both LTE4 and histamine after desensitisation with aspirin (212).  
Regulation of cysteinyl leukotriene production has been shown to be especially important 
in AERD patients. Urinary concentrations of LTE4 have been used clinically as a direct 
measure of cysteinyl leukotriene production. About 6-8 % of cysteinyl leukotriene 
produced is excreted as LTE4 (213). Basal levels of urinary LTE4 are higher in aspirin-
sensitive asthmatics compared to aspirin-insensitive asthmatics. Interestingly, this level of 
urinary LTE4 is significantly increased upon aspirin challenge, suggesting a possible 
pathway of cysteinyl leukotriene production by cyclooxygenase inhibitors such as aspirin 
(214,215). Urinary concentrations of LTE4 are also significantly higher in aspirin-tolerant 
asthmatics that have frequent asthmatic attacks, compared to the stable condition 
(215,216). Atopic asthmatics also show higher levels of urinary LTE4 after bronchial 
provocation with allergen but not with histamine, and patients with exercise-induced 
asthma, a phenotype of asthma, had significantly higher levels of urinary LTE4 post-
exercise challenge (201,214).  
LTE4 can also induce cell recruitment. Inhalation of LTE4 in humans significantly increases 
infiltration of eosinophils, neutrophils and lymphocytes into the lamina propria of the 
airway mucosa (171,217). In comparative studies, there is a significant increase in 
infiltration of eosinophils into the sputum and lamina propria induced by LTE4 inhalation 
compared to LTD4 suggesting that LTE4 is a far more potent chemo-attractive agent(172). 
Treatment with the selective CysLT1 antagonist, Zafirlukast, can inhibit LTE4-induced 
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eosinophilia and airway obstruction suggesting that LTE4 actions are mediated by CysLT1 
or a CysLT1-like receptor (171). 
 
CysLT3? 
LTE4’s potent nature and unique characteristics that distinguish it from LTC4 and LTD4 has 
further strengthened the idea of the existence of a third cysteinyl leukotriene receptor. As 
previously discussed, cysteinyl leukotrienes can mediate vascular permeability (see 
section 1.1.5 Increased vascular permeability). In a mouse model of vascular oedema, 
analysing ear thickness after intradermal injection of ligand, LTE4 has been shown to be 
the most potent cysteinyl leukotriene that can induce vascular leakage (218). Knockout of 
neither CysLT1 nor CysLT2 was able to affect LTE4-induced responses. In double deficient 
CysLT1/2-/- knockout mice, vascular permeability was increased. This finding has been 
repeated in a low-dose OVA-induced asthma mouse model (170). Pulmonary 
inflammation, denoted by bronchial vascular inflammation and goblet cell metaplasia was 
significantly increased in LTE4 challenged mice. Knockout of both CysLT1 and CysLT2 
revealed that LTE4-induced inflammation remained intact. Both these studies have 
identified an LTE4 mechanism that is independent of the known cysteinyl leukotriene 
receptors, CysLT1 and CysLT2. Identification of this LTE4 preferential receptor would lead 
to the elucidation of specific mechanisms that could aid our understanding of the 
pathogenesis of asthma and other related inflammatory disorders, and potentially lead to 
the development of more effective therapies. 
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1.2 Project Aims 
Cysteinyl leukotrienes have been implicated in many of the key features of asthma. They 
are involved in mediating vascular permeability, smooth muscle contraction and 
proliferation, bronchial hyperresponsiveness, increased mucus secretion, decreased 
mucus transport and migration of inflammatory cells such as eosinophils and Th2 cells. 
LTE4, the most stable of the cysteinyl leukotrienes, has been shown to induce constriction 
in human bronchi to a similar degree as the other cysteinyl leukotrienes and is even more 
potent at eliciting airway eosinophilia than LTD4. LTE4 has also been shown to selectively 
augment airway responsiveness to histamine and human airways have been shown to be 
more sensitive to LTE4 stimulation when comparing healthy and asthmatic individuals 
than to LTC4 and LTD4. However, characterisation of the cysteinyl leukotriene receptors, 
CysLT1 and CysLT2, have presented LTE4 as a weak, “partial” agonist, as intracellular 
signalling responses are significantly lower than what is induced by LTC4 and LTD4. These 
observations do not match with the pharmacological profile of LTE4, as a ligand that is just 
as potent and in some cases, even more potent, than LTD4, which strongly suggests that 
responses to LTE4 could be mediated via a previously unidentified cysteinyl leukotriene 
receptor(s).      
The aim of this project is to aid our understanding of LTE4, as a potent, “full” agonist by 
trying to identify a novel cysteinyl leukotriene receptor, preferentially signalling in 
response to LTE4. This will be achieved through various approaches as follows: 
1. Characterising potential cysteinyl leukotriene receptors that have already been 
identified in mouse models of inflammation. Human recombinant overexpression 
systems and primary cells will be used to analyse whether LTE4 directly induces 
signal transduction. Various assays that measure secondary signalling cues such as 
intracellular calcium mobilisation and cAMP will be employed to verify this. 
2. LTE4 has already been shown to exert potent effects on human mast cells. Using 
two human mast cell lines, LAD2 and LUVA, intracellular calcium mobilisation and 
gene expression in response to cysteinyl leukotriene stimulation will be analysed. 
Gene screening by microarrays will then be used to analyse differential GPCR 
expression in order to identify a potential LTE4 specific receptor. Target GPCRs 
will be analysed in recombinant systems and shRNA technology used to verify any 
promising target GPCRs that respond to cysteinyl leukotrienes.  
3. Sequencing data of any target GPCR gene will be analysed to ascertain whether any 
polymorphisms within the gene may alter receptor structure or functions. 
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4. Finally, LTE4 signal transduction pathways within human mast cell lines will be 
comprehensively analysed to ascertain what signalling requirements are 
necessary for LTE4 to act as a “full”, potent agonist. This will be achieved by using 
specific signalling pathway antagonists and analysing their effect on LTE4-induced 
gene expression and intracellular calcium mobilisation.  
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Chapter   2 
 
2 Materials and Methods 




Cell culture media and supplements were purchased from Invitrogen (UK) unless 
otherwise stated.  All cysteinyl leukotrienes were obtained from Cayman Chemical (Ann 
Arbor, MI). ADP, 2-MeS-ADP, isoproterenol, forskolin and PMA were purchased from 
Sigma-Aldrich (UK). Antibiotics ampicillin, pen step, kanamycin and puromycin were also 
purchased from Sigma-Aldrich. All primers stated were designed using on-line program 
(Roche) and synthesized by MWG (Germany). All other reagents were purchased from 
Sigma-Aldrich unless otherwise stated. Antibodies and plasmids were purchased from 
various companies as stated in the relevant methodology sections. 
 
2.2 Cell culture 
HEK293T cells were a gift from Dr Susan John (King’s College London). These cells were 
cultured in high glucose (4500 mg/L) Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with glutamine (2 mmol/L), 10 % foetal bovine serum (FBS) and 
penicillin/streptomycin (50 units/ml / 50 ug/ml) in a 37oC humidified 5 % CO2 incubator. 
Cells were passaged every 3-4 days replacing all medium with fresh cell culture medium. 
Cells were counted using NucleoCounter (Chemometec).  
LAD2 cells (a kind gift from Dr. Arnold Kirshenbaum, NIAID, NIH, USA; (19)) were cultured 
in StemPro-34 SFM supplemented with StemPro-34 nutrient supplement, 
penicillin/streptomycin (50 units/ml / 50 ug/ml), L-glutamine (200 mmol/L) and stem 
cell factor (SCF; 100 ng/ml) in a 37oC humidified 5 % CO2 incubator. Cells were 
hemidepleted weekly by replacing half the medium with equal volumes of fresh culture 
medium ensuring cell growth did not exceed 0.5x106/ml. 
LUVA cells (a kind gift from Dr. John Steinke, University of Virginia, USA; (219)) were 
cultured in StemPro-34 SFM supplemented with StemPro-34 nutrient supplement, 
penicillin/streptomycin (50 units/ml / 50 ug/ml) and L-glutamine (200 mmol/L) in a 
37oC humidified 5 % CO2 incubator. Cells were hemidepleted twice a week ensuring cell 
growth did not exceed 0.5x106/ml. 
 
2.3 Plasmid preparation 
3xHA tagged CYSLTR1 used in Figure 6.2B-D was cloned into specific plasmids suitable for 
lentiviral transfections. All other vectors shown in Table 2.1 were purchased from 
commercial sources. 
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Polymerase chain reaction (PCR). PCR was carried out to amplify 3xHA tagged CYSLTR1 
that was within a pcDNA3.1+ plasmid (UMR cDNA Resource Centre) using Platinum Taq 
Polymerase High Fidelity (Invitrogen) following manufacturers protocols. Primers were 
custom designed containing restriction enzyme sites for NheI and BamHI. These were 
made by Eurofin MWG (5'-AGTGCTAGCATGTACCCATACGATGTT-3' and 5'-
GCGGGGATCCCTATACTTTACATATTTC-3'). Reactions were performed under the following 
conditions; 94oC for 1 minute, followed by 35 cycles of 94oC for 30 seconds, 50oC for 30 
seconds and 68oC for 30 seconds, finally 68oC for 10 minutes using a Veriti 96 well thermal 
cycler (Applied Biosystems).  
 
Purification of PCR product. PCR products were identified and purified on a 1 % agarose 
gel using ethidium bromide in a 1x tris-acetate-EDTA (TAE) buffer. Samples were run 
alongside either DNA ladder φX174 DNA/BsuRI (HaeIII) (φ, Thermo Scientific) or λ 
DNA/EcoRI+HindIII (λ, Thermo Scientific). Gels were imaged using ChemiDoc™ MP imager 
(Bio-RAD). Appropriate bands were cut and purified by QIAquick gel extraction kit 
(Qiagen) following manufacturers protocol and eluted in the supplied EB reagent. 
 
Digestion. The purified PCR product and target plasmid, pCDH (encoding GFP, ampicillin 
and puramycin resistance under EF1 promoter and a multiple cloning site under CMV 
promoter (System Biosciences) were digested twice using NheI and BamHI (Thermo 
Scientific) following manufacturers protocols. Digestions were performed under the 
following conditions; overnight incubation at 37oC then finally 65oC or 80oC (NheI or 
BamHI) for 20 minutes. After digestion the plasmid was dephosphorylated using FastAP 
phosphatase (Thermo Scientific) following manufactures protocols. Reactions were 
performed at 37oC for 10 minutes then 65oC for 15 minutes. All DNA was purified using 
QiaQuick gel extraction columns following the manufacturers PCR purification protocol 
and was eluted in the supplied EB reagent. DNA concentrations were measured using 
NanoDrop ND 1000 spectrophotometer (Thermo Scientific) and ND-1000 software 
version 3.2.0. 
 
Ligation. The digested PCR product and plasmid were ligated using T4 Ligase (Thermo 
Scientific) following manufacturers protocols. In brief, the digested 3xHA tagged CYSLTR1 
and pCDH plasmid were ligated at a 16:1 ratio (insert:plasmid) under the following 
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reaction conditions; 22oC for 20 minutes and 65oC for 10 minutes. Products were purified 
on a 1 % agarose gel following section 2.3 Purification of PCR product protocol. 
 
Plasmid amplification. Plasmids containing genes of interest were amplified by 
transforming Top10 chemically competent cells (Life Technologies) by heat shock at 42oC. 
After a 1 hour recovery period in Soc-medium (Life Technologies), cells were incubated on 
LB-agar plates (1 % w/v NaCl (VWR), 1 % w/v tryptone (BD), 0.5 % yeast (BD), 1.5 % 
agarose type II) supplemented with the appropriate antibiotic overnight at 37oC. Plates 
intended for use with cells transformed with mouse-P2Y12 were supplemented with 
Kanamycin (10 μg/ml); all others were supplemented with Ampicillin (50 μg/ml). 
Colonies were amplified in LB medium (1 % w/v NaCl, 1 % w/v tryptone, 0.5 % yeast) 
supplemented with the previously indicated concentrations of antibiotics at 37oC. 
Plasmids were extracted and purified using an Endofree Plasmid Maxi kit (Qiagen) and 
concentrations were quantified using NanoDrop ND 1000. All plasmids were sequenced by 
Eurofins MWG Operon and stored at -20oC.     
 
Table 2.1 Plasmid information.  
Gene Clone ID Company Species Antibiotic  
GNA15 GNA1500000 UMR cDNA Resource Centre* Human Ampicillin 
CYSLTR1 CLR0100000 UMR cDNA Resource Centre Human Ampicillin 
CYSLTR2 CLR0200000 UMR cDNA Resource Centre Human Ampicillin 
ADRB2  (3xHA)  AR0B20TN00 UMR cDNA Resource Centre Human Ampicillin 
P2RY12 (3xHA) P2Y120TN00 UMR cDNA Resource Centre Human Ampicillin 
P2RY12  MC204030 OriGene** Mouse Kanamycin 
MAS1L SC305709 OriGene Human Ampicillin 
MRGPRX2 SC120221 OriGene Human Ampicillin 
GPR65 GPR6500000 UMR cDNA Resource Centre Human Ampicillin 
OXGR1 OXGR100000 UMR cDNA Resource Centre Human Ampicillin 
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2.4 Transient transfection of HEK293T cells 
HEK293T cells cultured to above 60 % confluence were transiently transfected with a 
mixture of Lipofectamine 2000 (Life Technologies) and 24 µg (total) plasmid containing 
the gene of interest in serum free conditions (Opti-MEM, Life Techologies) according to the 
manufacturer’s protocol. After a 5 hour incubation at 37oC, the transfection medium was 
removed and the cells were cultured for a further 36 hours in standard culture medium at 
37oC in a humidified 5 % CO2 incubator. 
 
2.5 Preparation of lentiviral particles and transduction of human mast cells 
Glycerol stocks of shRNA cloned into pGIPZ vectors (Thermo Scientific) were amplified in 
standard LB medium (see section 2.3 Plasmid preparation) supplemented with ampicillin 
(50 μg/ml) and purified using Endofree Plasmid Maxi kit (Table 2.2). Insertion of the 
shRNA component into the amplified pGIPZ vectors were validated by a KpnI restriction 
digest run on a 1 % agarose gel.  
Preparation of lentiviral particles. Plasmids containing either shRNA or 3xHA tagged 
CysLT1 were transfected into HEK293T cells using CaCl2, In brief, a mixture of the plasmid, 
with packaging vectors psPAX2, pDM2.G (System Biosciences) and CaCl2 were bubbled 
through HEPES buffered saline (HBS). The transfection mixture was added to actively 
growing HEK293T cells and incubated for 24 hours at 37oC in a humidified 5 % CO2 
incubator. Medium was replaced with fresh standard culture medium and HEK293T cell 
supernatants were collected at 24 and 48 hour time points. Supernatants were centrifuged 
at 200 g for 10 minutes and medium filtered (0.20 μm) to ensure no cellular 
contamination. Virus was precipitated by a 12 hour incubation at 4oC with PEG-it solution 
(x1, System Biosciences) and collected by a centrifugation at 1500 g for 30 minutes. Viral 
pellets were resuspended in culture medium of target cells. 
 
Transduction of LAD2 and LUVA cells with lentiviral particles. LAD2 cells (1x106) or LUVA 
cells (2x105) were hemidepleted and seeded in 6 well plates 24 hours prior to 
transfection. According to the manufacturer’s protocol, virus was added directly to the 
LAD2 cells and incubated for 24 hours at 37oC in a humidified 5 % CO2 incubator.  Medium 
was replaced with fresh culture medium and cells were incubated for a further 48 hours. 
Transfection efficiency was assessed by analysing GFP expression using flow cytometry 
(see section 2.14 Flow cytometry). Cells were then puromycin (2 μg/ml) selected to allow 
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only the cells that had incorporated the plasmid to continue growing. GFP expression of 
the cell line was monitored every 1-2 weeks using flow cytometry. 
 
Table 2.2 pGIPZ shRNA specifications 
Clone ID Target Accession Mature Antisense 
V3LHS_305475 (475) CYSLTR1 Human NM_006639 5’-TTAGTTTGATTGTCTTGTG-3’ 
V3LHS_305478 (478) CYSLTR1 Human NM_006639 5’-TACCTACACACACAAACCT-3’ 
V2LHS_90946 (946) CYSLTR1 Human NM_006639 5’-TCATGTATACTTGGAAGGC-3’ 
V2LHS_90947 (947) CYSLTR1 Human NM_006639 5’-TAGAGGTTGACATACAAAG-3’ 
V2LHS_111190 (190) CYSLTR2 Human NM_020377 5’-TTCAATTGTGCAGTTCCTG-3’ 
V3LHS_642322 (322) CYSLTR2 Human NM_020377 5’-ACATGTTGACATACAAGGA-3’ 
V3LHS_642324 (324) CYSLTR2 Human NM_020377 5’-AGAGCAGAGGATTGAAGCA-3’ 
V3LHS_642328 (328) CYSLTR2 Human NM_020377 5’-TCAGCTCTAAGCATGATGT-3’ 
 
2.6 Isolation of platelet-rich plasma 
Blood was collected over citrate-dextrose solution (ACD, 6:1) from healthy volunteers who 
had given informed consent according to the regulations of the Research Ethics Committee 
of Guy’s Hospital. Platelet-rich plasma (PRP) was prepared by centrifugation at 150 g for 
15 minutes at room temperature. The upper layer was collected (PRP) and centrifuged for 
a further 5 minutes at 150 g to reduce erythrocyte contamination.  
 
2.7 Intracellular calcium mobilisation assay 
Calcium mobilisation assays were conducted using FLIPR calcium 4 assay kit and 
FlexStation 3 (Molecular Devices, Sunnydale, CA). The changes in fluorescence (Excitation 
– 485 nm, Emission – 525 nm, Emission Cut-Off – 515 nm) were recorded as relative 
fluorescence units (RFU) at 37°C every 4 seconds over selected time course with 
compound loading at 17 seconds. 
 
Analysing transiently transfected HEK293T cells. HEK293T cells (1.5x105/well) were plated 
into poly-D-lysine (0.01 % w/v) coated 96 well plates in RPMI 1640 supplemented with 
HEPES (10 mmol/L). After a 5 hour incubation at 37oC, cells were further incubated for 1 
hour with FLIPR loading buffer and fluorescent intensity was measured at 37oC using a 
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Flexstation 3 (Molecular Devices). Results were analysed with SoftMax Pro software 
version 2.4 (Molecular Devices).  
 
Analysing isolated human platelets. PRP was washed in modified Tyrode’s buffer (pH 6.2, 
NaCl 150 mol/L, KCl 3 mmol/L, glucose 5 mmol/L, MgCl2 1 mmol/L, HEPES 10 mmol/L, 
0.1 % BSA) supplemented with PGE1 (0.5 μmol/L). Platelets (20x106) were plated into 96 
well plates in modified Tyrode’s buffer supplemented with CaCl2 (1.26 mmol/L) and 
incubated for 30 minutes with FLIPR loading buffer supplemented with probenecid (2.5 
mmol/L). Florescence was measured using a Flexstation 3 machine at 37oC. 
 
Analysing human mast cell lines. LAD2 or LUVA cells (1.5x105/well) were plated on poly-L-
lysine (0.01 % w/v) coated 96 well plates in RPMI supplemented with HEPES (10 
mmol/L) and incubated with FLIPR loading buffer for 1 hour at 37oC. Fluorescent intensity 
induced upon stimulation was measured at 37oC using a Flexstation 3 (Molecular Devices). 
 
2.8 cAMP accumulation assay 
Analysing transiently transfected HEK293T. Intracellular cAMP accumulation was analysed 
in HEK293T cells using a Cyclic AMP assay kit (Meso Scale Discovery, Gaithersburg, MD, 
USA) following the manufacturer’s protocol. HEK293T cells with the addition of IBMX (1 
μmol/L) were plated on anti-cAMP coated MULTI-ARRAY 96 well small spot plates (MSD), 
stimulated with forskolin and agonists for 15 minutes as indicated, lysed and run on the 
ImageSector 6000 (MSD). Results were analysed using MSD workbench software (MSD).  
 
Analysing isolated human platelets. Intracellular cAMP accumulation was analysed in PRP 
using the HitHunter cAMP XS+ assay kit (DiscoverX, UK) following the manufacturer’s 
protocol. PRP was centrifuged at 1000 g for 10 minutes and washed three times with pre-
chilled DPBS supplemented with EDTA (2 mmol/L). Platelets (2.5x108) suspended in DPBS 
supplemented with EDTA (2 mmol/L) and IBMX (1 μmol/L), were plated on a 96 well 
plate, stimulated with forskolin and other agonists for 15 minutes as indicated and 
incubated with detection reagents. Luminescent signal was measured 4 hours after lysis 
using a Flexstation 3. Results were analysed with SoftMax Pro Software. 
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2.9 β-arrestin recruitment assay 
Analysis of β-arrestin recruitment was conducted using a PathHunter eXpress β-arrestin 
kit (DiscoverX) following the manufacturer’s protocol. In this system, the GPCR and β-
arrestin are fused to two fragments of β-galactosidase and the interaction of the two 
proteins results in an enzymatic reaction. In brief, CHO cells stably transfected with the C-
terminally modified human or mouse P2Y12 receptor and with the β-arrestin, N-terminally 
tagged with deletion mutant of β-galactosidase, were seeded on 96 well plates in OCC 
medium for a 48 hour recovery period at 37oC. Cells were stimulated for 90 minutes at 
37oC as indicated and then incubated with detection reagents for a further 90 minutes at 
room temperature. Luminescent signal, which is directly related to the recruitment of β-
arrestin to P2Y12 in the assay, was measured using Flexstation 3 and SoftMax Pro 
Software. 
 
2.10 Analysis of gene expression 
Stimulation of human mast cell lines. LAD2 or LUVA cells (5x105) in SCF free conditions 
were treated for 30 minutes with L-cysteine (3 mmol/L). In some experiments cells were 
preincubated for indicated time points prior to ligand addition with inhibitors. Cells were 
stimulated for 2 hours with indicated concentrations of ligand and then were centrifuged 
at 200 g for 5 minutes. RNA was isolated from the pellets and mRNA expression levels 
were analysed by qRT-PCR, see section 2.11 RNA isolation and analysis. 
 
Analysis of gene expression profiles of LUVA cells by microarray. LUVA cells (5x105) were 
treated for 30 minutes with L-cysteine (3 mmol/L) at 37oC, then stimulated for 2 hours 
with a vehicle control (medium/EtOH) at 37oC. Cells were then centrifuged for 5 minutes 
at 200 g and RNA was isolated, see section 2.11 RNA isolation and analysis. RNA was 
analysed using Affymetrix whole transcriptome expression arrays (Human Gene 1.0 ST 
Arrays; Affymetrix). Sense-strand cDNA was generated using the Ambion Whole 
Transcriptome (WT) expression kit (Applied Biosystems) following the manufacturer’s 
protocol.  RNA and cRNA yield and size distribution were analysed on an Agilent 2100 
Bioanalyzer (Agilent Technologies, CA, USA) using nanofluidic chips (Agilent 
Technologies). Results were analysed on Agilent 2100 software revision B.02.02  (Agilent 
Technologies). cRNA was fragmented and labelled using Affymetrix GeneChip WT terminal 
labelling and hybridization kit (Affymetrix) following the manufacturer’s protocol. Chips 
were run by FWB Genomics Facilities (King’s College London) using an Affymetrix 
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GeneChip Scanner 3000 (Affymetrix). Results were analysed using the Partek Genomics 
Suite software. 
 
2.11 RNA isolation and analysis 
RNA extraction and quantification. Cells lysed in Trizol (Life Technologies) were 
homogenised further using  QIAshredder columns (Qiagen). Total RNA was extracted and 
purified using an RNeasy mini kit (Qiagen) and an intermediate TURBO DNase (Ambion) 
treatment following the manufacturer’s protocol to ensure complete genomic DNA 
removal. RNA concentrations were measured using NanoDrop ND 1000 
spectrophotometer and ND-1000 software version 3.2.0. All samples were stored at -80oC. 
 
Random hexamer primed reverse transcription. Reverse transcription was carried out using 
RevertAid M-MuLV reverse transcriptase (Fermentas) and primed using random 
hexamers according to the manufacturer’s protocol. In brief, RNA was first incubated with 
random heaxmers in a Veriti 96 well thermal cycler for 5 minutes at 65oC. Primed RNA 
was then incubated with a mixture of 1x M-MuLV reaction buffer, dNTPs, Ribolock RNase 
inhibitor and RevertAid H Minus reverse transcriptase (all Fermentas) for sequential 
incubation steps of 10 minutes at 25oC, 60 minutes at 42oC and 10 minutes at 70oC. All 
cDNA samples were stored at -20oC. 
 
Quantitative real time polymerase chain reaction (qRT-PCR) qRT-PCR was carried out on an 
ABI PRISM 7900HT fast real-time PCR system (Applied Biosystems) and relative 
quantification studies were performed using SDS 2.4 and RQ Manager 1.2.1 software 
(Applied Biosystems) for Chapter 3-4 all other qRT-PCR experiments were carried out on 
a ViiA 7 PCR (Applied Biosystems) and analysed using ViiA 7 software version 1.0 (Applied 
Biosystems). mRNA expression levels were analysed in triplicate using relative 
quantification with 18s rRNA as the endogenous control. All UPL probes (Roche) and 
primers (synthesised by MWG Operon) were FAM labelled and designed at www.roche-
applied-science.com and previously tested for optimal efficiency of PCR amplification. See 
Table 2.3 for probe and primer specifications. 
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A comparative Ct method was used to analyse the data obtained. All samples were first 
normalised to an appropriate endogenous housekeeping gene (18s). ΔCt of samples of 
interest were then compared to a calibrator sample to acquire the ΔΔCt.  
Ct target gene – Ct endogenous gene = ΔCt 
ΔCt sample – ΔCt calibrator = ΔΔCt 
Relative mRNA expression levels of the samples of interest were then expressed as 2-ΔΔCt. 
 
2.12 Analysis of protein expression by ELISA 
Stimulation of isolated human platelets. PRP supplemented with PGE1 (0.5 μmol/L) was 
centrifuged at 1000 g for 10 minutes and washed three times with pre-warmed modified 
Tyrode’s buffer supplemented with PGE1 (0.5 μmol/L). PRP was stimulated for 15 minutes 
with indicated concentrations of ligand, centrifuged at 1000 g for 10 minutes and 
supernatant was collected and stored at -20oC.   
 
Analysis of supernatants by ELISA. CCL5 was measured in supernatants using human 
CCL5/RANTES duo set kits (R&D Systems, UK) following the manufacturer’s protocol. In 
brief, plates coated overnight with the capture antibody were washed three times with 
wash buffer (0.05 % Tween in PBS) and incubated overnight at 4oC with the supernatants 
of interest. Plates washed three times with wash buffer were incubated for 2 hours with 
the detection antibody. After a further three washes plates were incubated with 
streptavidin-HRP for 20 minutes and then washed for a final three times. Plates were then 
incubated for 15 minutes with TMB single solution (Life Technologies), a substrate for 
HRP and reactions stopped with HCl (1 N). Optical density was recorded on Anthos htIII 
(Anthos Labtech) using Stringray software (DazDaq). Measurements at 450nm were 
corrected by measurements at 578nm and protein concentrations were generated from 
the standard curve.  
 
2.13 Analysis of protein expression by Western blot 
Stimulation of human mast cell lines for Erk activation. LAD2 or LUVA cells (5x105) in SCF 
free conditions were stimulated for indicated times with 100 nmol/L of ligand and 
stimulations were stopped by the addition of chilled PBS. Cells were centrifuged at 200 g 
for 5 minutes at 4oC and pellets were processed as stated below.   
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Protein extraction. Pellets were lysed with a Western lysis buffer (50 mmol/L Tris.HCl, 1 
mmol/L EDTA, 1 % TritonX-100) supplemented with protease and phosphotase inhibitors 
(Roche) and homogenised by vortexing. Lysates were incubated on ice for 30 minutes and 
homogenised further on a rotary mixer for a further 30 minutes at 4oC. After a 
centrifugation at max speed for 20 minutes, supernatants were stored at -20oC. Protein 
concentrations were quantified using a BCA protein assay kit (Thermo Scientific) and run 
on Anthos htIII using Stingray software. Absorbance was measured at 560 nm and protein 
concentrations were generated from the standard curve. 
 
Western Blotting Proteins (20 µg) were denatured at 90oC for 10 minutes in the presence 
of NuPAGE sample reducing agent and NuPAGE LDS sample buffer. Samples and an 
appropriate ladder (Precision Plus, Bio-Rad, Richmond, CA) were loaded onto a NuPAGE 
Novex 10 % Bis-Tris 1.0 mm gel and run at 180 V for 1 hour in NuPAGE MES SDS running 
buffer supplemented with antioxidants. Proteins were transferred onto a nitrocellulose 
membrane (0.2 µm pore size) at 30 V for 1 hour in NuPAGE transfer buffer supplemented 
with antioxidants and then washed three times with TBS 0.05 % Tween (TTBS; Sigma-
Aldrich). Membranes were blocked for 2 hours with 5 % milk in TTBS and then incubated 
with the primary antibody overnight at 4oC (Table 2.4). After membranes were washed 
with TTBS, they were incubated with the secondary antibody for a further 1.5 hours at 
room temperature (Table 2.4). After a final wash in TTBS, membranes were developed 
using ECL plus detection reagents (GE Healthcare) and processed on a ChemiDoc MP (Bio-
Rad) using Image Lab software version 4.1 (Bio-Rad). 
Membranes were stripped using Restore PLUS Western blot stripping buffer (Thermo 
Scientific) in order to probe for the control protein. In brief, membranes washed with 
TTBS were incubated with the stripping buffer for 10 minutes at room temperature. 
Membranes were washed again with TTBS and blocked for 2 hours with 5 % milk in TTBS. 
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Table 2.4 Primary and secondary antibodies used for Western blotting.  
 
Antibody Clone Host Company 
COX-2 Monoclonal CX229 Mouse Cayman Chemical 
GAPDH Monoclonal 6C5 Mouse GeneTex* 
Phospho-p44/42 MAPK  T202/Y204 Rabbit Cell Signaling Technologies** 
p44/42 MAPK Polyclonal - Rabbit Cell Signaling Technologies 
Goat anti-mouse IgG-HRP - Goat Southern Biotech*** 
Goat anti-rabbit IgG HRP - Goat Southern Biotech 
* GeneTex Inc., San Antonio, TX, USA; ** Cell Signaling Technologies, Beverly, MA, USA; *** 
Southern Biotech, Cambridge, UK. 
 
2.14 Flow cytometry 
Analysis of GPCR surface expression. Transiently transfected HEK293T cells were stained 
with an Alexa Fluor 488 conjugated anti-HA monoclonal antibody (Clone 16B12, Covance, 
Ca) that recognises the HA epitope that is N-terminally located on the receptors of interest. 
In brief, cells washed twice with PBS were stained and incubated in the dark at room 
temperature for 20 minutes. After a further two washes with PBS, cells were analysed 
using the FL1 (530/30) laser on a FACScalibur with CellQuest Pro software (BD 
Biosciences). 
 
Analysis of platelet activation. Whole peripheral blood drawn over ACD (6:1) was 
stimulated with the indicated ligands immediately after collection for 10 minutes at room 
temperature. 5 μl of blood was directly stained with monoclonal antibodies against CD61 
(APC, clone VI-PL2) and CD62P (PE, clone Psel.KO2.3) or appropriate isotype controls (all 
eBiosciences) and incubated in the dark at room temperature for 20 minutes. Cells were 
fixed with 1 % formaldehyde and analysed using the FL2 (585/42, PE) and FL4 (661/16, 
APC) lasers on the FACScalibur. Signals were compensated accordingly.  
 
Analysis of lentiviral transduced LAD2 cells. Transfection efficiency of transduced LAD2 
cells was assessed by analysing GFP expression. In brief, transduced and untransduced 
LAD2 cells washed twice with PBS were stained with a fixable viability dye; eFluor 780 
(eBiosciences) and incubated in the dark on ice for 20 minutes. After a further two washes 
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with PBS, cells were fixed in 2 % formaldehyde and analysed using the FL1 (530/30, GFP) 
and FL3 (670, eFluor 780) lasers on a FACScalibur. No compensation was necessary.    
 
2.15 DNA isolation and analysis 
DNA extraction and quantification. Total DNA was extracted and purified by DNeasy Tissue 
kit (Qiagen) following manufacturers protocol for cultured cells. DNA concentrations were 
measured using NanoDrop ND 1000 spectrophotometer and ND-1000 software version 
3.2.0. All samples were stored at -80oC. 
 
PCR and purification. PCR was carried out to amplify specific fragments of the CYSLTR1 
gene using Platinum Taq Polymerase High Fidelity (Invitrogen) following manufacturers 
protocols. Primers were custom designed and made by Eurofin MWG (see Table 2.5 for 
primer information). Reactions were performed under the following conditions; 94oC for 1 
minute, followed by 35 cycles of 94oC for 30 seconds, 63oC or 58oC for 30 seconds 
(CYSLTR1 promoter or coding region amplification, respectively) and 68oC for 30 seconds, 
finally 68oC for 10 minutes using a Veriti 96 well thermal cycler. Purification of DNA was 
performed on a 1 % agarose gel, see section 2.3 Purification of PCR product. 
 
Table 2.5 Primer specifications for CYSLTR1 promoter and CDS amplification.  
Target Orientation Sequence 
CYSLTR1 promoter Forward 5’-AACTGGAGACTTGCAGGTTGCG-3’ 
CYSLTR1 promoter Reverse 5’-AACATCAAAGTGCTGCCCCAGG-3’ 
CYSLTR1 CDS Forward 5’-TCAATGCCTCACTACTATTGCTTG-3’ 
CYSLTR1 CDS Reverse 5’-TTGGTTTGGACTGGAAATGGG-3’ 
Gene coding region (CDS). 
 
Sequencing. All DNA sample concentrations were adjusted to 1 ng/μl per 100 base pairs 
and sequenced using custom designed primers (see Table 2.6 for primer information)  
made by Source Biosciences. Sequencing was carried out by Source Bioscience Sanger 
sequencing service and analysed using BLAST analysis (NCBI).  
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Table 2.6 Primer specifications for CYSLTR1 promoter and CDS sequencing. 
Target Orientation Sequence 
CYSLTR1 promoter Forward 5’-TAAGATGGGAAGCAGGGACG-3’ 
CYSLTR1 promoter Reverse 5’-GGCTTCAATCAGCACATACC-3’ 
CYSLTR1 CDS Forward 5’ATACCAAGTGCTTTGAGCC-3’ 
CYSLTR1 CDS Forward 5’-GCATTTGGCTCTTTGGTG-3’ 
CYSLTR1 CDS Reverse 5-‘GTTTGATTGTCTTGTGGGG-3’ 
Gene coding region (CDS). 
 
2.16 Statistical analysis 
Appropriate data were analysed by means of one- or two- way ANOVA using GraphPad 
Prism software (GraphPad, La Jolla, CA). Differences were considered significant at a p-
value less than 0.05. 
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P2Y12 (or SP1999 as it was originally known) was identified as the elusive platelet ADP 
receptor that was sensitive to antithrombotic drugs, ticlopidine and clopidogrel (220-
222). Using two completely separate approaches to GPCR identification, one using the 
ligand to identify the receptor and the reverse, using the receptor to identify the ligand, 
the P2Y12 Gαi signalling pathway that worked in concert with P2Y1’s ADP activated Gαq 
signalling pathway was elucidated. Knocking out of either receptor, P2Y1 or P2Y12, in 
platelets within mouse models significantly affected platelet functionality by attenuating 
shape change and aggregation (221,223). Although deemed a complex interplay it is still 
debatable whether their mode of action is by heterodimerisation of the two receptors or 
just cross reciprocal talk (224).  
P2Y12 is part of the “purinergic” family of GPCRs that are activated by purines and 
pyrimidines and is mainly expressed on platelets and in the brain e.g. astrocytes (225). 
The purinergic family of GPCRs was first defined in 1976 by Geoffery Burnstock and later 
subdivided into P1 (adenosine) and P2 (ATP and ADP) receptor terminology (226,227).  
P2 receptors are further divided based on pharmacology into P2X (ionotropic receptors) 
and P2Y (metatropic receptors) (228). To date, there are eight P2Y subtype receptors that 
have been recognised as true P2Y receptors (229). The P2Y family contains: P2Y1, P2Y2, 
P2Y4, P2Y6, P2Y11, P2Y12, P2Y13 and P2Y14. Original nomenclature was defined on 
chronological order of cDNA cloning but even though some receptors had similar 
sequence homology, when characterised they did not respond to nucleotides and so were 
excluded from the P2Y family (229). For example, P2Y7 was eventually characterised as a 
leukotriene B4 receptor (LTB4R)and P2Y15 was shown to be activated by the citric acid 
cycle intermediate, α-ketoglutarate (OXGR1) (230-232). P2Y5 and P2Y10 are still deemed 
to be orphan receptors and so are not currently included in this list. 
In silico screening using the P2Y1 and bovine rhodopsin as confirmation templates has 
revealed that P2Y12 could also respond to LTE4 (233). Nonaka et al.’s study showed that 
LTE4 as well as other potential ligands within the nucleotide and lipid families have 
sufficient binding energies to potentially elicit activation of this purinergic receptor. 
Interestingly, in their league table of ligands with the highest binding energy, LTE4 came 
12 and 31 places higher than P2Y12’s known ligands, 2-MeS-ADP and ADP respectively, 
showing that P2Y12 may have the potential for dual ligand functionality, as CysLT1 was 
initially described as activated by both nucleotide and lipid (125,140,233).  When 
overexpressed in CHO cells with the fusion protein, Gα16, Nonaka et al. were able to 
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observe intracellular calcium mobilisation in response to LTE4 stimulation (but to no other 
cysteinyl leukotrienes) showing that LTE4 could have the potential to activate P2Y12 (233). 
Paruchuri et al. analysed in vivo whether P2Y12 was involved in LTE4 mediated pulmonary 
inflammation (170). As previously described, their study showed that low dose OVA 
sensitised mice challenged intranasally with LTE4 showed significant increases in BAL 
eosinophilia, bronchial vascular infiltration and goblet cell metaplasia when compared to 
the control mice. This potent induction of pulmonary inflammatory responses remained 
intact in LTE4 challenged CysLT1/CysLT2-/- double knockout mice. P2Y12 knockout as well 
as platelet depleted mice saw a substantial reduction in all LTE4 mediated functions 
although direct binding of radiolabelled LTE4 to P2Y12 could not be demonstrated (170). 
Their study highlighted the involvement of P2Y12 in the LTE4-induced inflammatory 
cascade but it left unanswered a question whether LTE4 is a direct P2Y12 agonist. 
OXGR1, previously known as GPR99 or P2Y15, is a GPCR that was identified a decade ago as 
the receptor for the citric acid cycle intermediate, α-ketoglutarate (232). It is a receptor 
that shares sequence homology with the purinergic family of GPCRs and has been shown 
to signal by coupling to Gαq (232). OXGR1 has also been shown recently to recruit β-
arrestin upon stimulation with α-ketoglutarate (234).  General expression of OXGR1 
within mouse tissue has been shown to be primarily located in the kidney, smooth muscle 
and the testis (232). Using OXGR1 knockout mice models, α-ketoglutarate acting through 
OXGR1 has been shown to be extensively involved in paracrine regulatory signalling of the 
acid-base balance within the cortical collecting duct and the connecting tubule of the 
kidney (235). 
Recently OXGR1 has been suggested as a potential third cysteinyl leukotriene receptor 
that is preferentially activated by LTE4 (236). Kanaoka et al. identified OXGR1 as a 
potential target by using a reporter gene expression assay containing P2Y related 
receptors that responded to dicarboxylic acids. As previously described, CysLT1/CysLT2-/- 
knockout actually increases LTE4-induced ear oedema when compared to the wild type 
controls (237). Triple knockout mice, OXGR1/CysLT1/CysLT2-/-, revealed a substantial 
attenuation of LTE4, as well as LTC4 and LTD4,-induced ear oedema (236). This study 
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3.2 Study Aims 
Over the past decade several GPCRs have been highly speculated as the elusive third 
cysteinyl leukotriene receptor. P2Y12 and OXGR1 are the most recent of these to be 
identified as potential LTE4 receptors. Both receptors have been the subject of knockout 
experiments in mouse models of inflammation and showed that LTE4-induced 
inflammation was severely abrogated in the absence of these receptors (170,236). 
However, no convincing evidence for direct binding or activation of either of those 
receptors by cysteinyl leukotrienes was provided in the studies. 
The aim of this study is to elucidate whether LTE4 is a direct agonist of either P2Y12 or 
OXGR1. This will be achieved by comprehensive analysis of signalling events in 
heterologous overexpression models (HEK293T cells) and human platelets, a primary cell 
that constitutively expresses P2Y12.  
 
3.3 Results 
3.3.1 Validation of the heterologous expression model in HEK293T cells 
To ascertain whether LTE4 could mediate signal transduction through the P2Y12 receptor, 
a model of heterologous receptor expression was established in HEK293T cells. These 
cells do not natively express any known classical cysteinyl leukotriene receptors or P2Y12 
and when unmodified they do not respond to cysteinyl leukotriene stimulation (Figure 
3.1). To validate this model, forward constructs of human (h)-CysLT1 and h-CysLT2 in 
pcDNA3.1 expression vectors where transiently transfected into separate HEK293T 
populations and verified by qRT-PCR (Figure 3.2A-B). Transfectants were stimulated with 
exogenous LTC4, LTD4 and LTE4 and their intracellular responses were measured using 
FLIPR Calcium 4 assay kit and a Flexstation 3. Both [CysLT1] and [CysLT2] transfectants 
responded robustly with calcium mobilisation to cysteinyl leukotriene stimulation, with 
receptor potencies mimicking what has been previously published in literature 
(LTD4>LTC4>>LTE4 and LTD4=LTC4>>LTE4, respectively) (Figure 3.2C-D)(114,238,239). 
Pre-incubation with the selective CysLT1 antagonists, MK-571 and Montelukast, 
completely abrogated cysteinyl leukotriene mediated calcium mobilisation in [CysLT1] 
transfectants while having no effect on signalling in [CysLT2] transfectants. Similarly, the 
selective CysLT2 antagonist, HAMI 3379, diminished calcium mobilisation in [CysLT2] 
transfectants but had no effect on [CysLT1] signalling (Figure 3.2E-F). 
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Figure 3.1 The effect of cysteinyl leukotriene stimulation on HEK293T.  
Raw intracellular calcium flux data of empty vector transfected cells stimulated with 300 
nmol/L exogenous LTC4 (diamond), LTD4 (square), LTE4 (closed circle), vehicle control  
(open circle) and calcium ionophore, A23187, 1 µmol/L (triangle), representative of 3 
experiments run in triplicate, red arrow indicates start of stimulation. Relative 
fluorescence units (RFU).  
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Figure 3.2 The effect of cysteinyl leukotriene stimulation on HEK293T cells 
transiently transfected with h-CysLT1 and h-CysLT2.  
Forward constructs of h-CysLT1 and h-CysLT2 were transiently transfected into separate 
HEK293T populations by lipofection. Relative quantification of human (A) CYSLTR1 and 
(B) CYSLTR2 mRNA in [CysLT1] and [CysLT2] transfectants, respectively, compared to 
empty vector transfected HEK293T cells, 18s used as an endogenous control, n=3. Baseline 
corrected peak calcium fluxes in response to stimulation of (C) [CysLT1] transfectants and 
(D) [CysLT2] transfectants with indicated concentrations of exogenous LTC4 (circle), LTD4 
                                                                                                                                           Results: Chapter 3   
                                                                                                                                 
78 
 
(square) and LTE4 (triangle), n=2 run in triplicate. Baseline corrected peak calcium fluxes 
in response to 100 nmol/L exogenous LTD4 with or without a 15 minute pre-incubation 
with “MK” (MK-571) 1 µmol/L, “Mont” (Montelukast)100 nmol/L  or “HAMI” (HAMI 
3379)1 µmol/L  of (E) [CysLT1] transfectants and (F) [CysLT2] transfectants, n=3 run in 
triplicate. Data shown as mean ± SEM. Relative fluorescence units (RFU). 
 
 
3.3.2 Validation of functional overexpression of human P2Y12 in HEK293T cells 
 As previously stated, HEK293T cells do not respond to cysteinyl leukotriene stimulation 
but it is important to ascertain whether they respond to ADP, the natural ligand of P2Y12. 
3xHA N-terminally tagged h-P2Y12 and empty constructs in pcDNA3.1 vectors were 
transiently transfected into separate HEK293T populations. [h-P2Y12] transfectants 
stained with an anti-HA antibody (for surface receptor expression) were considered 85.45 
% ± 7.49 % positive for h-P2Y12 expression when compared to the [Empty] controls (Mean 
± SD, n=3, Figure 3.3A). There was also a substantial increase in P2RY12 mRNA in [h-
P2Y12] transfectants compared to [Empty] transfectants (Figure 3.3B), therefore validating 
the transfection procedure. 
Stimulation of [h-P2Y12] transfectants with exogenous ADP-induced potent intracellular 
calcium mobilisation that was similar to [Empty] transfectants (Figure 3.4A-B). 
Comparison of peak calcium flux data over a range of concentrations (10-0.01 µmol/L) 
revealed no statistically significant differences in both dose-dependent response curves to 
ADP (n.s., two-way ANOVA). These observations reflect constitutive expression of other 
purinergic receptors and that h-P2Y12 signal transduction does not occur through calcium 
mobilisation in this model.  
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Figure 3.3 Validation of the h-P2Y12 overexpression model.  
Forward constructs of 3xHA N-terminally tagged h-P2Y12 and empty constructs in 
pcDNA3.1+ expression vectors were transiently transfected into separate HEK293T 
populations by lipofection. (A) Flow cytometry analysis of h-P2Y12 expression in [h-P2Y12] 
and [Empty] transfectants using a Alexa Fluor labelled antibody specific for 3xHA, 1:1000, 
results from a single experiment representative of 3. (B) Relative quantification of human 
P2RY12 mRNA in [h-P2Y12] compared to [Empty] transfectants, 18s used as an 
endogenous control, n=3. Data represented as mean ± SEM. 
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Figure 3.4 The effect of ADP stimulation on calcium mobilisation of h-P2Y12 and 
empty vector transfected HEK293T cells.  
Forward constructs of 3xHA N-terminally tagged h-P2Y12 and empty constructs in 
pcDNA3.1+ expression vectors were transiently transfected into separate HEK293T 
populations by lipofection. (A) Raw intracellular calcium flux data of [h-P2Y12] (circle) and 
[Empty] (square) transfectants stimulated with exogenous ADP 10 µmol/L, representative 
of three experiments run in duplicate, red arrow indicates start of stimulation. (B) 
Baseline corrected peak calcium fluxes in response to stimulation of [h-P2Y12] (circle) and 
[Empty] (square) with indicated concentrations of exogenous ADP, n=3 run in duplicate, 
n.s. not statistically significant, two-way ANOVA. Data represented as mean ± SEM. 
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3.3.3 Analysis of second messenger signalling of cysteinyl leukotriene stimulated 
human P2Y12 transfectants 
Many recent studies have well documented CysLT1 receptors’ abilities to activate both the 
Gαq and the Gαi signalling pathways. This promiscuity of an already known cysteinyl 
leukotriene receptor coupled with the fact the Gαi coupled receptors can induce calcium 
signalling led us to also analyse potential calcium signalling upon cysteinyl leukotriene 
stimulation in [h-P2Y12] transfectants.  On stimulation of both [Empty] and [h-P2Y12] with 
varying concentrations of LTC4, LTD4 and LTE4 (0.3-300 nmol/L), no differences in 
intracellular calcium mobilisation were observed between both transfectants (Figure 
3.5A-C and Figure 3.6). 
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Figure 3.5 Cysteinyl leukotrienes do not induce calcium signalling in [h-P2Y12] 
transfectants.  
Forward constructs of 3xHA N-terminally tagged h-P2Y12 in pcDNA3.1+ expression vectors 
were transiently transfected into separate HEK293T populations by lipofection. Raw 
intracellular calcium flux data of [h-P2Y12] transfectants stimulated with a exogenous (A) 
LTC4, 300 nmol/L (triangle), 30 nmol/L (square), 0.3 nmol/L (open circle) and 10 µmol/L 
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ADP (closed circle) and vehicle control (diamond), (B) LTD4, 300 nmol/L (diamond), 30 
nmol/L (triangle), 0.3 nmol/L (square) and 10 µmol/L ADP (closed circle) and vehicle 
control (open circle), (C) LTE4, 300 nmol/L (open circle), 30 nmol/L (closed circle), 0.3 
nmol/L (triangle) and ADP (diamond) 10 µmol/L, representative of three experiments run 




Figure 3.6 Cysteinyl leukotrienes do not induce calcium signalling in [h-P2Y12] 
transfectants.  
Forward constructs of 3xHA N-terminally tagged h-P2Y12 and empty constructs in 
pcDNA3.1+ expression vectors were transiently transfected into separate HEK293T 
populations by lipofection. Peak calcium fluxes of [h-P2Y12] (closed bars) and [Empty] 
(open bars) transfectants stimulated with either vehicle control, ADP 10 µmol/L, LTC4 300 
nmol/L, LTD4 300 nmol/L or LTE4 300 nmol/L, n=3 run in duplicate. Data represented as 
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3.3.4 Validation of functional co-overexpression of human P2Y12 with Gα16 in 
HEK293T cells 
Gα16 is a promiscuous Gα subunit that has been previously demonstrated to direct signal 
transduction of GPCRs to activate PLC when co-expressed (240). This technique of 
directing signalling transduction via PLC allows the analysis of GPCRs that signal through 
alternative signalling pathways. To demonstrate the effectiveness of this approach in our 
recombinant model, constructs containing human β2 adrenergic (h-ADRβ2) receptor, N-
terminally 3xHA tagged were co-transfected with constructs containing h-Gα16 into 
HEK293T cells and flow cytometry analysis verified that 66.18 ± 9 % of cells were 
considered positively expressing the receptor  (mean ± SD, n=4, Figure 3.7A). On 
stimulation with isoproterenol, the natural ligand for ADRβ2, there was a statistically 
significant increase (p>0.001; 2-way ANOVA) in intracellular calcium mobilisation in 
transfectants co-expressing h-Gα16 compared to the single transfectant [h-ADRβ2] and the 
empty vector control [Empty + Gα16] (Figure 3.7B-C), therefore validating the 
susceptibility of GPCRs to signal modulation within our recombinant system.   
Constructs containing N terminally 3xHA tagged h-P2Y12 were then co-transfected with h-
Gα16 in HEK293T cells. qRT-PCR showed a significant increase in P2RY12 mRNA in the [h-
P2Y12 + Gα16] transfectants compared to the [Empty + Gα16] controls (Figure 3.7D).  
Analysis by flow cytometry confirmed that 71.32 ± 16.01 % of the cells were considered 
positively expressing P2Y12 (mean ± SD, n=5, Figure 3.7A). These transfectants were able 
to show a statistically significant increase in intracellular calcium mobilisation to ADP 
(p=0.022; 2-way ANOVA) and its more stable derivative, 2-MeS-ADP (p=0.019; 2-way 
ANOVA), compared to the control transfectants (Figure 3.7E-F). 
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Figure 3.7 Validation of Gα16 co-transfection model in HEK293T cells.   
HEK293T cells were transiently transfected by lipofection with the indicated forward 
constructs in pcDNA3.1+ vectors. (A) Receptor expression analysis of 3xHA tagged h-
P2Y12 (bold black) and h-ADRβ2 (bold grey) co-expressed with Gα16 compared to empty 
vector control (thin black) using an Alexa Fluor labelled antibody specific 3xHA, 1 in 1000, 
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results from a single experiment representative of 3. Baseline corrected peak calcium 
fluxes in response to stimulation with the indicated concentrations of isoproterenol of (B) 
[h-ADRβ2] (circle), [h-ADRβ2 + Gα16] (square) and (C) [h-ADRβ2 + Gα16] (circle) and 
[Empty + Gα16] (square), n=2-4. (D) Relative quantification of human P2RY12 mRNA in [h-
P2Y12 + Gα16] compared to [Empty + Gα16] control, 18s used as an endogenous control, 
n=3. Baseline corrected peak calcium fluxes in response to [h-P2Y12 + Gα16] and [Empty + 
Gα16] transfectants stimulated with the indicated concentrations of exogenous (E) ADP 
and (F) 2-MeS-ADP, n=3. Data represented as mean ± SEM, two-way ANOVA, * p<0.05, *** 
p<0.001. Relative fluorescence units (RFU). 
 
 
3.3.5 Analysis of second messenger signalling of cysteinyl leukotriene stimulated 
human P2Y12 transfectants co-transfected with Gα16 in HEK293T 
[h-P2Y12 + Gα16] transfectants were stimulated with varying concentrations (300-0.3 
nmol/L) of cysteinyl leukotrienes and their effect on intracellular calcium mobilisation 
was analysed.  As previously reported, ADP induced a robust flux in intracellular calcium 
(Figure 3.8A-C and Figure 3.9). All LTC4, LTD4 and LTE4 stimulations induced calcium 
fluxes that were similar to the vehicle control, shown by the raw calcium flux data in 
Figure 3.8A-C and no statistically significant differences were observed in peak flux data in 
cysteinyl leukotriene responses between [h-P2Y12 + Gα16] and [Empty + Gα16] 
transfectants (two-way ANOVA, Figure 3.9).   
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Figure 3.8 Cysteinyl leukotrienes do not induce intracellular calcium mobilisation in 
[h-P2Y12 + Gα16] transfectants.  
Forward constructs of 3xHA N-terminally tagged h-P2Y12 and empty constructs in 
pcDNA3.1+ expression vectors were co-transiently transfected with constructs containing 
Gα16 into separate HEK293T populations by lipofection. Intracellular calcium fluxes of [h-
P2Y12 + Gα16] transfectants stimulated with varying concentrations exogenous (A) LTC4 
(B) LTD4 (C) LTE4; 300 nmol/L (triangle), 30 nmol/L (square), 0.3 nmol/L (circle), each 
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with controls; ADP 10 µmol/L (closed circle) and vehicle control (diamond), 
representative of three experiments run in duplicate, red arrow indicates start of 
stimulation. Relative fluorescence units (RFU). 
 
 
Figure 3.9 Cysteinyl leukotrienes do not induce intracellular calcium mobilisation in 
[h-P2Y12 + Gα16] transfectants.  
Forward constructs of 3xHA N-terminally tagged h-P2Y12 and empty constructs in 
pcDNA3.1+ expression vectors were co-transiently transfected with constructs containing 
Gα16 into separate HEK293T populations by lipofection. Peak calcium fluxes of [h-P2Y12 + 
Gα16] (closed bars) and [Empty + Gα16] (open bars) transfectants stimulated with either 
vehicle control, ADP 10 µmol/L, LTC4 300 nmol/L, LTD4 300 nmol/L or LTE4 300 nmol/L, 
n=3 run in duplicate. Data represented as mean ± SEM, two-way ANOVA with Bonferroni 
post-hoc, *** p<0.001. Relative fluorescence units (RFU). 
 
3.3.6 Analysis of alternative GPCR signalling pathways that could be activated by 
cysteinyl leukotrienes  
Human P2Y12 has been shown to signal physiologically through Gαi and by inhibition of 
intracellular cAMP generation. To analyse this potential signalling pathway, [h-P2Y12] 
transfectants were stimulated with forskolin to activate adenylyl cyclase and to increase 
cAMP levels, together with either ADP or cysteinyl leukotrienes, intracellular cAMP was 
measured using a competitive immunoassay. ADP induced a significant, concentration-
dependent inhibition of forskolin-induced cAMP in [h-P2Y12] transfectants (p=0.0048, 
two-way ANOVA, Figure 3.10A). LTE4 treatment showed no statistical difference in cAMP 
accumulation compared to the empty vector control (p=0.81, two-way ANOVA, Figure 
3.10B) confirming that [h-P2Y12] does not signal directly through the coupling of either 
Gαq or Gαi upon LTE4 stimulation.  
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Figure 3.10 LTE4 stimulation of [h-P2Y12] does not activate Gαi signalling pathways. 
Intracellular cAMP concentrations were analysed in models of HEK293T cells transiently 
transfected with forward constructs of 3xHA N-terminally tagged h-P2Y12 and empty 
constructs in pcDNA3.1+ expression vectors. [h-P2Y12] and [Empty] transfectants were 
stimulated with forskolin 10 μmol/L and the indicated concentration of either (A) ADP or 
(B) LTE4, n=6, data expressed as % of forskolin stimulated control, mean ± SEM, two-way 
ANOVA, ** p<0.01.   
 
Recruitment of β-arrestin is another activation event that can be analysed as a measure of 
GPCR activation. Until recently, an agonist’s efficacy for β-arrestin recruitment was 
believed to be proportional to its efficacy for G-protein activities. However, it has been 
demonstrated that “biased ligands” can selectively activate β-arrestin function and elicit 
specific biological effects (241). To address the question of β-arrestin specific signalling 
induced by LTE4, C-terminally modified h-P2Y12 stably transfected into CHO cells with β-
arrestin N-terminally tagged with a deletion mutant of β-galactosidase were stimulated 
with either 2-MeS-ADP or cysteinyl leukotrienes and processed according to 
manufacturer’s protocols (Figure 3.11). Stimulation with 2-MeS-ADP induced a 
concentration-dependent luminescent signal relating to the recruitment of β-arrestin to 
the h-P2Y12 receptor. Stimulation with LTE4 and other cysteinyl leukotrienes (data not 
shown) showed no significant increase in signal suggesting a lack of β-arrestin pathway 
activation by leukotrienes. Collectively these observations show that cysteinyl 
leukotrienes do not induce G-protein-dependent or -independent signalling pathways 
directly through h-P2Y12 indicating that h-P2Y12 alone is not a cysteinyl leukotriene 
receptor. 
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Figure 3.11 LTE4 stimulation of [h-P2Y12] does not activate β-arrestin recruitment. 
β-arrestin recruitment was analysed in models of stably modified CHO cells with 
transfected with h-P2Y12 and β-arrestin (DiscoverX). [h-P2Y12] transfectants were 
stimulated with the indicated concentrations of either 2-MeS-ADP or LTE4, n=3, expressed 
as relative luminescence units (RLU), mean ± SEM.  
 
3.3.7 Analysis of second messenger signalling of cysteinyl leukotriene stimulated 
mouse P2Y12 transfectants 
The ability of LTE4 to mediate pulmonary inflammation has been shown to be dependent 
on P2Y12 expression in mouse models, as indicated by Paruchuri et al. (170). Strong 
evidence shows that on removal of the P2Y12 receptor, either by knockout or by platelet 
depletion, the influx of inflammatory cells to the mouse lung can be significantly 
diminished. Although these findings are contradictory to our results, the lack of LTE4 
mediated signalling in out recombinant model could be due to species differences as 
mouse (m)-P2Y12 shares only 89 % homology to its human derivative (Table 1.2) (120). To 
test this possibility a construct encoding m-P2Y12 was transiently co-transfected with h-
Gα16 into HEK293T cells and stimulated with exogenous 2-MeS-ADP, LTC4, LTD4 or LTE4. 
qRT-PCR confirmed that the transfection successfully incorporated mouse P2RY12 DNA 
(Figure 3.12A). 2-MeS-ADP stimulation of these co-transfections was able to induce a 
statistically significant increase in calcium mobilisation compared to the control 
transfectants (p=0.0101, two-way ANOVA, Figure 3.12B) indicating that h-Gα16 is 
sufficiently able to direct the signalling pathway of m-P2Y12, similar to that of h-P2Y12 
(Figure 3.12F). No specific calcium fluxes were observed on stimulation of these co-
transfectants with LTE4 (Figure 3.12C). These fluxes in calcium were similar to that of the 
vehicle control (open circle). 
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Figure 3.12 Cysteinyl leukotrienes do not induce calcium signalling in [m-P2Y12] 
transfectants.  
Forward constructs of m-P2Y12 and empty constructs in pcDNA3.1+ expression vectors 
were co-transiently transfected with constructs containing Gα16 into HEK293T cells by 
lipofection. (A) Relative quantification of mouse P2RY12 mRNA in [Empty + Gα16] and [m-
P2Y12 + Gα16] transfectants, respectively, compared with [Empty + Gα16] transfectants, 18s 
used as an endogenous control, n=3. (B) Baseline corrected peak intracellular calcium 
fluxes were analysed in [m-P2Y12 + Gα16] (circle) and [Empty + Gα16] (square) 
transfectants stimulated with the indicated concentrations of 2-MeS-ADP or LTE4, n=3, 
mean ± SEM. (C) Raw intracellular calcium fluxes were analysed in [m-P2Y12 + Gα16] 
stimulated with 100 nmol/L of either LTE4 (closed circle), LTD4 (triangle), LTC4 
(diamond), 2-MeS-ADP 1 μmol/L (square) and vehicle control (open circle), 
representative of three experiments run in triplicate, cysteinyl leukotrienes (cysLTs), red 
arrow indicates start of stimulation. Relative fluorescence units (RFU). 
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3.3.8 Analysis of alternative signalling pathways in cysteinyl leukotriene stimulated 
mouse P2Y12 transfectants 
To determine whether LTE4 could activate m-P2Y12 via the recruitment of β-arrestin, 
stable CHO cell transfectants of C-terminally modified m-P2Y12 and N-terminally tagged β-
arrestin were stimulated with either 2-MeS-ADP or cysteinyl leukotrienes. Although 
stimulation with 2-MeS-ADP induced a dose-dependent luminescent signal, LTE4 
stimulation produced negligible effects (Figure 3.13A). These results show that m-P2Y12 
signalling responses are similar to those of h-P2Y12. 
 
 
Figure 3.13 LTE4 stimulation of [m-P2Y12] does not activate β-arrestin recruitment. 
β-arrestin recruitment was analysed in models of stably modified CHO cells transfected 
with m-P2Y12 and β-arrestin (DiscoverX). [m-P2Y12] transfectants were stimulated with 
the indicated concentrations of either 2-MeS-ADP or LTE4, n=4, expressed as relative 
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3.3.9 Analysis of second messenger signalling in platelets stimulated with cysteinyl 
leukotrienes 
Physiologically, the signalling capability of P2Y12 is highly modulated by another ADP 
purinergic receptor, P2Y1 (224). Signal modulation, whether this is through 
heterodimerisation or reciprocal cross-talk, allows the potentiation of signalling responses 
from both P2Y12 and P2Y1. To determine whether the importance of P2Y12 in LTE4 
mediated pulmonary inflammation in vivo could be due to such interactions or 
heterodimerisation of GPCRs, isolated human platelets, one of very few cell types that 
highly expresses P2Y12, were stimulated with 2-MeS-ADP and LTE4 and their intracellular 
signalling responses were analysed. A robust dose-dependent intracellular calcium 
mobilisation and a statistically significant inhibition of forskolin-induced cAMP were 
generated by 2-MeS-ADP stimulation (p<0.001 one-way ANOVA, Figure 3.14A + Figure 
3.15A) indicating that the platelets isolated from whole blood were functionally intact and 
are responsive to P2Y12 agonists. Stimulation with LTE4 induced no specific fluxes of 
intracellular calcium (Figure 3.14B-C). LTD4 induced a dose-dependent trend, although not 
statistically significant, of inhibition of forskolin generated cAMP (Figure 3.15B) but LTE4 
was unable to induce any specific inhibition of cAMP (Figure 3.15C).    
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Figure 3.14 Cysteinyl leukotrienes do not induce intracellular calcium mobilisation 
within human platelets.  
Human platelets isolated from peripheral blood were analysed for second messenger 
signalling responses upon stimulation. Raw calcium flux data of platelets stimulated with 
(A) 2-MeS-ADP; 10 μmol/L (square), 1 μmol/L (triangle), 0.1 μmol/L (diamond) and 
vehicle control (Ctl., circle), representative of 3 donors run in at least duplicate, (B) LTE4; 
100 nmol/L (triangle), 10 nmol/L (diamond), 1 nmol/L (closed circle), 2-MeS-ADP 10 
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μmol/L (circle) and vehicle control (open circle), representative of 3 donors run in at least 
duplicate. (C) Baseline corrected peak intracellular calcium fluxes of platelets stimulated 
with the indicated concentrations of 2-MeS-ADP or LTE4, data from 3 donors run in 





Figure 3.15 Cysteinyl leukotrienes do not induce the inhibition of intracellular cAMP 
within human platelets.  
Human platelets isolated from peripheral blood were stimulated with forskolin 50 μmol/L 
and with the indicated concentrations of (A) 2-MeS-ADP, data from 5 donors run in 
triplicate, (B) 2-MeS-ADP or LTD4, data from 3-5 donors run in triplicate, (C) 2-MeS-ADP 
or LTE4, data from 3-6 donors run in triplicate. Data expressed as % of forskolin 
stimulated control, mean ± SEM, one-way ANOVA with Dunnetts post hoc, * p<0.05, *** 
p<0.001. 
                                                                                                                                           Results: Chapter 3   
                                                                                                                                 
96 
 
3.3.10 Analysis of platelet activation by cysteinyl leukotrienes 
Activated platelets enter into an aggregation cascade where adhesion molecules are 
upregulated on the cell surface and a range of stored mediators are released to enhance 
this process. To address the question of whether cysteinyl leukotrienes are able to activate 
platelets through P2Y12 or physiologically expressed receptor heterodimers, platelet 
activation was measured by expression of P-selectin (CD62P) and release of the stored 
chemokine CCL5 (RANTES). Whole blood was stimulated with either ADP, 2-MeS-ADP or 
cysteinyl leukotrienes and CD62P expression was measured by flow cytometry on the 
CD61+ population of human platelets (Figure 3.16A). ADP and 2-MeS-ADP induced a 
statistically significant increase in CD62P+ in platelets (p<0.001, two-way ANOVA, Figure 
3.16B) while LTC4, LTD4 or LTE4 were unable to induce any specific effects. Similarly, 
human platelets stimulated with calcium ionophore or ADP released increased amounts of 
CCL5 but no such response was identified upon stimulation with LTC4, LTD4 or LTE4 
(Figure 3.17A-C). 
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Figure 3.16 Cysteinyl leukotrienes do not upregulate the platelet activation marker 
CD62P.  
Whole blood stimulated with either ADP 10 μmol/L, 2-MeS-ADP 1 μmol/L, LTC4 0.3 
μmol/L, LTD4 0.3 μmol/L or LTE4 0.3 μmol/L for 10 minutes was stained with monoclonal 
antibodies for CD61 and CD62P.  (A-B) Flow cytometric analysis of platelet activation was 
performed on the gated platelet population shown in the oval gate on forward and side 
scatter dot plot of peripheral blood, (A) Dot plot representative of 3 experiments with 
different donors, (B) cumulative mean ± SEM of % CD62P+ platelets, 3 experiments with 
different donors, one-way ANOVA with Dunnetts post-hoc, *** p<0.001. 
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Figure 3.17 Cysteinyl leukotrienes do not induce the release of CCL5 from human 
platelets.  
Human platelets isolated from peripheral blood were stimulated and their supernatants 
collected for protein analysis. (A-C) CCL5 concentrations were analysed by ELISA of 
supernatants collected from platelets stimulated with the indicated concentrations of (A) 
LTC4, (B) LTD4, (C) LTE4, and vehicle control (Ctl.), 2-MeS-ADP, calcium ionophore 
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A23187, data expressed as fold change compared to the vehicle control, mean ± SEM of 3 
experiments with different donors run in duplicate. 
 
 
3.3.11 Analysis of OXGR1 as a potential third cysteinyl leukotriene receptor 
To ascertain whether LTE4 could mediate signal transduction through the OXGR1 receptor, 
heterologous expression models were generated and second messenger signalling was 
analysed. As OXGR1 has previously been identified as a Gαq coupled receptor when 
stimulated with α-ketoglutarate, HEK293T cells transiently transfected with constructs 
containing human OXGR1 were stimulated with α-ketoglutarate and intracellular calcium 
mobilisation was analysed (232). Native HEK293T cells did not respond to α-ketoglutarate 
stimulation. [h-OXGR1] transfectants stimulated with α-ketoglutarate generated a dose-
dependent flux in intracellular calcium mobilisation confirming a functional 
overexpression of this receptor (Figure 3.18A). Cysteinyl leukotriene stimulation of these 
transfectants using varying concentrations (1-100 nmol/L) did not produce any specific 
fluxes in intracellular calcium mobilisation (Figure 3.18B). To make sure cysteinyl 
leukotrienes were not activating any other signalling pathways, OXGR1 was co-transfected 
with h-Gα16 into HEK293T cells. [h-OXGR1 + Gα16] transfectants stimulated with α-
ketoglutarate again produced a dose-dependent flux in intracellular calcium mobilisation 
which was of similar intensity to the single transfectant model (Figure 3.18C). Varying 
concentrations of cysteinyl leukotrienes did not induce mobilisation of intracellular 
calcium (Figure 3.18D).      
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Figure 3.18 Cysteinyl leukotrienes do not induce signalling through human OXGR1. 
HEK293T cells were transfected with forward constructs of (A-B) h-OXGR1 (GPR99) or 
(C-D) co-transfected with h-OXGR1 and Gα16 using lipofection and were analysed for 
intracellular calcium mobilisation upon cysteinyl leukotriene stimulation. Baseline 
corrected peak intracellular calcium flux data of (A + C) transfectants and the empty 
vector control stimulated with the indicated concentrations of α-ketoglutarate, n=1-3 run 
in triplicates, (B + D) transfectants and the empty vector control stimulated with the 
indicated concentrations of α-ketoglutarate 100 nmol/L, LTC4 100 nmol/L, LTD4 100 
nmol/L and LTE4 100 nmol/L, n=3 run in triplicates, mean ± SEM. Relative fluorescence 
units (RFU). 
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Recent studies have suggested that LTE4’s potent activity does not involve activation of 
any of the classical cysteinyl leukotriene receptors, i.e. CysLT1 or CysLT2, but rather the 
activation of a third novel cysteinyl leukotriene receptor, “CysLT3”. Low dose OVA-induced 
allergic lung inflammation in mice lacking P2Y12 functionality either by knockdown, 
platelet depletion or receptor antagonism, exhibited a substantial reduction in LTE4 
mediated pulmonary inflammation, a phenomenon not observed in CysLT1/CysLT2 double 
knockout mice (170). More recently, triple knockout mice OXGR1/CysLT1/CysLT2 have 
been shown to have a substantial abrogation of LTE4-induced ear oedema compared to the 
wild type suggesting that OXGR1 could be another potential LTE4 receptor (236). This 
study was  undertook to determine whether these observations were specifically related 
to direct receptor-LTE4 interactions, therefore determining whether P2Y12 or OXGR1 are 
in fact cysteinyl leukotriene receptors. 
Firstly, a heterologous expression model was established in which the recombinant 
receptor of interest could be transiently overexpressed in HEK293T cells. The best 
understood cysteinyl leukotriene receptor signalling pathway couples to Gαq; thus, 
functional validation of the expression model was carried out by analysing intracellular 
calcium mobilisation. The pattern of ligand efficacies in both [CysLT1] and [CysLT2] 
transfectants matched those observed in the literature, LTD4 being the most potent 
agonist and LTE4 being the weakest (238,239). The receptor responses were also 
susceptible to their selective antagonists (CysLT1 antagonists; MK-571 and Montelukast 
and CysLT2 antagonist; HAMI 3379), therefore validating the expression model (Figure 
3.2). Unsurprisingly, calcium mobilisation was not induced by cysteinyl leukotriene 
stimulation of [P2Y12] transfectants, as the purinergic receptor has been well 
characterised as a GPCR that mainly activates Gαi signalling pathways, affecting 
intracellular cAMP levels. However, the lack of LTE4 calcium mobilisation in [P2Y12] 
transfectants co-expressing the Gα16 protein was in stark contrast with the initial study by 
Nonaka et al. identifying LTE4 as a surrogate ligand for P2Y12 (233). They showed that 
LTE4, but not LTC4 or LTD4, was able to induce intracellular calcium flux in CHO cells stably 
overexpressing both P2Y12 and Gα16. As different platforms for the recombinant model 
were utilised, as well as different transfection techniques, this could be a reason why 
different signalling responses were observed. Further confirmation of our observations 
was shown by the negligible effect of LTE4 and other cysteinyl leukotrienes on cAMP 
accumulation and β-arrestin recruitment (Figure 3.10, Figure 3.11), two intracellular 
signalling pathways being potently activated in the same assays by known P2Y12 agonists, 
ADP and 2-MeS-ADP. This lack of LTE4-induced signalling was mimicked in transfectants 
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containing the mouse version of the P2Y12 receptor (Figure 3.12, Figure 3.13) suggesting 
that the deficiency in signalling responses was not merely a human phenomenon and was 
independent of species variation. As no direct P2Y12 signalling upon cysteinyl leukotriene 
stimulation was observed in any of our recombinant experiments, the possibility that LTE4 
could activate cells through another GPCR forming a heterodimer with P2Y12 in vivo was 
addressed. Platelets are one of very few cell types that functionally express P2Y12 and 
platelet depletion potently inhibited LTE4-mediated pulmonary inflammation so human 
platelets were used to verify whether those cells are able to respond to cysteinyl 
leukotrienes (170). No specific responses to LTE4 or other leukotrienes were observed 
when intracellular signalling (calcium, cAMP) as well as cell activation (P-selectin 
expression and CCL5 release) was measured. In contrast, human platelets strongly 
responded to known P2Y12 agonists and non-specific activators in those assays showing 
that the cells were able to respond to appropriate stimulations implying that platelets are 
not a direct target for leukotrienes. 
If platelets and P2Y12 do not respond to LTE4 as our data suggest, a question arises of how 
observations from Paruchuri et al. on LTE4 mediated pulmonary inflammation may be 
explained? Our hypothesis is that LTE4 must activate specific receptors present on cells 
other than platelets, potentially structural cells such as endothelial cells, smooth muscle 
cells or tissue resident cells i.e. mast cells. Upon LTE4 activation, such cells would produce 
(release) mediators that activate platelets or platelet-adhering leukocytes, facilitating cell 
adhesion to endothelium, cell activation and migration to tissue and as a result enhancing 
inflammatory responses. Platelet involvement in proinflammatory reactions, especially in 
pulmonary inflammation observed in asthma has been of increased interest recently. 
Clinical evidence has demonstrated increases in circulating platelets in atopic asthmatics, 
as well as increases in leukocyte-platelet aggregates after allergen challenge (242-244). 
Recent advancements in the field have shown the direct importance of platelets in 
leukocyte recruitment and airway remodelling in allergic inflammation (170,245-248), 
therefore the reduction in LTE4-mediated pulmonary inflammation seen in the study by 
Paruchuri et al. could be directly due to loss of P2Y12 functionality rather than an LTE4 
specific phenomenon (170).  
As OXGR1 had also been potentially identified as a third cysteinyl leukotriene receptor in 
mouse models of inflammation, second messenger signalling events in [h-OXGR1] 
transfectants were analysed(236). Using the same heterologous expression model as the 
P2Y12 study, human OXGR1 overexpressed in HEK293T cells showed robust intracellular 
calcium mobilisation to its known ligand, α-ketoglutarate, indicating a functional 
overexpression of this receptor (Figure 3.18). However, cysteinyl leukotrienes did not 
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induce any specific fluxes in intracellular calcium even in the presence of Gα16, strongly 
indicating that cysteinyl leukotrienes do not directly activate this receptor.  
Cysteinyl leukotrienes can induce vascular permeability but the mechanism of their action 
has not been fully elucidated. Maekawa et al.’s study shows that cysteinyl leukotrienes can 
induce a local vascular reaction that does not involve cellular infiltration into the tissue 
(237).  Curiously it was only the knockdown of all three receptors CysLT1, CysLT2 and 
OXGR1 that enabled significant inhibition of vascular oedema (236). As OXGR1 has been 
shown not to be a cysteinyl leukotriene receptor this would suggest that potentially all 
three receptors are involved in this mechanism, with OXGR1 not acting as a direct target 
for leukotrienes but being rather indirectly involved in leukotriene-induced inflammation. 
Unfortunately the role of α-ketoglutarate, the natural ligand for OXGR1, in vascular 
permeability does not support the data presented by Kanaoka et al.. α-Ketoglutarate is a 
major component in the Krebs cycle and has been shown to modulate cell cycle by 
increasing the levels of cyclin-cell-dependent kinase inhibitors and can also act as a 
substrate for the degradation of the hypoxia-inducible factor 1, which is a key protein in 
regulating responses to hypoxia (249-251). α-Ketoglutarate is thought to have anti-
tumour properties and can also suppress vascular endothelial growth factor (VEGF) 
transcription and release (249). VEGF is a major angiogenetic factor involved in 
endothelial cell proliferation, tubule formation and increased microvascular permeability. 
However, whether any of these observations were receptor mediated is debatable and so 
the identification of OXGR1’s involvement in cysteinyl leukotriene-induced vascular 
oedema could suggest a new role for α-ketoglutarate/OXGR1 which needs further 
investigation.  
Interestingly, both knockout mouse models provide strong evidence for LTE4-induced 
responses mediated independently of the classical  cysteinyl leukotriene receptors, CysLT1 
and CysLT2 (170,237) showing that LTE4 may preferentially signal via another, as yet 
unidentified,  cysteinyl leukotriene receptor. 
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4 Results: Identification of the GPCR responsible   
for preferential LTE4 signalling within          
human mast cells 
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Mast cells are derived from hematopoietic stem cells that originate from bone marrow. 
These CD34+ and CD117+ (c-kit+) progenitors are released into the circulation where on 
specific cues they can migrate into the tissue. Maturation into terminal mast cells is 
thought to only occur in the tissue in response to specific mediators and cytokines that are 
released into the tissue moiety. It is mostly dependent on c-kit activation which is a 
receptor tyrosine kinase that binds stem cell factor (SCF) and is essential for mast cell 
growth. c-kit activation can occur in two ways; SCF-induced c-kit dimerization or auto-
phosphorylation (252,253). Mast cells are thought to be pluripotent cells unique in the fact 
that on activation with an appropriate ligand, they are able to release a magnitude of pro-
inflammatory mediators by a process known as degranulation, when cytoplasmic 
granules, rich in amines, glycoproteins and proteases are exocytosed into the extracellular 
space. Mast cells are also able to release newly generated mediators, such as metabolites 
of arachidonic acid (prostaglandins and leukotrienes) as well as various cytokines and 
chemokines. The most clinically relevant of these are histamine, prostaglandins and 
leukotrienes which contribute to the asthmatic phenotype such as induction of bronchial 
constriction and chemotaxis of inflammatory cells (eosinophils, Th2 cells and basophils). 
Mast cells have been shown to express both functional CysLT1 and CysLT2 receptors that 
leads to an interesting regulatory pathway of cysteinyl leukotrienes acting in both a para- 
and autocrine fashion (125,140,254). 
Research using human mast cells is difficult due to the scarce nature of these cells in tissue 
and the complex isolation processes. Cells differentiated in vitro from cord/peripheral 
blood do offer an alternative approach but these cells are difficult to culture and are not 
fully representative of tissue-derived cells. There are currently three human mast cell lines 
available that have spontaneously arisen from CD34+ cultures; HMC-1, LAD2 and the 
recently developed LUVA cells (19,219,255).  Both HMC-1 and LAD2 cells are derived from 
patients with mast cell leukaemia but LUVA cells are the first mast cell line derived from a 
patient without any mast cell abnormalities. On comparison to skin mast cells, HMC-1 and 
LAD2 cells were found to express many mast cell markers (e.g. FcεRI, c-kit) although HMC-
1 has a mutated form of c-kit that causes auto-phosphorylation and so does not require 
SCF for proliferation (255,256). HMC-1 cells were also found to have very low levels of 
FcεRI and on IgE cross–linking they were not able to release any detectable levels of 
histamine (256). LAD2 and skin mast cells had comparable levels of FcεRI and 
spontaneous release of histamine was only slightly reduced in LAD2 cells. The major 
differences seen in these two cell lines compared with skin mast cells was the significantly 
reduced levels of tryptase and chymase in HMC-1 and LAD2 cells. It is thought that these 
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two enzymes are produced late in mast cell differentiation and thus HMC-1 is considered a 
very immature mast cell line while LAD2 cells are believed to represent more mature mast 
cell phenotype (intermediate level of differentiation) (256).   
LUVA cells are a relatively new mast cell line that has been shown to express both c-kit 
and FcεRI. The c-kit receptor in LUVA cells is not mutated, it is phosphorylated at very low 
level at baseline and cells respond to the c-kit ligand (SCF) with accelerated proliferation. 
LUVA cells do not require SCF for proliferation which suggests a c-kit-independent 
pathway that is currently unknown (19). Immunochemical staining and transcript 
expression show that LUVA cells express both tryptase and chymase, similarly to LAD2 
and CD34+ derived primary mast cells, suggesting LUVA cells to be another partially 
mature mast cell line.      
Jiang et al. first highlighted the role of cysteinyl leukotrienes in inducing co- mitogenesis of 
primary human mast cells derived from cord blood with the growth factor SCF (254). LTE4 
was the most potent of the three cysteinyl leukotrienes for inducing mast cell 
proliferation, an effect that was attenuated by the use of the selective CysLT1 antagonist, 
MK-571. These observations of LTE4’s potency were repeated in LAD2 cells (19,257). LTE4 
was more potent than LTD4 at inducing proliferative signals, mimicking Jiang et al.’s 
original paper and regulated cytokine and chemokine mRNA expression (IL-5, IL-8, TNF-α, 
CCL4 and CCL2), either greater than or equal to that of LTD4 (254,257). CCL4 and 
prostaglandin D2 were both measurable in the supernatants of LAD2 cells with again LTE4 
being the most potent cysteinyl leukotriene. All responses were sensitive to CysLT1 
antagonism by MK-571 but LTE4’s response was relatively unaffected by knockdown of 
CysLT1 using short-hairpin RNA (shRNA) suggesting the involvement of a MK-571 
sensitive GPCR other than CysLT1 (257). 
LTD4 and LTE4’s ability to robustly regulate gene expression in human mast cell lines has 
previously been analysed in our group (unpublished data). Microarray analysis of LAD2 
cells stimulated with either vehicle control, LTD4 (100 nmol/L) or LTE4 (100 nmol/L) for 2 
hours was carried out in the presence of L-cysteine (inhibits the dipeptidase enzyme that 
converts LTD4 to LTE4). The heat map representation of the hierarchal clustering of the 
array data reveals how extensively cysteinyl leukotrienes regulate gene expression in 
LAD2 cells (Figure 4.1, Table 4.1). LTD4 robustly up and down regulates genes within 
LAD2 cells and LTE4 in many instances is more potent at doing this than LTD4. The genes 
most highly upregulated by LTE4 are a multitude of chemokines, growth and 
transcriptional factors that are also upregulated by LTD4. Unsurprisingly, CCL4 is one of 
the most highly upregulated genes by both LTE4 and LTD4. It is also the highest 
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differentially expressed gene when comparing responses to LTE4 and LTD4 (8.3 fold 
change), which is supportive of data already published in the literature (170,257). 
 
Figure 4.1 Microarray analysis of cysteinyl leukotriene stimulated LAD2 cells. 
LAD2 cells (n=3) were stimulated with vehicle control, LTD4 or LTE4 (100 nM) for 2 hours 
and gene expression was analysed using Affymetrix Human Gene 1.0 ST microarrays. 
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Hierarchical clustering of significantly (ANOVA p<0.05, >2 fold change) regulated genes is 
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4.2 Study Aims 
LTE4 induces potent responses in LAD2 cells offering an interesting model to identify the 
elusive GPCR responsible for LTE4 signalling. LAD2 cells have already been shown to 
proliferate and release mediators upon LTE4 stimulation equal to or greater than LTD4 
(170,254,257). Our own microarray analysis of LAD2 cells has also confirmed LTE4’s 
potency supporting published data and identified new leukotriene-regulated genes, such 
as GMCSF. LUVA cells are another mast cell line that was spontaneously generated from 
peripheral blood CD34+ cell cultures and have morphology similar to that of LAD2 cells i.e. 
they contain tryptase and chymase, express c-Kit and IgE receptors and degranulate on 
cross-linking of FcεRI (219). qRT-PCR analysis has shown detectable levels of CYSLTR1 
and CYSLTR2 but their responses to cysteinyl leukotriene stimulation are as yet to be 
characterised (219).  
The aim of this study is to identify GPCR receptor(s) responsible for LTE4 signalling in 
human mast cells. Cysteinyl leukotriene-induced signalling and gene expression will be 
compared between two human mast cell lines, LAD2 and LUVA, in order to characterise a 
receptor responding to LTE4.  
 
4.3 Results 
4.3.1 Analysis of cysteinyl leukotriene-induced responses in human mast cells 
In our initial microarray studies, LTD4 and LTE4 were shown to robustly regulate gene 
expression in the human mast cell line, LAD2. To analyse this further, the relative 
responsiveness to the cysteinyl leukotrienes, LTD4 and LTE4, specifically looking at genes 
that were highly upregulated in the microarray study i.e. PTGS2 (COX2), CCL4 and GMCSF, 
was analysed in two human mast cell lines, LAD2 and LUVA. qRT-PCR analysis of LAD2 
cells stimulated with cysteinyl leukotrienes for 2 hours showed induction of COX2, CCL4 
and GMCSF expression with LTE4 consistently matching or being the more potent of the 
two ligands (Figure 4.2A). LUVA cells stimulated with LTD4 induced gene expression in a 
similarly robust way to LAD2 cells, however LTE4 induced only very weak responses 
(Figure 4.2B).   
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Figure 4.2 Human mast cell lines respond to cysteinyl leukotriene stimulation. 
Human mast cell responsiveness was analysed to cysteinyl leukotriene stimulation in the 
presence of L-cysteine 3 mmol/L. Relative quantification of PTGS2 (COX2), CCL4 and 
GMSCF mRNA in human mast cell lines (A) LAD2 and (B) LUVA when stimulated for 2 
hours with either vehicle control, LTD4 100 nmol/L or LTE4 100 nmol/L, data compared to 
vehicle control, 18s used as an endogenous control, n=3. All data expressed as mean ± 
SEM.  
 
As intracellular calcium mobilisation is a secondary messenger signalling cue for CysLT1 
and CysLT2 (Figure 3.2C-D), cysteinyl leukotrienes induced calcium mobilisation was 
analysed in our two human mast cell lines. In LAD2 cells, all cysteinyl leukotrienes induced 
a concentration-dependent flux in intracellular calcium (Figure 4.3A). LTD4 and LTC4 were 
very similar in potency and LTE4 was the weakest of all three ligands but still induced a 
robust response. In contrast, in LUVA cells, LTD4 was the most potent ligand followed by 
LTC4, while LTE4 induced very weak, non-specific fluxes in intracellular calcium (Figure 
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4.3B). The order of ligand potencies for inducing intracellular calcium mobilisation in 
LUVA cells was very similar to that of CysLT1 transfected HEK293 cells (Figure 3.2C).  
 
 
Figure 4.3 Cysteinyl leukotrienes induce intracellular calcium mobilisation in 
human mast cell lines.  
Human mast cell lines were analysed for intracellular calcium mobilisation upon 
stimulation. Baseline corrected peak intracellular calcium fluxes of (A) LAD2 and (B) 
LUVA cells stimulated with the indicated concentrations of LTC4 (circle), LTD4 (square) 
and LTE4 (diamond). Data from 2-3 experiments run in triplicate, presented as mean ± 
SEM. Relative fluorescence units (RFU).  
 
4.3.2 Comparison of GPCR gene expression profiles between LAD2 and LUVA cells 
LAD2 and LUVA cells represent two human mast cell lines that respond differently to LTE4 
stimulation. Previous studies have suggested that LTE4 signals in LAD2 cells through a 
different receptor than CysLT1 so it could be hypothesised that the lack of LTE4 signalling 
in LUVA cells could be due to a lack of expression (or lower expression) of the elusive, 
LTE4 preferential receptor (257). Using our Affymetrix Human Gene 1.0 ST microarray 
data, gene transcript relative intensities were compared in LAD2 and LUVA cells using 
Partek Genomics Suite and a list of genes expressed differently between cell lines (ANOVA 
p<0.05; 2 fold difference) was generated. GPCR genes were filtered using GPCR databases 
from IUPHAR (119). 27 GPCRs differed significantly in LAD2 cells with a change in relative 
intensities of more than 2-fold (Figure 4.4, Table 4.1). Analysing all 27 differentially 
expressed GPCR would be inappropriate as many (17 GPCRs) are already well 
characterised GPCRs, for example the adrenergic β2 receptor (ADRB2), the histamine H4 
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receptor (HRH4) and the chemokine receptors, CCR4 and CXCR3. Target GPCRs were 
identified based on expression levels from the group of 10 GPCRs that were considered 
orphans; GPR12, GPR37, GPR65, GPR85, GPR114, GPR137B, GPR174, MAS1L, MRGPRX2 
and P2RY8. GPR65, MAS1L and MRGPRX2 (shown in grey, Figure 4.4) were the most 
differentially expressed orphan GPCRs (9.9, 32.4 and 70.2 fold change LAD2 vs. LUVA 
respectively) and so were considered the most promising targets for further study. 
Interestingly, CysLT1 was also a GPCR that was identified as being differentially expressed 
in LAD2 cells compared to LUVA (shown as open bar, Figure 4.4, 4.3 fold change).  
 
 
Figure 4.4 Comparison of differential GPCR expression between LAD2 and LUVA 
cells.  
Analysis of differential GPCR mRNA expression levels in unstimulated LAD2 and LUVA 
cells. Fold change of relative intensities of mRNA expression levels of LAD2 cells compared 
to LUVA cells. Data represented as comparisons > 2 fold and p<0.05 ANOVA, grey bars 
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Table 4.2 Differentially expressed GPCRs in LAD2 cells compared to LUVA cells 
(more than 2 fold difference).  
Gene Description Orphan? 
Fold Change 
LAD2 vs. LUVA 
ADORA3  Adenosine A3 receptor No 2.27 
ADRB2  Adrenergic β2 receptor No 2.39 
ADRB3  Adrenergic β3 receptor No 6.52 
CCR4  Chemokine receptor No 4.16 
CD97  Adhesion class receptor No 2.87 
CX3CR1  Chemokine receptor No 4.76 
CXCR3  Chemokine receptor No -3.60 
CYSLTR1  Cysteinyl leukotriene receptor 1 No 4.32 
DRD2  Dopamine receptor D2 No 4.90 
EDNRB  Endothelin receptor type B No 6.83 
EMR2  Adhesion class receptor No 4.50 
GPR12    Yes -2.41 
GPR37    Yes -2.05 
GPR65    Yes 9.93 
GPR85    Yes 2.94 
GPR114  Adhesion class receptor? Yes -2.14 
GPR137B    Yes 4.12 
GPR174    Yes -8.04 
HRH4  Histamine H4 receptor No 5.06 
MAS1L    Yes 32.41 
MC1R  Melanocortin 1 receptor No 2.02 
MRGPRX2    Yes 70.23 
NPY2R  Neuropeptide Y2 receptor No 2.30 
P2RY8    Yes -6.34 
PTGER3  Prostaglandin E receptor 3 No 11.40 
PTGER4  Prostaglandin E receptor 4 No 3.96 
TPRA1  
Transmembrane protein, adipocyte 
associated 1 No 2.52 
 
To ascertain whether LTE4 could mediate signal transduction through either of the target 
genes identified, GPR65, MAS1L or MRGPRX2, models of HEK293T cells overexpressing 
genes of interest were generated with or without the co-expression of h-Gα16. Intracellular 
calcium mobilisation was analysed within these transfectants upon stimulation with 
cysteinyl leukotrienes. [CysLT1] transfectants were run in parallel as a control for the 
experiments. LTC4 and LTD4 induced intracellular calcium mobilisation in [CysLT1] 
transfectants with very weak responses upon LTE4 stimulation (Figure 4.5A-F). 
Unfortunately, cysteinyl leukotriene stimulation did not induce any specific fluxes in 
intracellular calcium in any of our target transfectants (Figure 4.5A-F). 
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Figure 4.5 Cysteinyl leukotrienes do not activate GPR65, MAS1L or MRGPRX2 
receptors.  
Intracellular calcium mobilisation was analysed in models of HEK293T cells transiently 
transfected with the genes of interest. Baseline corrected peak intracellular fluxes of (A) 
[GPR65] (B) [GPR65 + Gα16] (C) [MAS1L] (D) [MAS1L + Gα16] (E) [MRGPRX2] (F) 
[MRGPRX2 + Gα16] transfectants stimulated with either LTC4 100 nmol/L, LTD4 100 
nmol/L or LTE4 100 nmol/L, all with control [CysLT1] and the appropriate empty vector 
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control. Data from 2-3 experiments run in triplicate, presented as mean ± SEM. Relative 
fluorescence units (RFU). 
 
 
4.3.3 Analysis of cysteinyl leukotriene responses using selective receptor inhibitors 
To determine whether CysLT1 could be involved in LTE4 signal transduction, LAD2 and 
LUVA cells were pretreated with selective CysLT1 and CysLT2 receptor antagonists, 
Montelukast and HAMI 3379, respectively. Antagonist selectivity was previously verified 
in HEK293T cell transfection models (Figure 3.2E-F). qRT-PCR analysis of COX2 and CCL4 
in LAD2 cells showed that both LTD4 and LTE4 signalling was sensitive to Montelukast 
while HAMI 3379 had no affect (Figure 4.6A). In LUVA cells, LTD4 signalling was again 
sensitive to Montelukast pretreatment but not to HAMI 3379 (Figure 4.6B). Responses to 
LTE4 in LUVA cells, as previously described (Figure 4.2B), were very weak so it is difficult 
to draw a conclusion as to whether its response was susceptible to either antagonist. 
Analysis of intracellular calcium mobilisation in these cells showed a very similar picture. 
LTD4-induced calcium mobilisation was sensitive to Montelukast pretreatment in both 
LAD2 and LUVA cells while HAMI 3379 had no affect (Figure 4.6C-D). LTE4-induced 
calcium responses were inhibited only by Montelukast in LAD2 cells. Again the very weak 
calcium responses to LTE4 in LUVA did not allow for any proper analysis of selective 
inhibition (Figure 4.6D).  
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Figure 4.6 Cysteinyl leukotriene responses are sensitive to CysLT1 antagonism in 
human mast cell lines.  
Human mast cell lines were analysed for their sensitivity to CysLT1 or CysLT2 antagonism 
upon cysteinyl leukotriene stimulation. Relative quantification of COX2 and CCL4 mRNA in 
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(A) LAD2 and (B) LUVA cells stimulated for 2 hours with either vehicle control, LTD4 100 
nmol/L or LTE4 100 nmol/L with or without a 10 minute pre-incubation with either 
“Mont” (Montelukast) 100 nmol/L or “HAMI” (HAMI 3379) 1 μmol/L, all in the presence of 
L-cysteine 3 mmol/L, data compared to vehicle control, 18s used as endogenous control, 
n=3. Baseline corrected peak calcium flux data of human mast cell lines (C) LAD2 and (D) 
LUVA stimulated with either vehicle control, LTD4 100 nmol/L or LTE4 100 nmol/L with 
or without a 15 minute pre-incubation with Montelukast 100 nmol/L or HAMI 3379 1 
μmol/L, n=3. All data represented as mean ± SEM. Relative fluorescence units (RFU). 
 
 
4.3.4 Analysis of cysteinyl leukotriene receptor knockdown in LAD2 cells 
To verify whether the potent LTE4-induced, Montelukast sensitive, response in LAD2 cells 
was attributable specifically to CysLT1 signalling and not via another Montelukast sensitive 
receptor, CysLT1 and CysLT2 receptor knockdowns were generated in LAD2 cells. Four 
shRNA targeting different regions of CYSLTR1 or CYSLTR2 were transduced into separate 
LAD2 cell populations using lentiviral particles (see section 2.5 Preparation of lentiviral 
particles and transduction of human mast cells for shRNA specifications). qRT-PCR analysis 
of CysLT1 transfectants revealed shRNA “475” successfully knocked down CYSLTR1 
without significantly affecting CYSLTR2 mRNA expression (Figure 4.7A). While in the 
CysLT2 transfectants, shRNA “190” and “324” significantly knocked down CYSLTR2 mRNA 
while not significantly affecting CYSLTR1 (Figure 4.7B). As shRNA “190” was able to 
knockdown CYSLTR2 mRNA to a greater extent than “324”, this as well as LAD2 
populations transduced with shRNA “475” were continued for analysis.         
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Figure 4.7 Validation of CysLT1 and CysLT2 receptor knockdown in LAD2 cells.  
LAD2 cells stably transfected with the indicated CYSLTR1 and CYSLTR2 shRNA were 
analysed by qRT-PCR for successful gene knockdown. Relative quantification of CYSLTR1 
and CYSLTR2 mRNA in LAD2 cells transfected with shRNA targeting different regions of 
(A) CysLT1 and (B) CysLT2 receptor coding regions. n=3, mean ± SEM. 
 
To ascertain whether knocking down of either of CysLT1 or CysLT2 had an effect on 
cysteinyl leukotriene-induced responses, intracellular calcium mobilisation was analysed 
in CysLT1 and CysLT2 knockdown LAD2 cells. Knocking down of CysLT1 substantially 
inhibited fluxes in intracellular calcium mobilisation in response to cysteinyl leukotriene 
stimulation (Figure 4.8A-C). At their optimal concentrations (10 nmol/L), LTC4, LTD4 and 
LTE4-induced responses were inhibited by 69.4, 55.9 and 63.1 % (respectively, mean), 
when compared to control cells. No such inhibition was observed in CysLT2 knockdown 
LAD2 cells with LTC4, LTD4 and LTE4 dose-dependent curves matching that of the control 
cells (Figure 4.8D-F). qRT-PCR analysis of CysLT1 and CysLT2 knockdowns in LAD2 
showed a similar outcome (Figure 4.9). COX2 CCL4 and GMCSF mRNA expression upon 
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LTD4 and LTE4 stimulation were almost completely abrogated in CysLT1 knockdown LAD2 
cells while knocking down of CysLT2 had no real effect.  
 
Figure 4.8 CysLT1 knockdown in LAD2 cells significantly reduces intracellular 
calcium mobilisation to cysteinyl leukotriene stimulation.  
Baseline corrected peak calcium flux data of LAD2 cells stably transduced with lentivirus 
containing shRNA targeting (A-C) CYSLTR1 and (D-F) CYSLTR2 with empty vector 
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transduced cells used as control. Cells were stimulated with the indicated concentrations 
of either LTC4, LTD4 or LTE4. Data from 1-3 experiments, run in triplicate, presented as 
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Figure 4.9 CysLT1 knockdown in LAD2 cells significantly reduces gene up-regulation 
in response to cysteinyl leukotriene stimulation. 
Relative quantification of COX2, CCL4 and GMCSF mRNA expression of LAD2 cells stably 
transfected with lentivirus containing shRNA targeting (A-C) CYSLTR1 and (D-F) 
CYSLTR2 with empty vector transduced cells used as control. Cells were stimulated with 
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either LTD4 100 nmol/L or LTE4 100 nmol/L for 2 hours in the presence of L-cysteine 3 
mmol/L, data relative to vehicle control (“Ctl.”), 18s used as endogenous control, (A-C,F) 
n=3-5, (D-E) n=1. All data expressed as mean ± SEM. Knockdown (KD). 
 
4.4 Discussion 
Mast cells are one of only a few cell types identified that potently respond to LTE4 
stimulation (254,257). Due to the rarity of primary tissue-derived human mast cells, lines 
spontaneously derived from CD34+ cell cultures have dominated the field of human mast 
cell research. LAD2 cells are considered the best studied human mast cell line, deemed to 
be more representative of tissue-derived human mast cells than any other line previously 
generated (19,256). Paruchuri et al. have already shown that they effectively respond to 
cysteinyl leukotriene stimulation and it was considered the best cell line to study in order 
to identify the LTE4 preferential receptor (257). LUVA cells have been recently generated 
and their responses to cysteinyl leukotriene stimulation have not been previously 
analysed (219). So using LAD2 and LUVA cells as a comparison, this study was undertaken 
to identify the GPCR responsible for LTE4 preferential signalling. 
Microarray data of LAD2 cells, generated in our laboratory, revealed that LTE4 is more 
potent at inducing gene expression than LTD4. This observation was confirmed by qRT-
PCR at an mRNA level for specific genes, such as COX2, CCL4 and GMCSF (Figure 4.2A). 
Surprisingly another mast cell line, LUVA, showed very weak responses to LTE4 even 
though LTD4-induced mRNA expression was at a similar level as in LAD2 cells (Figure 
4.2B). This discrepancy between the two mast cell lines was further extended when 
comparing cysteinyl leukotriene-induced intracellular calcium mobilisation (Figure 4.3). 
Even though LTE4 induced the weakest responses in LAD2, the dose-dependent 
intracellular fluxes were very robust. The response to LTE4 in LUVA cells was negligible, 
with non-specific fluxes in intracellular calcium. This lack of response to LTE4 and the 
pattern of cysteinyl leukotriene potencies in LUVA cells mimic the initial observations of 
“classical” CysLT1 signalling seen in literature and in our over-expression models (Figure 
3.2)(114,239).  
This lack of LTE4 responsiveness in LUVA cells led us to postulate that an additional GPCR, 
the LTE4 preferential GPCR, was functionally expressed in LAD2 cells and not in LUVA. 
Comparison of microarray data from both cell lines revealed 10 differentially expressed 
orphan GPCRs. 3 of these orphan GPCRs were significantly overexpressed in LAD2 cells 
compared to LUVA but unfortunately when tested none of these target GPCRs responded 
to cysteinyl leukotriene stimulation (Figure 4.5). Since the study was conducted, GPR65 
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has been suggested as a proton-sensing GPCR involved in the regulation of matrix 
metalloproteinases (258,259). MRGPRX2 has been suggested to signal via β-defensins 
while MAS1L remains relatively unstudied (260,261). However all three are still 
considered class A orphan GPCRs according to the IUPHAR databases (119,258-261). 
Interestingly, CysLT1 was also differentially expressed with a 4.32 fold increase in LAD2 
cells compared to LUVA. Responses to LTD4 and LTE4 in LAD2 cells (as well as LUVA) were 
sensitive to the CysLT1 antagonist, Montelukast (Figure 4.6). Cysteinyl leukotriene 
sensitivity to CysLT1 antagonism in human mast cells has been well documented in the 
literature but with another selective CysLT1 antagonist, MK-571(170,254,257). As 
previously described, both Montelukast and MK-571 were synthesised before any 
cysteinyl leukotriene receptor had been cloned and characterised (106,109,262). 
Numerous studies have indicated that both antagonists may have anti-inflammatory 
actions that are CysLT1-independent, suggesting that they also act via other GPCRs with 
similar sequence homology (263-267). Knockdown of CysLT1 in LAD2 cells elucidated that 
the signalling pathway of LTE4 within this cell system is CysLT1-dependent. Both the 
mobilisation of intracellular calcium and upregulation of mRNA expression of COX2, CCL4 
and GMCSF to cysteinyl leukotriene stimulation were attenuated in these CysLT1 
knockdowns while knocking down of CysLT2 had no effect (Figure 4.8 and Figure 4.9).  
This LTE4-CysLT1-dependent pathway in LAD2 cells is contradictory to previous 
observations. Paruchuri et al. has analysed CysLT1 knockdown LAD2 cells in two separate 
studies (170,257). Although LTD4 responses were consistently attenuated by CysLT1 
knockdown, the responses to LTE4 were only slightly inhibited when analysing CCL4 
release and had no effect on PGD2 release. Lentiviral transfection of shRNA were both used 
in Paruchuri et al.’s studies and our study to knockdown CysLT1, although slight 
differences in methodologies and analysis targets might account for the differences seen. 
Firstly, different regions of the CYSLTR1 gene were targeted which might affect how 
significantly these responses to LTE4 are altered. Analysing several different shRNA’s 
targeting different regions of the gene of interest is important for acquiring the optimal 
efficiency of knockdown (Figure 4.7). Secondly, our transfectants underwent puromycin 
selection unlike in the Paruchuri et al. studies, a process used to obtain a stable population 
of LAD2 cells of which over 95 % were expressing GFP (the shRNA reporter gene). This 
allowed the cells to recover from the transfection procedure and more importantly 
increased the proportion of cells that had incorporated the shRNA which might increase 
the ability to discriminate whether a knockdown has had an effect. Finally, different 
outputs were analysed. Intracellular calcium mobilisation is our most sensitive tool for 
analysing initial GPCR signalling events, with responses seen within seconds of 
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stimulation. These responses are unaffected by potential secondary auto/paracrine 
signalling from other mediators released upon cysteinyl leukotriene stimulation that 
might potentially be seen with longer stimulations to analyse protein/lipid release.  
This study has shown that LTE4-induced signalling response in LAD2 cells involves the 
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Polymorphisms within DNA are a source of diversity that affects phenotypes ranging from 
hair colour to disease susceptibility. The most common are single nucleotide 
polymorphisms (SNPs) which can alter single base pairs and can occur in both coding and 
non-coding regions of genes. SNPs that affect the coding region are categorised as either 
nonsynonymous or synonymous i.e. they do or do not affect the protein sequence. 
Nonsynonymous SNPs can lead to either the resulting codon encoding a different amino 
acid affecting protein structure or even to a non-functional protein (missense) or the 
resulting codon being a termination codon leading to truncated proteins (nonsense). SNPs 
that occur within the non-coding region are more complex as they have no effect on actual 
protein sequence. It is thought that they could alter processes such as transcript 
expression, splice variation, transcription factor binding and mRNA degradation that could 
in turn significantly affect downstream cell functions.  
As previously stated, the CYSLTR1 gene resides on chromosome Xq13.2-q21.1 and 
encodes a protein that is 337 amino acids long. The major transcript, which has been 
identified in many cell types, contains three exons in which the third exon contains the full 
coding region and is intronless (118,268). Numerous SNPs have been identified in the 
promoter and coding region of CYSLTR1, shown in Figure 5.1 (further information in 
Table 5.1). In the promoter region, which is thought to be located between -125 and -786, 
four SNPs have been identified; rs321029 T>C (SNP 1), rs2637204 C>A (SNP 2), 
rs2806489 A>G (SNP 3) and rs7066737 C>T (SNP 4) (118).  
 
Figure 5.1 Schematic representation of the CYSLTR1 gene structure.  
SNP locations are shown by red arrows, exons are shown by boxes, coding region (CDS) 
and 3’ untranslated region (3’UTR). 
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Table 5.1 Single nucleotide polymorphisms in the CYSLTR1 gene.  
 
Position relative to CYSLTR1 gene NG_012809.1 sequence, non-applicable (NA), Glycine 
(Gly), Glutamic acid (Glu), Phenylalanine (Phe). 
 
Several studies have analysed whether there are any disease associations with SNPs in the 
promoter region. Duroudier et al. found that in a British 1958 birth cohort, SNP 3 had no 
association with age of asthma onset, wheeze or serum total IgE levels (269). The A allele 
was, however, associated with increased risk of atopy in females only. SNP 4 showed no 
association with the above mentioned variables (269). Kim et al. analysed SNPs 1, 2 and 3 
collectively to see whether a specific promoter haplotype had any disease associations. It 
was revealed that males had a higher risk of aspirin-sensitive asthma with the CYSLTR1 
promoter haplotype TCG (SNPs 1-2-3) and a lower risk of disease with haplotype CAA 
(270). There were no associations made in females. This TCG haplotype was shown to 
have higher promoter activity than CAA which could relate to higher CysLT1 expression 
(270). This increased TCG promoter activity was further confirmed by Zhang et al. 
although in their study of a Japanese cohort, no associations were made with development 
of asthma or rhinitis with any promoter haplotype (SNPs 1-2-3) (268).  
SNPs have also been shown to be located in the coding region. In a Spanish cohort of 
children with asthma and atopic dermatitis, Arriba-Mendez et al. showed that in males 
only there was an increased risk of allergic asthma with atopic dermatitis with the C allele 
of SNP 6 (Table 5.1) (271). Hong et al. analysed two separate Chinese populations and 
were able to associate SNP 6 with increased risk of asthma but this was comparable in 
both males and females. However, Hao et al. and Zhang et al. found no associations with 
asthma related phenotypes with SNP 6, with the former study linking SNP 6 to atopy 
severity in females, with the T allele associated with higher severity than the C allele 
(272). A novel SNP identified in a Tristan da Cunha population, G300S (SNP 5), has been 
also associated with an increased risk of atopy and asthma (273). This CysLT1 variant was 
shown, when transfected into HEK293 cells, to have a significant reduction in EC50 when 
analysing LTD4-induced intracellular calcium mobilisation (273). 
 SNP Reference Location Position 
Allele 
(reverse) Residue Change 
1 rs321029 Promoter 4342 T>C NA  
2 rs2637204 Promoter 4501 C>A NA  
3 rs2806489 Promoter 4640 A>G NA  
4 rs7066737 Promoter 4721 C>T NA  
5 G300S Coding region 59743 G>A G (Gly) > E (Glu) 
6 rs320995 Coding region 59771 T>C F (Phe) > F (Phe) 
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5.2 Study Aims 
There is compelling evidence that genetic variations in the CYSLTR1 gene could lead to 
increased risk of asthma and allergy. This could be due to altered receptor functionality as 
shown for SNPs in both the promoter and the coding region (268,270,273). Our data has 
suggested that cysteinyl leukotrienes signal through CysLT1 in both LAD2 and LUVA cells 
but there is differential LTE4 signalling that is currently unexplained (see Chapter 4). LTE4 
can induce intracellular calcium mobilisation to a greater extent in LAD2 cells compared to 
LUVA and is just as potent at inducing CCL4, COX2 and GMCSF mRNA expression as LTD4 
in LAD2 cells. In LUVA cells, the responses to LTE4 are weak and are similar to the initial 
observations made by Lynch et al. and Sarau et al. (113,114). 
The aim of this study is to analyse whether there is any genetic variation in the CYSLTR1 
gene between LAD2 and LUVA cells that could account for these observations. This will be 
achieved by sequencing the promoter and coding regions of CYSLTR1 in LAD2 and LUVA 
cells and comparing the two mast cell line sequences. 
 
5.3 Results 
5.3.1 Comparison of CYSLTR1 promoter sequence between LAD2 and LUVA cells 
To determine whether there are variations in the CYSLTR1 promoter region between 
LAD2 and LUVA cells that may affect receptor expression and therefore functionality, DNA 
from both cell lines was analysed. As previously stated, the CYSLTR1 gene resides on the X 
chromosome. Both LAD2 and LUVA cells originate from male patients, so any allele change 
identified will be homozygous. PCR of DNA extracted from LAD2 and LUVA cells using 
primers 5’-AACTGGAGACTTGCAGGTTGCG-3’ and 5’-AACATCAAAGTGCTGCCCCAGG-3’ 
amplified a 616 base pair (bp) product (part of CYSLTR1 promoter) that was confirmed by 
agarose gel electrophoresis (Figure 5.2A). BLAST analysis of the sequenced PCR products 
from both LAD2 and LUVA cells revealed three SNPs at gene locations 4342 T>C (SNP 1), 
4501 C>A (SNP 2) and 4640 G>A (SNP 3) (rs321029, rs2637204 and rs2806489 
respectively, compared to CYSLTR1 RefSeqGene NG_012809.1). No point mutations were 
identified at any other sites including the other main promoter SNP location 4721 C=C 
(rs7066737) (Figure 5.2A and B-C). The sequencing data revealed that LAD2 and LUVA 
cells share the same promoter haplotype, “CAAC”.  
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Figure 5.2 Comparison of the CYSLTR1 promoter haplotype in LAD2 and LUVA cells. 
CYSLTR1 promoter regions from genomic DNA were isolated from LAD2 and LUVA cells 
and analysed by DNA sequencing. (A) PCR products specific for amplified CYSLTR1 
promoter from LAD2 and LUVA cells were run on agarose gels with the DNA ladder φX174 
DNA/BsuRI (HaeIII) (φ), numbers represent size in base pairs (bp). Sequencing data of 
CYSLTR1 promoter region in reverse orientation from (B) LAD2 and (C) LUVA cells, red 
boxes represent SNP locations.   
 
5.3.2 Comparison of CYSLTR1 coding region sequence between LAD2 and LUVA cells 
To determine whether there are any variations in the protein sequence of CysLT1 between 
LAD2 and LUVA cells that may affect receptor functionality, the coding region of CYSLTR1 
from both cell lines were analysed. PCR of DNA extracted from LAD2 and LUVA cells using 
primers 5'- TCAATGCCTCACTACTCTTGCTTG -3' and 5'- TTGGTTTGGACTGGAAATGGG -3' 
amplified a 1198 bp product containing the coding region (Figure 5.3A). BLAST analysis of 
the sequenced PCR products revealed the presence of one point mutation at gene position 
59771 C>T (SNP 6) (compared to CYSLTR1 RefSeqGene NG_012809.1) in both LAD2 and 
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LUVA cells (Figure 5.3B and D).  SNP at this location has been recorded previously and are 
identified as “rs320995” (Table 5.1). This transitional mutation from cytosine to thymine 
was further confirmed by DNA sequencing chromatograms showing a clear peak for 
thymine at this SNP location (highlighted in grey, Figure 5.3C and E). The allele change 
from TTC to TTT is a synonymous mutation as the two codons encode the same amino acid 
(phenylalanine). The sequencing data revealed that the coding regions of LAD2 and LUVA 
cells were 100 % identical.   
 
Figure 5.3 Comparison of CYSLTR1 coding regions from LAD2 and LUVA cells. 
CYSLTR1 coding regions from genomic DNA isolated from LAD2 and LUVA cells were 
analysed. (A) PCR products specific for amplified CYSLTR1 coding region from LAD2 and 
LUVA cells were run on agarose gels with the DNA ladder λ DNA/EcoRI+HindIII (λ), 
numbers represent size in base pairs (bp). BLAST analysis of sequencing data of CYSLTR1 
coding region in reverse orientation from (B) LAD2 and (D) LUVA cells, compared to 
CYSLTR1 gene NG_012809.1 sequence, data shows 60 bp extract of data with SNP location 
in red text, red box indicates data highlighted in DNA sequencing chromatograms (C) 
LAD2 and (E) LUVA, grey highlighted base represents SNP location. 
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Two human mast cell lines, LAD2 and LUVA, have been shown to differentially respond to 
LTE4 (see Chapter 4). On comparison of GPCR expression profiles, CysLT1 was shown to be 
more highly expressed in LAD2 cells than LUVA and when knocked down, all cysteinyl 
leukotriene-induced responses were significantly reduced. This suggested that LTE4’s 
“full” agonist characteristics were being mediated by CysLT1 but unfortunately did not 
explain how the responses to LTE4 can differ significantly between the two mast cell lines. 
Polymorphisms such as SNPs, are the most common source of genetic variation and have 
been shown to affect CYSLTR1 promoter activity and responsiveness to cysteinyl 
leukotrienes , so it is fully possible that SNPs can alter CysLT1 functionality (136,270,273). 
This study was undertaken to identify whether any genetic variations could account for 
the differential LTE4 signalling in LAD2 and LUVA cells. 
Sequencing of the promoter region identified numerous SNP sites that when compared in 
LAD2 and LUVA cells, were 100 % identical. They contained the promoter haplotype CAAC 
which has been shown to be the major haplotype in both healthy and asthmatic 
populations (274). There are no disease associations with the CAAC CYSLTR1 promoter 
haplotype but studies are limited and there is a distinct lack of reproducible data that 
could be due to small sample sizes, the fact that asthma isn’t just one disease state 
(heterogeneity) and potentially geometric differences (268-270).  
Sequencing of the coding region again identified that LAD2 and LUVA cells were 100 % 
identical and a common SNP (SNP 6, rs320995, Table 5.1) was observed replacing the C 
allele for a T. This SNP is synonymous as the codons TTT and TTC encode the same amino 
acid, phenylalanine. This means that there would be no differences in the protein structure 
of CysLT1. However Duan et al. have suggested that changes in alleles could alter mRNA 
translation and stability, even in the case of a synonymous SNP (275). Their study 
identified two functional synonymous SNPs in the dopamine D2 receptor that altered 
receptor expression and regulation. Although this is an interesting concept, that 
synonymous SNPs might not just be “silent” mutations, this unfortunately cannot help to 
explain why there is differential CysLT1 expression and responses to LTE4 in LAD2 and 
LUVA cells, as both regions, promoter and coding, are identical. If genetic variations are 
not involved in LTE4’s “full” agonist characteristics then some other factors must be 
contributing to this phenomenon.  
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Leukotrienes have been thought to have two modes of action. Primary mechanisms are a 
direct result of leukotriene stimulation, such as observed in Guinea pig trachea, vascular 
smooth muscle and human bronchioles. Secondary mechanisms arise from cysteinyl 
leukotriene-induced activation of arachidonic acid release, which could lead to either 
leukotriene or prostanoid (prostaglandins, thromboxanes and prostacyclin) production. In 
guinea pig lungs, LTD4 has been shown to induce the production of thromboxanes and 
prostaglandins (276). More recently, LAD2 cells have been shown to robustly produce 
prostaglandin D2 (PGD2) upon stimulation with LTD4 and LTE4 (257). Interestingly, in Th2 
cells, LTE4 was able to significantly potentiate PGD2-induced cytokine production. This 
suggests that such cysteinyl leukotriene-induced eicosanoid production could have the 
ability to potentiate responses in an auto/paracrine fashion.  
Signalling transduction pathways of CysLT1 have been previously studied but 
unfortunately, the majority of the studies have focused only on LTD4 signalling. Another 
issue that has arisen from previous reports is CysLT1’s G-protein promiscuity (also 
discussed in section 1.1.4 Cysteinyl leukotriene receptors). CysLT1 has the ability to activate 
several different G-protein associated pathways. Both signalling pathways and GPCR 
coupling differ hugely from cell to cell.  
In isolated human monocytes, LTD4-induced intracellular calcium mobilisation and gene 
expression were fully inhibited by MK-571 and pertussis toxin suggesting signalling 
occurs through CysLT1 coupled to Gαi (134). Intracellular calcium was also inhibited by the 
IP3 receptor inhibitor, 2APB, the PLC inhibitor, U73122, calcium chelators BAPTA 
(intracellular calcium) and EGTA (extracellular calcium), and finally by the thapsigargin, 
which depletes endoplasmic reticulum stores. This means that LTD4-induced calcium 
mobilisation is mediated by PLC and the IP3 receptor, the activation of store-operated 
calcium channels and both intracellular and extracellular calcium are required for 
signalling. Gene expression was inhibited by 2APB and BAPTA but also by p38 and Erk 
inhibitors. This suggests that LTD4-induced gene expression in primary monocytes is 
mediated by CysLT1 in a Gαi/calcium/MAPK dependent manner (134). 
Interestingly, two other studies have analysed LTD4 responses in the monocytic cell lines 
THP-1 and U937 and have identified two distinct CysLT1 signalling pathways; pertussis 
toxin-sensitive and pertussis toxin-insensitive. Hoshino et al. observed ~30 % inhibition 
of intracellular calcium mobilisation induced by LTD4 in THP-1 cells by pertussis toxin 
pretreatment (133). This LTD4-induced pertussis toxin-sensitive pathway, which implies 
coupling to Gαi, was able to inhibit forskolin-induced cAMP and was also implicated in 
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chemotaxis. The LTD4-induced pertussis toxin-insensitive pathway was shown to involve 
Erk activation. Erk phosphorylation was only slightly sensitive to pertussis toxin and 
partially inhibited by BAPTA and the pan-PKC inhibitors GF101203X and staurosporine. 
Complete abrogation of Erk activation was observed by TPA, which depletes endogenous 
PKCs. This suggests that the pertussis toxin insensitive pathway in THP-1 cells activates 
Erk in a PKC-dependent pathway that is only partially dependent on calcium. 
In differentiated U937 (dU937) cells, these CysLT1 mediated LTD4-induced pertussis toxin-
sensitive and –insensitive pathways were observed but a different signal transduction 
pathway was suggested (277). The difference stems from the Erk activation. LTD4-induced 
Erk phosphorylation is completely inhibited by pertussis toxin in dU937 cells where as it 
is only slightly inhibited in THP-1 cells (133). This activation of Erk was partially inhibited 
by Clostridium sordellii lethal toxin, which inhibits small GTPases such as Ras, Rap and Rac. 
LTD4 was shown to induce Ras activation in these cells and was completely inhibited by 
pertussis toxin, BAPTA and by an inhibitor of PLC. This suggests that the pertussis toxin-
sensitive pathway in dU937 cells, which is mediated by Gαi, activates Ras in a calcium-
dependent manner which is only partially responsible for Erk activation.  
To complicate the picture more, in the intestinal epithelial cell line, Int407, LTD4-induced 
Ras activation was shown to be insensitive to pertussis toxin treatment and the Gαi 
mediated pathway activated Erk through PKC-epsilon and Raf-1. This shows that CysLT1 
signal transduction pathways must be highly regulated from cell to cell which could be 
influenced by constitutive expression levels of these effector molecules and by GPCR 
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6.2 Study Aims 
Our previous data strongly suggested that CysLT1 is responsible for cysteinyl leukotriene 
signalling in the human mast cell lines, LAD2 and LUVA. As there were no genetic 
variations identified in the CYSLTR1 gene sequence between LAD2 and LUVA cells, other 
factor/s must be contributing to the potent responses to LTE4 in LAD2 cells.  Most of the 
previous studies analysing CysLT1 signalling pathways focused on LTD4, as the major 
agonist for the receptor, excluding LTE4 from the analysis (as a final leukotriene 
metabolite and partial agonist) thus any differences between LTD4 and LTE4 signalling are 
poorly understood. 
The aim of this study is to elucidate the signalling requirements that allow LTE4 to act as a 
“full” agonist in LAD2 cells.  LTD4 and LTE4 signalling pathways will be compared between 




6.3.1 Comparison of CYSLTR1 and CYSLTR2 in human mast cell lines LAD2 and LUVA 
Our initial results already suggested that CYSLTR1 is differentially expressed in LAD2 and 
LUVA cells. Looking more comprehensively at the microarray data, CYSLTR1 was 
consistently more highly expressed in LAD2 cells than in LUVA, while CYSLTR2 expression 
levels were very low and similar in both cell lines (Figure 6.1A-B). qRT-PCR also confirmed 
that LAD2 cells have higher expression of CYSLTR1 mRNA than LUVA cells (Figure 6.2A). 
Generally both cell lines have a much higher expression level of CYSLTR1 than CYSLTR2 
and 2 hour stimulations with LTD4 or LTE4 had no effect on the expression of either 
receptor. 
To ascertain whether the expression level of CysLT1 is relevant for mast cells 
responsiveness to cysteinyl leukotrienes, CysLT1 was overexpressed in LUVA cells. 
Forward constructs of human CysLT1 tagged with 3xHA and vectors without the gene 
(Empty controls) were stably transfected into LUVA cells using lentiviral transduction and 
positive clones selected using puromycin. qRT-PCR confirmed a 3-fold increase in 
CYSLTR1 expression in the [CysLT1-3xHA] transfectant population (Figure 6.2B) but 
unfortunately when using an antibody against the HA tag, no increase in fluorescence was 
observed compared to the control cells, suggesting lack of receptor surface expression 
(Figure 6.2C). Stimulation for 2 hours with either LTD4 or LTE4 revealed no differences in 
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responses to both leukotrienes, measured as CCL4 mRNA between CysLT1 transfectants 
and empty control cells (Figure 6.2D).  
 
 
Figure 6.1 Comparison of CYSLTR1 and CYSLTR2 expression levels between LAD2 
and LUVA cells.  
(A) CYSLTR1 and (B) CYSLTR2 mRNA expression levels in LAD2 and LUVA cells 
stimulated for 2 hours in the presence of L-cysteine 3 mmol/L with either vehicle control 
(Ctl.), LTD4 100 nmol/L or LTE4 100 nmol/L analysed using Affymetrix Human Gene 1.0 ST  
arrays, data expressed as log2 of expression intensity values. 
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Figure 6.2 The effect of CysLT1 overexpression in LUVA cells.  
(A) mRNA expression level of CYSLTR1 and CYSLTR2 in LAD2 and LUVA cells measured 
by qRT-PCR, n=3, 18s used as endogenous control, data expressed as arbitrary units. 
Forward constructs of 3xHA tagged CysLT1 were stably transfected into LUVA cells using 
lentivirus, (B) relative quantification of CYSLTR1 mRNA in [CysLT1-3xHA] transfectants, 
data relative to [Empty] control, 18s used as endogenous control, n=3, (C) Flow cytometric 
analysis of CysLT1 expression in [CysLT1-3xHA] (grey line) and [Empty] (filled black) 
transfectants using a Alexa Fluor labelled antibody specific for 3xHA, 1:1000, results from 
a single experiment representative of 3, (D) relative quantification of CCL4 mRNA in 
[Empty] (open bars) and [CysLT1-3xHA] (closed bars) transfectants stimulated for 2 hours 
in the presence of L-cysteine 3 mmol/L with either LTD4 100 nmol/L, LTE4 100 nmol/L or 
vehicle control (Ctl.), data relative to Ctl., 18s used as endogenous control, one experiment 
run in triplicate. Data in (A) and (B) represented as mean ± SEM. 
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6.3.2 Analysis of CysLT1 G-protein coupling in human mast cell lines 
As previously stated, CysLT1 has the potential to signal via two different Gα proteins, Gαi 
and Gαq, and so it is important to first ascertain how CysLT1 couples in both mast cell lines. 
Pertussis toxin (Ptx) is a protein that specifically catalyses the ADP-ribosylation of Gαi, 
therefore inhibiting the G-protein’s ability to bind to GPCRs and thus is an invaluable tool 
for differentiating signalling pathways (61,73). Cysteinyl leukotrienes induce robust 
intracellular calcium fluxes in both LAD2 and LUVA cells (Figure 4.3). Intracellular calcium 
mobilisation can be induced by GPCRs coupled to either Gαq or Gαi so responses were 
analysed in both cell lines when pretreated with pertussis toxin. LTC4, LTD4 and LTE4 
induced a robust concentration-dependent calcium mobilisation in LAD2 cells that was 
completely unaffected by pertussis toxin pretreatment (Figure 6.3A). This lack of 
sensitivity to pertussis toxin treatment was also observed in LUVA cells where the 
concentration-dependent calcium fluxes were unaltered suggesting that calcium 
responses are exclusively Gαq mediated in both these cell lines (Figure 6.3B). The effect of 
pertussis toxin treatment on gene expression was also analysed. Looking at COX2 and 
CCL4 mRNA expression, pertussis toxin treatment did not affect LTD4 or LTE4-induced 
responses in both LAD2 and LUVA cells (Figure 6.4). This suggests that CysLT1 signalling 
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Figure 6.4 Cysteinyl leukotriene-induced gene expression is not mediated by Gαi in 
human mast cell lines.  
Relative quantification of COX2 and CCL4 expression in (A) LAD2 and (B) LUVA cells 
stimulated for 2 hours with either LTD4 100 nmol/L, LTE4 100 nmol/L or vehicle control 
(Ctl.) in the presence of L-cysteine 3 mmol/L with or without overnight pertussis toxin 
(Ptx) 100 ng/ml preincubation, data relative to untreated Ctl. 18s used as endogenous 
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6.3.3 Analysis of potential modifiers of the cysteinyl leukotriene signalling pathway  
Cyclooxygenases (COX1 or COX2) are key enzymes involved in the production of 
prostaglandins (278). As previously stated, a cross talk of leukotriene and prostaglandin 
pathways has been hypothesised for many years as a potential way to potentiate 
responses. To ascertain whether this could be the cause of the potent responses to LTE4 in 
LAD2 cells, relative quantification of CCL4 mRNA expression was analysed in response to 
cysteinyl leukotriene stimulation with or without pretreatment with specific inhibitors.  
Indomethacin, a nonselective inhibitor of cyclooxygenase, and NS-398 a selective COX2 
inhibitor had no effect on LTE4 or LTD4-induced responses in LAD2 cells (Figure 6.5A). 
This lack of response attenuation was mirrored in LUVA cells (Figure 6.5B).  To analyse 
whether CRTH2 (a receptor for prostaglandin D2 expressed on mast cells) plays a role in 
these responses, the specific inhibitor CAY10471 was used. LTD4 and LTE4-induced mRNA 
expression in both LAD2 and LUVA cells were unaffected by inhibiting CRTH2 (Figure 
6.5A-B). 
Previous reports have suggested that PPAR-γ is involved in the leukotriene signalling 
pathway in mast cells, almost exclusively in LTE4-induced responses (257). To analyse 
whether cysteinyl leukotrienes responses are mediated by PPAR-γ in either LAD2 or LUVA 
cells, relative quantification of CCL4 mRNA was measured with or without a pretreatment 
with the PPAR-γ inhibitor, GW9662. Surprisingly, GW9662 had no effect on LTD4 or LTE4-
induced CCL4 mRNA expression in LAD2 cells, contradictory to what has been reported 
(Figure 6.5C)(257). This was also mimicked in the LUVA cells (Figure 6.5D). To confirm 
these findings another PPAR-γ inhibitor, T0070907, was tested. Pretreatment of LAD2 and 
LUVA cells with T0070907 again had no effect on LTD4 or LTE4-induced CCL4 mRNA 
expression (Figure 6.5C-D). 
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Figure 6.5 The effect of COX, CRTH2 and PPAR-γ inhibition on cysteinyl leukotriene 
responses in mast cell lines.  
Relative quantification of CCL4 mRNA expression in the indicated mast cell lines 
stimulated with either LTD4 100 nmol/L, LTE4 100 nmol/L or vehicle control (Ctl.) for 2 
hours in the presence of L-cysteine 3 mmol/L with or without the pretreatment of either 
(A-B) indomethacin 10 μmol/L for 30 minutes, NS-398 10 μmol/L for 30 minutes or 
CAY10471 100 nmol/L for 10 minutes, n=2-4 (C-D) GW9662 10 μmol/L or T0070907 1 
μmol/L for 1 hour, n=2.  Data relative to untreated Ctl. 18s used as endogenous control. 
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6.3.4 Analysis of cysteinyl leukotriene signalling pathways in LAD2 and LUVA cells 
As intracellular calcium mobilisation and gene expression is mediated by a Gαq coupled 
CysLT1 receptor in both LAD2 and LUVA cells, it is important to ascertain whether there 
are any differences in downstream signalling pathways that might explain the potency of 
LTE4 in LAD2 cells. Pretreatment of both mast cell lines with the intracellular and 
extracellular calcium chelators, BAPTA-AM and EDTA, fully abrogated LTD4 and LTE4-
induced CCL4 expression, suggesting that calcium is essential for gene expression to occur 
(Figure 6.6A-B). Inhibition of JNK had no effect on cysteinyl leukotriene responses in 
either cell line (Figure 6.6C-D). PI3K inhibition surprisingly did not affect LTD4 responses 
in LAD2 cells, as this has been previously reported, but did inhibit CCL4 expression 
induced by LTD4 in LUVA cells (Figure 6.7A-B)(257). Responses to LTE4 were insensitive 
to PI3K inhibition in both mast cell lines. Pretreatment of LAD2 and LUVA cells with the 
MEK inhibitor (Erk pathway) U-0126 significantly inhibited LTD4 and LTE4-induced CCL4 
expression (Figure 6.7C-D).  
Cysteinyl leukotriene-induced CCL4 expression in LAD2 cells was also affected by 
pretreatment with the pan-PKC inhibitor Gö 6983 (Figure 6.8A). This partial inhibition of 
leukotriene-induced responses was not observed when analysing intracellular calcium 
mobilisation (Figure 6.8C) and in LUVA cells, where all responses, gene expression and 
intracellular calcium mobilisation were completely insensitive to PKC inhibition (Figure 
6.8B and D). Microarray data of both cell lines comparing PKC isozymes revealed 
substantial differences in expression levels of PKC alpha, beta, epsilon and eta that could 
potentially attribute to the difference observed (Figure 6.8E).  
This means that in both cell lines CysLT1-Gαq mediated gene expression requires both 
intracellular and extracellular calcium and is dependent on Erk activation. Gene 
expression is not dependent on the activation of COX, CRTH2, PPAR-γ or JNK. In LAD2 cells, 
LTD4 and LTE4-induced gene expression is partially dependent on the activation of a 
calcium-independent PKC. While in LUVA cells, gene expression is not dependent on 
activation of PKC. Only LTD4-induced gene expression in LUVA cells seems to require the 
activation of PI3K.    
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Figure 6.6 The effect of calcium depletion and JNK inhibition on cysteinyl 
leukotriene responses in mast cell lines.  
Relative quantification of CCL4 mRNA expression in the indicated mast cell lines 
stimulated with either LTD4 100 nmol/L, LTE4 100 nmol/L or vehicle control (Ctl.) for 2 
hours in the presence of L-cysteine 3 mmol/L with or without the pretreatment of either 
(A-B) BAPTA-AM 30 μmol/L for 30 minutes or EDTA for 10 minutes, n=3 (C-D) SP600125 
1 μmol/L for 1 hour, n=2.  Data relative to untreated Ctl. 18s used as endogenous control. 
Data represented as mean ± SEM. 
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Figure 6.7 The effect of PI3K and MEK inhibition on cysteinyl leukotriene responses 
in mast cell lines.  
Relative quantification of CCL4 mRNA expression in the indicated mast cell lines 
stimulated with either LTD4 100 nmol/L, LTE4 100 nmol/L or vehicle control (Ctl.) for 2 
hours in the presence of L-cysteine 3 mmol/L with or without the pretreatment of either 
(A-B) LY294002 10 μmol/L for 30 minutes, n=3 (C-D) U-0126 1 μmol/L for 30 minutes, 
n=3.  Data relative to untreated Ctl. 18s used as endogenous control. Data represented as 
mean ± SEM. 
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Figure 6.8 The effect of PKC inhibition on cysteinyl leukotriene responses in mast 
cell lines.  
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Relative quantification of CCL4 mRNA expression in (A) LAD2 and (B) LUVA cells 
stimulated with either LTD4 100 nmol/L, LTE4 100 nmol/L or vehicle control (Ctl.) for 2 
hours in the presence of L-cysteine 3 mmol/L with or without a 30 minute pretreatment 
with Gö 6983 1 μmol/L, n=2, data relative to untreated Ctl. 18s used as endogenous 
control. Baseline corrected peak calcium flux data of (C) LAD2 and (D) LUVA cells 
stimulated with either LTD4 100 nmol/L or LTE4 100 nmol/L with or without a 30 minutes 
pretreatment with Gö 6983 1 μmol/L, n=2-3. (E) Relative expression of PKC isozymes in 
LAD2 (closed bar) and LUVA (open bar) cells analysed using Affymetrix microarrays, n=3. 
Data represented as mean intensity values ± SEM. Relative fluorescence units (RFU). 
 
6.3.5 Analysis of cysteinyl leukotrienes agonist dynamics 
Since there were no differences identified in signalling pathways between LTD4 and LTE4 
in LAD2 cells there must be another explanation to why LTE4 is a potent agonist in this 
model and not in any other cell models analysed such as our overexpression models and 
LUVA cells. In previous experiments it was shown that cysteinyl leukotriene-induced gene 
expression is partially dependent on Erk activation (Figure 6.7C-F). To further analyse the 
agonist actions of LTE4, time course experiments of Erk phosphorylation were conducted 
and analysed by Western blot. In LAD2 cells stimulated with LTD4, Erk phosphorylation 
peaked at 7 minutes with a gradual decrease until 60 minutes where detected Erk 
phosphorylation was very weak (Figure 6.9A). LTE4 induced a peak of Erk 
phosphorylation at around 10-15 minutes with a more sustained phosphorylation, still 
being detectable at the 60 minutes time point.  In LUVA cells the point at which Erk 
phosphorylation peaked was very similar to LAD2 cells (LTD4 ~ 5-7 minutes and LTE4 ~ 
10-15 minutes, Figure 6.9B). LTE4-induced Erk phosphorylation in LUVA cells was far less 
prolonged than in LAD2 cells with detected phosphorylation being similar to that of the 
control at 60 minutes (Figure 6.9B).  
To analyse how the prolonged signalling caused by LTE4 in LAD2 cells could potentially 
effect gene expression, long and short ligand exposure experiments were set up and CCL4 
mRNA expression was analysed. For the short ligand exposure, cells were stimulated with 
either LTD4 or LTE4 for 5 minutes, washed and then lysed for mRNA analysis after a 2 hour 
(total) incubation. For the long ligand exposure, cells were stimulated for 2 hours 
(continuously) with either LTD4 or LTE4 then lysed for mRNA analysis. In LAD2 cells, the 2 
hour exposure revealed similar results to what has been seen previously, the response to 
LTE4 was 97 % of LTD4(mean, Figure 4.2A and Figure 6.9C). In the 5 minute exposure, the 
overall induction of CCL4 mRNA was much lower but interestingly, the response to LTE4 
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was much weaker than LTD4 with LTE4 being able to reach only 32 % of the response to 
LTD4 (mean).  In LUVA cells, the order of ligand potencies remained the same between the 
two exposure times: LTE4 was far less potent than LTD4 (31 % and 13 %, mean, 2 hours 
and 5 minutes respectively; Figure 6.9D).  
 
Figure 6.9 The effect of cysteinyl leukotrienes dynamics in human mast cell lines.  
Western blot analysis of cell lysates obtained from either (A) LAD2 or (B) LUVA cells 
stimulated for the indicated times with either vehicle control (Ctl.), LTD4 100 nmol/L or 
LTE4 100 nmol/L using antibodies specific for phosphorylated (P) Erk and total Erk,  
results from a single experiment representative of 2. Relative quantification of CCL4 
mRNA expression in (C) LAD2 and (D) LUVA cells exposed, in the presence of L-cysteine 3 
mmol/L, for either 5 minutes (open bar) or 2 hours (closed bar) to either vehicle control, 
calcium ionophore A23187 (Ca2+), LTD4 100 nmol/L or LTE4 100 nmol/L for a total 
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incubation period of 2 hours, data relative to Ctl., 18s used as endogenous control, (C) n=3 
(D) n=2. Data represented as mean ± SEM. 
 
 
An important regulatory feature of GPCRs is receptor desensitisation. As previously 
described, this mechanism allows essentially the termination of signalling through certain 
pathways such as receptor phosphorylation and receptor internalisation. To ascertain 
whether each cysteinyl leukotriene could induce receptor desensitisation, stimulations 
were performed at 20 and 120 seconds on the same cell population and intracellular 
calcium mobilisation was analysed. In LAD2 cells, all three cysteinyl leukotrienes induced 
a robust flux in intracellular calcium in the initial 20 second stimulation (Figure 6.10A-C). 
The calcium response to LTD4 was completely abrogated by prior stimulation with either 
LTC4 or LTD4, suggesting that both LTC4 and LTD4 can fully desensitise CysLT1 in LAD2 
cells (Figure 6.10A-B). Interestingly, the calcium response to LTD4 was only partially 
inhibited by prior stimulation with LTE4 showing that LTE4 can only partially desensitise 
CysLT1 (Figure 6.10C). In LUVA cells, a similar pattern of ability to desensitise was 
exhibited. LTC4 and LTD4 were able to fully abrogate the second stimulation by LTD4 while 
LTE4 was unable/partially inhibited the calcium response to LTD4 (Figure 6.11A-C).  
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Figure 6.10 The effect of cysteinyl leukotrienes on receptor desensitisation in LAD2 
cells.  
Raw calcium flux data of LAD2 cells stimulated at 20 and 120 seconds with 100 nmol/L of 
(A) LTC4 then LTD4, (B) LTD4 then LTD4, (C) LTE4 then LTD4, representative of 3 
experiments run in triplicate, relative fluorescence units (RFU), black arrows indicates 
start of stimulation. 
 
                                                                                                                                            Results: Chapter 6   




Figure 6.11 The effect of cysteinyl leukotrienes on receptor desensitisation in LUVA 
cells.  
Raw calcium flux data of LUVA cells stimulated at 20 and 120 seconds with 100 nmol/L of 
(A) LTC4 then LTD4, (B) LTD4 then LTD4, (C) LTE4 then LTD4, representative of 3 
experiments run in triplicate, relative fluorescence units (RFU),  black arrows indicates 
start of stimulation. 
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Comparison of GPCR expression levels in LAD2 and LUVA cells showed higher constitutive 
CysLT1 mRNA expression in LAD2 cells. This finding was also confirmed by qRT-PCR 
(Figure 6.1 and Figure 6.2A). To ascertain whether the amount of expression of the CysLT1 
receptor plays an important role in the responses to LTE4, HA tagged CysLT1 was 
overexpressed in LUVA cells to see if the potency of LTE4 could be increased (Figure 6.2B-
D). Although an increase in CYSLTR1 was observed at an mRNA level, there was no change 
in HA expression detected on the cell surface compared to the [Empty] control. As mRNA 
expression doesn’t necessary relate to protein surface expression and due to the lack of 
reliable CysLT1 antibodies for flow cytometry our aim was to measure receptor surface 
expression using an antibody to the N-terminal tag peptide. Compared to other tags such 
as GFP, HA is a relatively small peptide which has been used extensively in previous 
studies (Chapter 3) and so it was disappointing that the HA-tagged receptor could not be 
detected on the cell surface (279). CysLT1 itself is well known to be difficult to overexpress 
in cell systems so this coupled with an N-terminal tag might have significantly affected 
successful protein folding and/or surface expression. The possibility that a very low 
number of recombinant CysLT1 molecules were present on the cell surface but not 
detected due to sensitivity of the assay cannot also be excluded. Unfortunately no 
conclusion can be made at this stage from this overexpression model. Further experiments 
need to be carried out, potentially using different expression vectors or an untagged 
version of CysLT1 in LUVA cells, although with the lack of good antibodies, assessing 
surface expression will be difficult.   
Responses of both cell lines to cysteinyl leukotrienes were unaffected by pertussis toxin 
treatment revealing that gene expression is mediated by CysLT1 that couples mainly to Gαq 
in these cells (Figure 6.3 and Figure 6.4). As previously stated, CysLT1 is a GPCR that has 
the ability to couple to different G-proteins which seems to be cell type dependent. For 
example, in overexpression models using cRNA injected Xenupus laevis oocytes and 
transfected HEK293 cells, LTD4-induced responses were not inhibited by pertussis toxin 
treatment suggesting a Gαq coupled receptor (114,239). CysLT1 responses in Th2 cells and 
the monocytic cell lines THP-1 and dU937 show partial pertussis toxin sensitivity i.e. 
CysLT1 coupling to Gαi and Gαq (130,133,277). Eosinophil and monocyte responses to 
cysteinyl leukotrienes are completely inhibited by pertussis toxin i.e. CysLT1 couples to Gαi 
in those cells and in alveolar macrophages leukotriene mediated responses are unaffected 
by pertussis toxin treatment (134,280,281). In human mast cells, LTD4 mediated 
proliferation has been shown to be mediated by a Gαi coupled CysLT1 receptor (254).  
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For LTE4 to be a potent agonist in LAD2 cells and no other cell type previously analysed it 
was hypothesised that there must be differences in how LTE4 signals compared to LTD4. 
COX and CRTH2 inhibition had no effect on cysteinyl leukotriene-induced gene expression 
which suggests initial responses activated by cysteinyl leukotrienes only are being 
observed (Figure 6.5A-B), however this does not rule out LTE4 activating such secondary 
mechanisms, as shown by the induction of COX2 mRNA expression (Figure 4.2A) and by 
PGD2 release (257). PPAR-γ inhibition also had no effect on gene expression. In Paruchuri 
et al.’s study, LTE4-induced responses were almost exclusively liable to PPAR-γ inhibition 
by GW9662 (257). As our results were contradictory to their findings a second PPAR-γ 
inhibitor, T0070907, was also analysed confirming our initial observations (Figure 6.5).    
It has been reported in many studies that LTE4 is much weaker activator of intracellular 
calcium mobilisation than LTD4 (170,239,257,282). Calcium flux is essential for gene 
expression in both mast cell lines (Figure 6.6A-B) which might explain why the LTE4-
induced upregulation of genes such as CCL4 or GMCSF in LUVA cells is not observed, since 
the calcium signalling threshold might not have been reached (Figure 4.2B). LTE4- induced 
calcium in LAD2 cells was almost half that of LTD4’s but at a gene expression level, 
responses to LTE4 matched responses to LTD4, suggesting additional signalling 
mechanisms being involved. Analysis of potential leukotriene-induced signalling pathways 
revealed no differences between LTD4 and LTE4 signalling in LAD2 cells. Gene expression 
was partially affected by inhibitors specific for the MEK (Erk) and the PKC pathways 
(Figure 6.7C-D and Figure 6.8). Calcium mobilisation was unaffected by pan-PKC 
inhibition, revealing a signalling pathway independent of calcium mobilisation. As 
previously stated, PKC isozymes have been classified by their signalling requirements. As 
PKC inhibition did not affect calcium mobilisation, isozymes from either novel or atypical 
classification groups i.e. delta, epsilon, eta, mu, theta, lambda or zeta, are potential 
candidates for mediating cysteinyl leukotriene-induced gene expression in LAD2 cells.   
GPCR signalling is highly regulated by constitutive expression levels of a plethora of 
signalling components such as surface proteins, G-proteins and PKCs. As PKC inhibition 
did not affect cysteinyl leukotriene responses in LUVA cells, the expression levels of the 
PKC isozymes between the two mast cell lines was compared (Figure 6.8E). Interestingly, 
out of the novel and atypical PKCs only epsilon and eta were quite highly differentially 
expressed (epsilon: LAD2 685, LUVA 72; eta: LAD2 543, LUVA 31, mean, relative 
expression units). Previous studies have linked PKC-epsilon with cysteinyl leukotriene-
induced responses. In intestinal epithelium it has been shown that responses to LTD4 are 
regulated by PKC-epsilon in a calcium-dependent manner using anti-PKC-epsilon 
antibodies (283). While anti-PKC-alpha and delta antibodies had no effect on LTD4-
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induced calcium. Recently, Kondeti et al. identified by shRNA knockdown that LTD4 and 
LTE4-induced PKC-epsilon activation was calcium-independent, while PKC-alpha 
negatively regulated calcium mobilisation in LAD2 cells (284). PKC-eta has never been 
studied as a PKC involved in cysteinyl leukotriene signalling so both isozymes need to be 
more comprehensively analysed to elucidate whether the increased responses to LTE4 is a 
direct result of specific PKC expression and function in LAD2 cells.    
Erk activation is an important signalling mechanism that links signalling events from the 
cytoplasm to the nucleus and is also thought to regulate receptor functionality such as 
internalisation through GRK and arrestins. For example, Alblas et al. observed significant 
changes in the signalling kinetics, specifically a switch from transient to sustained Erk 
activation, when the GPCR for neurokinin A was modified to abrogate internalisation 
(285,286).  Eisinger et al. reported that  morphine’s ability to induce sustained Erk 
activation was directly attributed to its inability to prevent opioid receptor internalisation 
(287), while etorphine, another opioid receptor agonist, induced transient Erk activation 
and strongly internalised its receptor. Morphine’s ability to induce internalisation was 
reinstated by inhibition of the Erk pathway, while etorphines was further enhanced. As 
desensitisation is linked to internalisation, although not exclusively, the fact that LTE4 can 
only partially desensitise CysLT1 signalling while LTD4 shows full desensitisation activity 
suggests that CysLT1 desensitisation could be potentially explained by the ligands ability 
to induce sustained/transient Erk activation. Although CysLT1 internalisation would be 
very difficult to quantify, due to the unavailability of specific CysLT1 antibodies, it could be 
hypothesised that LTE4-induced sustained Erk activation lowers CysLT1 ability to 
internalise and so it can only partially desensitise its receptor. LTD4 on the other hand 
induces transient Erk activation that can robustly promote receptor internalisation and 
that is why full desensitisation can be observed. Partial desensitisation may also account 
for LTE4’s need for longer exposure times to be as potent as LTD4 at inducing gene 
expression (Figure 6.9C).  
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These studies highlight the complexities in leukotriene receptor biology and leukotriene 
signalling pathways involved in the immune response in chronic diseases such as asthma. 
Ever since the elucidation and cloning of the two human cysteinyl leukotriene receptors, 
CysLT1 and CysLT2, LTE4 has become the “forgotten” mediator in cysteinyl leukotriene 
biology (288). Its apparent weak efficacy in recombinant systems, poor binding affinities 
compared to LTC4/LTD4 and the availability of selective CysLT1 antagonists side-lined 
LTE4 as an important target for basic and clinical research. However, even though LTE4 has 
been perceived as a weak agonist, it possesses some unique characteristics that cannot be 
explained by our current knowledge of the known cysteinyl leukotriene receptors. Recent 
studies using mouse models have brought LTE4 back into the limelight by revealing 
specific LTE4-induced inflammation that was not associated with CysLT1 or CysLT2 and in 
turn potentially identifying two GPCRs that could be responsible for such responses 
(170,218,236). This led us to investigate those receptors and to search for other GPCRs 
potentially responsible for the potent responses to LTE4 that are observed within human 
cell models.      
Our recombinant overexpression models as well as primary cell models analysing 
leukotriene mediated responses have provided strong evidence that P2Y12 and OXGR1 are 
not directly activated by LTE4, a conclusion which has been further strengthened by a 
recent report analysing both these receptors in human eosinophils (Chapter 3) (289). The 
identification of two human mast cell lines that differentially respond to LTE4 has allowed 
comparative analysis to elucidate firstly the receptor involved in LTE4 signalling and 
secondly the cell specific elements (signalling proteins) necessary for potent LTE4 activity. 
Our data supports a new model of LTE4 signalling in LAD2 cells, presented in Figure 7.1. It 
could be hypothesised that the regulation of gene expression by LTE4 requires cells to 
express high levels of Gαq coupled CysLT1. Upon stimulation this activates robust 
intracellular calcium mobilisation and sustained Erk activation, combined with activation 
of the PKC pathway. All of these elements required for LTE4 activities are present in LAD2 
cells but only partially present or absent in the case of LUVA cells.  
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Figure 7.1 A Schematic diagram showing LTE4 signalling pathways through CysLT1 
in both LAD2 and LUVA cells.  
The activation of CysLT1 by LTE4 in LAD2 cells was confirmed by knockdown and selective 
CysLT1 antagonist experiments, showing almost complete abrogation of both calcium 
mobilisation and gene expression (Figure 4.6 and 4.8-9). CysLT1 signals via Gαq in both cell 
lines as LTE4-induced responses were insensitive to pertussis toxin treatment in both 
LAD2 and LUVA cells (Figure 6.3 and 6.4). Finally, sequencing of the promoter and coding 
region of CYSLTR1 revealed no differences between LAD2 and LUVA cells suggesting that 
no CYSLTR1 genetic variations are responsible for such a selective LTE4 activity (Chapter 
5). 
LTE4 acting through CysLT1 activates intracellular calcium fluxes and Erk kinases to 
regulate gene expression. In LAD2 but not in LUVA cells, LTE4-induced PKC activation is 
required for gene transcription (Figure 6.8B). Pan-PKC inhibition partially abrogated gene 
expression but had no effect on calcium mobilisation suggesting that PKC activation and 
calcium mobilisation are regulated separately (Figure 6.8C). LTE4-induced calcium 
mobilisation in both, LAD2 and LUVA cells (Figure 4.3), but a much more robust response 
was observed in LAD2 cells. The ability of LTE4 to induce alternative signalling pathways 
in LAD2 cells, such as PKC activation and robust calcium fluxes may be a direct 
consequence of receptor expression levels. Analysis of mRNA levels by microarray and 
qRT-PCR, suggests that CysLT1 is much more highly expressed in LAD2 cells than in LUVA 
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(Figure 6.1A and 6.2A). Certainly, in the case of LTD4, the lower expression level that is 
observed in LUVA cells is sufficient to induce gene expression but for a partial agonist such 
as LTE4, the constitutive receptor expression level needs to be higher to fully activate the 
pathway. The higher CysLT1 expression in LAD2 cells would allow LTE4 to generate a 
greater flux in intracellular calcium that could reach a threshold level required for 
regulation of gene transcription. Receptor expression is also important for the activation 
of multiple signalling pathways. In recombinant overexpression models, lower GPCR 
expression can limit signal pathway activation, a phenomenon that could explain lack of 
PKC pathway activation in LUVA cells (290). Similarly, PKC activation may also be 
influenced by constitutive expression of various PKC isozymes. Comparison of microarray 
data from LAD2 and LUVA cells revealed substantial differences in PKC alpha, beta, epsilon 
and eta expression (Figure 6.8E). PKC epsilon and eta can be activated independently of 
calcium and so may also contribute to the lack of PKC activation seen in LUVA cells. The 
involvement of the PKC pathway in cysteinyl leukotriene-induced CysLT1 signal 
transduction has already been noted for LTD4 (133,291). In a recent study by Kondeti et al. 
it was shown that knockdown of PKC-epsilon by siRNA in LAD2 cells can significantly 
inhibit LTD4 and LTE4-induced CCL4 release and expression of the transcription factor, c-
fos (284). Although only a partial inhibition was observed, this study strengthens the idea 
that PKC activation is important for “normal” cysteinyl leukotriene functionality and 
potentially the lack of PKC expression, especially PKC-epsilon, may be critical to LTE4 
being able to achieve its “full” agonist characteristics.   
Another potential factor contributing to the potency of LTE4 is agonist exposure time. 
Experiments analysing long (2 hours) versus short (5 minutes) exposure times revealed 
that LTE4 matched the potency of LTD4 only with the longer exposure (Figure 6.9C). This 
could be a direct consequence of the inability of LTE4 to fully desensitise CysLT1, as LTD4 
can (Figure 6.10). Partial desensitisation means that receptors are still partially 
responsive even after the first stimulation, so that even though LTE4 is the weaker agonist 
for calcium mobilisation, prolonged signalling could push gene expression to a similar 
level as that of LTD4. This difference in receptor desensitisation may stem from subtle 
changes in Erk activation, since LTE4 induced sustained Erk activation while that induced 
by LTD4 was only transient. These changes in Erk signalling kinetics have been linked to a 
GPCR’s ability to induce signal termination events (285-287). 
Early studies analysing the effects of cysteinyl leukotriene in vivo revealed a 
disproportionate augmentation in relative responses to cysteinyl leukotriene inhalation in 
asthmatic patients when compared to healthy individuals (211). Arm et al.’s observations 
revealed that LTC4 and LTD4 were 6.2 and 9.1 fold, respectively, more potent in asthmatic 
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patients while LTE4 induced a 219 fold change. Although CysLT1 expression was never 
analysed in Arm et al.’s study (indeed the receptor hadn’t yet been identified) recent 
clinical studies would suggest that CysLT1 is more highly expressed in asthmatics 
compared to healthy individuals. For example, Zhu et al. have shown in bronchial biopsies 
of asthmatic patients that there is a significant increase in CysLT1 expressing cells 
compared to healthy individuals (confirmed at mRNA and protein level) (292). There were 
also increased numbers of CysLT1 expressing cells in asthmatics with frequent 
exacerbations compared to stable asthmatics. In patients with aspirin-exacerbated 
respiratory disease (AERD), an increase in CysLT1 expression was observed in CD45+ 
leukocytes in comparison to aspirin-tolerant patients (293). As the number of CD45+ 
leukocytes did not differ between the two patient subsets, this increase in CysLT1 levels 
was directly attributed to increase of surface expression. Aspirin desensitisation was able 
not only to reduce the number of CysLT1 expressing leukocytes but also to blunt aspirin-
induced increases in urinary LTE4 and reduce hyperresponsiveness to LTE4 (293). This 
increase in CysLT1 expression in AERD patients has also been observed in mucosal 
inflammatory leukocytes and interestingly no changes in CysLT2 expression were 
observed (294). Zhu et al. have also associated CysLT1 expression with bronchial 
inflammation in patients with COPD (295).  
Analysing data from our own studies has revealed the same disproportionate 
augmentation in cysteinyl leukotriene-induced responses in LAD2 cells compared to 
LUVA, a model of relatively high CysLT1 expression versus lower CysLT1 expression. LTC4 
and LTD4 were more potent at inducing intracellular calcium mobilisation (2.7 and 2.3 
respectively) in LAD2 cells compared to LUVA while LTE4 induced a 61.8 fold change 
(Figure 4.2, 100 µmol/L, mean). A similar phenomenon was also observed when 
comparing control LAD2 cells with CysLT1 knockdown LAD2, another model of relatively 
high CysLT1 expression versus lower CysLT1 expression. LTC4 and LTD4 again showed very 
similar fold changes in intracellular calcium mobilisation (1.9 and 1.8 respectively) in 
control LAD2 cells compared to the CysLT1 knockdown LAD2 while LTE4 was able to 
induce a 6.4 fold change (Figure 4.8, 100 µmol/L, mean). Arm et al. initially suggested that 
this phenomenon was attributed to LTE4 distinct signalling properties (separate LTE4 
receptor) different from that of LTC4 and LTD4 that had relatively similar fold changes in 
responses but our data have revealed that this phenomenon is observed even within the 
same cell type by just lowering CysLT1 expression through knockdown (212). This 
provides strong evidence that CysLT1 expression level is one of the critical factors in how 
responsive individual cells are to LTE4. As this phenomenon is inducible even within the 
same cell system it also suggests the genetic variations (SNPs) do not play an important 
role in constitutive CysLT1 expression level within our human mast cell models. 
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A higher GPCR expression level in disease states is not an uncommon phenomenon. In 
multiple sclerosis (MS) many chemokine receptors are elevated in MS lesions (CCR2, 
CCR3, CCR5, CCR7, CXCR2), demyelinating plaques (CCR1) and in specific cell subsets, 
leukocytes (CCR4), T cells (CCR5, CXCR3) and monocytes (CXCR3, CXCR4) (296). Although 
many specific functions are still being elucidated, chemokine receptors are being utilised 
as therapeutic targets with two promising CCR2 modulators (MK-0812 and MLN1202) 
already completing phase II clinical trials (296). In cancer, GPR116 expression has been 
linked to breast cancer cell metastasis and a poor prognosis. PAR1, a protease-activated 
GPCR, has increased expression in highly invasive breast carcinomas and prostate cancer 
(297,298). GPCRs are highly regulated proteins and any dysfunction, including receptor 
overexpression, could arise from either genetic or environmental changes (or both). Our 
data have revealed that there are no genetic variations in the CYSLTR1 gene between 
LAD2 and LUVA cells and as previously stated, disproportionate responsiveness to LTE4 
can be observed within the same cell type, so genetic variations do not account for higher 
CysLT1 expression in LAD2 cells compared to LUVA. As no specific genetic variations have 
been identified driving the differential CysLT1 expression observed in 
asthmatic/rhinosinusitic and healthy individuals, it is likely that there are other factors 
affecting CysLT1 expression. One explanation may be immunoregulation (see section 1.1.4 
Cysteinyl leukotriene receptors). CysLT1 expressing cells that are tissue resident in 
asthmatic patients will be exposed to an extracellular environment containing many pro-
inflammatory mediators. This would be a unique feature not present in healthy 
individuals. These pro-inflammatory mediators could be released from activated cells i.e. 
mast cells themselves, recruited Th2, eosinophils and structural cells, which could all 
contribute to the regulation and differentiation of these cells. For example, in asthmatic 
patients the Th2 cell related cytokines IL-4, IL-13 and IL-5 have been shown to be 
significantly increased at both an mRNA and protein level in the serum, BAL and within 
bronchial biopsies compared to healthy individuals (299-301). IL-4, IL-13 and IL-5, which 
can also be released from mast cells and eosinophils, have been shown to be able to prime 
human mast cells to release Th2 cell associated cytokines and increase cysteinyl 
leukotriene production both in an IgE-dependent manner (280,302-304). What is 
interesting about these cytokines is that even in the absence of IgE, they are able to up-
regulate CysLT1 expression and so their level of “priming” could be far more extensive 
than just mediator production/release (121,123,126). This would suggest that the 
responses to LTE4 are potentiated through an increase in CysLT1 expression, occurring 
mainly after cell activation/priming during a chronic state of disease progression. This is 
reflective of the fact that leukotriene pathway antagonists have been shown to have a clear 
clinical benefits as therapies in adults and children with chronic asthma and are routinely 
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used as add on therapies for asthma that cannot be completely controlled by 
corticosteroids (191,305,306). 
The first line treatment for asthma is inhaled corticosteroids but suppression of 
inflammation remains incomplete. Several studies have indicated that leukotriene levels 
were still detectable in the urine of moderate to severe asthmatic adults and children 
being treated with inhaled corticosteroids alone (307,308). Studies have also shown that 
the addition of a leukotriene receptor antagonist, Montelukast, to inhaled corticosteroid 
treatment reduces cysteinyl leukotriene and LTB4 concentrations as well as improving 
symptoms (309). Eosinophilic inflammation can also be observed in asthmatics even with 
high dose inhaled corticosteroid treatment (310). This suggests that corticosteroids alone 
are insufficient to completely control airway inflammation and that the cysteinyl 
leukotriene pathway is relatively unaffected by such treatment. This implies that there is a 
necessity for leukotriene pathway antagonists in the treatment of asthma but 
unfortunately LTRAs such as Montelukast do have varying effects from patient to patient. 
This could be due to several reasons. Firstly, genetic polymorphisms within the 
leukotriene pathway have long been thought to be one of the main reasons for high inter-
patient variability in response to treatment. Several pharmacogenetic studies have 
identified multiple sites that could be associated with LTRA responsiveness; for example, 
Asano et al. observed that homozygotes for the C(-444) LTC4S allele in moderate 
asthmatics were more responsive to Pranlukast treatment than A(-444) homozygotes 
(311). Lima et al. observed polymorphisms in multiple genes; ALOX5, LTC4S A(-444)C, 
LTA4H and MRP1 that could influence Montelukast treatment (312). Also polymorphisms 
within the gene that encodes the OATP2B1 transporter protein, thought to be a carrier 
protein for Montelukast, have also been associated with Montelukast inconsistencies in 
asthma treatment (313). Unfortunately, due to the complexities of analysing a 
heterogeneous disease and the relatively small sample size of these studies some of these 
associations have already been questioned (314,315).  
Secondly, Montelukast, Pranlukast and Zafirlukast are selective cysteinyl leukotriene 
receptor antagonists i.e. they inhibit CysLT1 mediated responses and not CysLT2, but they 
are not specific antagonists. As previously mentioned, Montelukast, Pranlukast and 
Zafirlukast, were all developed before any cysteinyl leukotriene receptor had been 
identified. Several reports have observed that these antagonists can in fact inhibit other 
receptors/enzymes independently of CysLT1. For example, purinergic receptors (P2Y) that 
are activated by ADP, ATP, UDP and UTP are GPCRs that can potentiate inflammatory 
responses. These receptors, namely P2Y1, P2Y2, P2Y4 and P2Y6, are inhibited by micromolar 
concentrations of Montelukast, Pranlukast and Zafirlukast in primary human monocytes 
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and monocyte/macrophage cell lines independently of CysLT1 (263,267). Micromolar 
concentrations (≥1 mol/L) of Montelukast have also been shown to inhibit 5-lipoxygenase, 
a key enzyme in leukotriene production, in primary human monocytes and mast cell lines 
(human and rat) (267,316). This additional attenuation of cysteinyl leukotriene and LTB4 
production could be a complementary therapeutic property to receptor antagonism and 
has already generated interest in the treatment of other diseases such as cystic fibrosis 
(317,318). Other studies have also reported that Pranlukast can inhibit NF-κB in activated 
monocytes, T-cells and epithelial and endothelial cell lines independently of CysLT1 and 
also may inhibit eosinophil adhesion to vascular cell adhesion molecule-1 (VCAM-1) 
(265,319-321). Although current findings suggest that cysteinyl leukotriene receptor 
antagonists, Montelukast, Pranlukast and Zafirlukast have additional anti-inflammatory 
effects, it is still theoretically possible due to the extent of off-target antagonism that some 
pathways may be detrimental to the original treatment.   
Finally, the heterogeneous nature of asthma may play a very important role. In recent 
years, phenotyping asthmatic patients by clinical presentation and biological features has 
become of great interest for tailoring treatments. Montelukast has been shown to be very 
effective in specific subphenotypes of asthma. For example, in exercise-induced 
bronchoconstriction, Montelukast has been shown to be a more effective treatment than 
the long acting β2 agonist salmeterol (322,323). Several studies have also indicated that 
asthmatic patients with allergic rhinitis have a significant improvement in lung function 
and therefore asthma control when Montelukast is added to current therapies (324-327). 
Montelukast may also be effective in asthmatics with low airway inflammation or in non-
eosinophilic phenotypes that are not necessarily associated with cysteinyl leukotrienes 
although more studies need to be carried out to assess its significance. In obese asthmatics 
(low airway inflammation) it has been observed that Montelukast was more effective at 
controlling asthma than inhaled corticosteroids and in the case of viral-induced 
bronchoconstriction (typically non-eosinophilic) and wheezing, leukotriene receptor 
antagonists improved disease control although further investigations need to be carried to 
understand these mechanisms (328,329). However, it is clear that phenotyping of asthma 
might reduce the heterogeneity that is seen in Montelukast treatment. This could be 
directly related to the heterogeneity in CysLT1 expression level. For example, in aspirin-
sensitive asthmatics, CysLT1 expression level on CD45+ leukocytes is significantly higher 
than in aspirin-insensitive asthmatics and healthy individuals (294). Several studies have 
reported that aspirin-sensitive asthmatics are more responsive to LTE4 than asthmatics 
without aspirin sensitivity, which our data have suggested, could be related to the 
increased CysLT1 expression (212,330). Urinary LTE4 levels are elevated in aspirin-
sensitive asthmatics compared to tolerant patients indicating a constitutive 
                                                                                                                                               Final Discussion   
                                                                                                                                 
163 
 
overproduction in this phenotype. Taken together, overproduction and higher sensitivity 
to cysteinyl leukotrienes would suggest that leukotriene receptor antagonists (or general 
inhibition of the leukotriene pathway) could be a very effective treatment in selected 
subpopulations in asthma (331-333). Although studies are limited, promising clinical trials 
have observed significant increases in lung function and general asthma control with 
LTRA treatment in aspirin-sensitive asthmatics compared to inhaled corticosteroid 
treatment alone (204,334).   
Better characterisation of asthmatic phenotypes could lead to improved treatment and by 
extension fewer hospitalisations and less strain on the health care system. Unfortunately 
urinary LTE4 levels, or any biological fluid measurement, are not an indicator of how 
responsive individuals are to cysteinyl leukotrienes. Our data suggest that CysLT1 
expression is a critical factor and so it would be interesting to see whether CysLT1 
expression is directly related to patients’ response to Montelukast treatment. If there is a 
direct relationship then CysLT1 expression level could be used as a biomarker in the 
characterisation of asthmatic phenotypes and therefore more effective treatments could 
be administered based on such characterisations.   
The question whether there is a third cysteinyl leukotriene receptor still remains 
unanswered. The mouse models of inflammation set up by Maekawa et al. and Paruchuri 
et al. provide strong evidence that CysLT1 and CysLT2 are not the only cysteinyl 
leukotriene receptors as their knockout did not diminish cysteinyl leukotriene mediated 
inflammation (170,218). Unfortunately, the two receptors identified from these studies, 
P2Y12 and OXGR1, have been clearly shown in the present study not to be directly 
activated by cysteinyl leukotrienes (see Chapter 3) and so this leaves the question of how 
LTE4-mediated inflammation remains intact in the absence of CysLT1 and CysLT2 
unanswered (170,236,335). Our data presented here cannot explain such a phenomenon 
nor do they rule out the possibility of a third cysteinyl leukotriene receptor. Our study 
shows for the first time that the CysLT1 expression as well as a functional PKC signalling 
pathway, are critically important for responsiveness to LTE4 within a human cell system. 
This could potentially be relevant for other human cell types other than mast cells and 
could thus have important implications for the treatment of specific phenotypes of asthma.   
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9.1 Characterisation of P2Y12 receptor responsiveness to 
cysteinyl leukotrienes 
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